Novel prodrugs derived from nicotinic acid and ribose

By designing new compound structures and pharmaceutical compositions, the problem of poor penetration and retention of niacin in important organs has been solved, and its bioavailability and efficacy in key organs has been improved, which has reduced side effects and achieved more efficient treatment. Mitochondrial dysfunction-related diseases.

CN118922189APending Publication Date: 2024-11-08MITOPOWER LLC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380029760.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-02
Filing Date
2023-03-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing drugs used to treat mitochondrial dysfunction have poor penetration and retention in important organs, resulting in the need for high doses to achieve efficacy, and there are problems with flushing side effects and poor tolerance.

Method used

A novel compound structural formula (I) and pharmaceutical compositions are provided, through improved delivery and conversion of niacin to NAD+, to improve its bioavailability and efficacy in key organs, and through the pharmaceutical composition and carriers Design to improve the safety and effectiveness of niacin.

Benefits of technology

It significantly increases the intracellular concentration of niacin in organs such as the liver, kidneys and muscles, enhances its pharmacological effects, reduces side effects, and improves the efficacy of treating cardiovascular, metabolism, cerebrovascular and other diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922189A_ABST
    Figure CN118922189A_ABST
Patent Text Reader

Abstract

Disclosed are novel prodrugs derived from nicotinic acid and pharmaceutical compositions thereof, which are useful for the treatment or prevention of various medical diseases characterized by mitochondrial dysfunction. The compound and the pharmaceutical composition thereof can be used for treating or preventing metabolic diseases, cardiovascular diseases, cerebrovascular diseases, liver diseases, kidney diseases or muscle diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 315,640, filed on March 2, 2022, 35 U.S.C. 119(e), the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present invention discloses novel prodrugs derived from nicotinic acid and pharmaceutical compositions thereof, which can be used to treat or prevent various medical diseases characterized by mitochondrial dysfunction. The compounds and pharmaceutical compositions thereof can be used to treat or prevent metabolic diseases, cardiovascular diseases, cerebrovascular diseases, liver diseases, kidney diseases or muscle diseases. Background Art

[0004] Mitochondrial dysfunction is a hallmark of chronic and acute inflammatory and metabolic conditions and is often associated with NAD+ depletion. There are 3 established pathways for NAD+ synthesis: the salvage pathway utilizes nicotinamide, de novo synthesis utilizes tryptophan, and the Preiss-Handler pathway utilizes niacin. The Preiss Handler pathway is particularly important in metabolically active organs including the liver, kidneys, brain, and skeletal muscle. In addition, niacin directly regulates key metabolic enzymes involved in lipid metabolism.

[0005] Nicotinic acid, or niacin, has been used to treat hypertriglyceridemia and, more recently, mitochondrial myopathy. These benefits are based on a unique mechanism of direct regulation of several key metabolic enzymes, as well as the broad benefits of increased NAD+ levels in key vital organs. However, niacin is associated with a dose-limiting adverse event of flushing that restricts its use. Flushing is mediated by the interaction of niacin with the GPR109A receptor. In addition, niacin has poor penetration and / or retention in vital organs and is rapidly cleared. This requires large doses to achieve efficacy; escalating doses of niacin are poorly tolerated by most patients.

[0006] There is a major unmet need for a new approach to increase bioavailability and significantly improve intracellular concentrations of niacin to maximize the pharmacological effects of niacin. Currently, niacin is unable to do this. Maintaining sustained levels of niacin in key vital organs such as the kidney, liver and muscle would provide greater efficacy in diseases associated with severe organ damage. Summary of the invention

[0007] These and other needs are addressed herein, as the disclosed content can uniquely reverse mitochondrial and metabolic dysfunction in vital organs. In one aspect, structural formula (I) is provided: A compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R 1 -H, R 8 C(O)-, R 2 Yes -H or R 9 C(O)-;R 3 Yes -H or R 10 C(O)-;R 4 is -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, heteroaralkyl, substituted heteroaralkyl, R 11 C(O)- or R 6 is -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl; R 5 , R 7 , R 8 , R 9 , R 10 and R 11 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl;

[0008] The condition is R 1 or R 4 At least one of Compared to niacin, the compound of structural formula (I) can provide more efficient delivery and subsequent conversion to NAD+, with higher efficacy and safety.

[0009] Also provided are derivatives, including salts, esters, enol ethers, enol esters, solvates, hydrates, metabolites and prodrugs of the compounds described herein.Further provided are pharmaceutical compositions comprising a compound provided herein and a pharmaceutically acceptable carrier.

[0010] In another aspect, a method of treating, preventing or ameliorating symptoms of a medical disease, such as a metabolic disease, cardiovascular disease, cerebrovascular disease, liver disease, kidney disease or muscle disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 Increase of NAD+ in Jurkat cells in RPMI medium supplemented with 30 μM compounds 100, 101 and 102 is depicted.

[0012] Figure 2 Depicted is the increase in NAD+ in Huh7 cells supplemented with 125 μM compounds 100, 101, and 102 and niacin.

[0013] Figure 3A Depicted is the dose-dependent increase in NAD+ in Huh7 cells supplemented with varying amounts of niacin.

[0014] Figure 3B Depicted is the dose-dependent increase in NAD+ in Huh7 cells supplemented with varying amounts of nicotinamide.

[0015] Figure 3C Depicted is the dose-dependent increase in NAD+ in Huh7 cells supplemented with varying amounts of Compound 100.

[0016] Figure 3D Depicted is the dose-dependent increase in NAD+ in Huh7 cells supplemented with varying amounts of Compound 101.

[0017] Figure 4A Shown are the results of NAD cycling assays in HEPG2 cells at 10 μM of compounds 100, 101, 103, 104 and niacin.

[0018] Figure 4B Shown are the results of NAD cycling assays in HEPG2 cells at 50 μM of compounds 100, 101, 103, 104 and niacin.

[0019] Figure 4C Shown are the results of NAD cycling assays in HEPG2 cells at 100 μM of compounds 100, 101, 103, 104 and niacin.

[0020] Figure 4D Shown are the results of NAD cycling assays in HEPG2 cells at 250 μM of compounds 100, 101, 103, 104 and niacin.

[0021] Figure 5 Shown are the effects of 250 μM compounds 103 and 104 on NAD+ levels in primary human hepatocytes.

[0022] Fig. 6A The in vitro cytotoxicity of compounds 103 and 104 at 10 μM on HEPG2 cells is shown.

[0023] Figure 6B In vitro cytotoxicity of compounds 103 and 104 at 100 μM on HEPG2 cells is shown.

[0024] Figure 7 The cytotoxicity of compounds 100, 101 and 102 at different concentrations on HepG72 cells is shown.

[0025] Fig. 8A The human plasma stability of Compound 100 was shown.

[0026] Figure 8B The human plasma stability of compound 101 was shown.

[0027] Figure 8C The human plasma stability of compound 102 was shown.

[0028] Fig.8D The human plasma stability of compound 103 was demonstrated.

[0029] Fig. 8E The human plasma stability of niacin was demonstrated.

[0030] Fig.9A Compound 103 was shown to be stable in human hepatocytes.

[0031] Fig. 9B Compound 104 was shown to be stable in human hepatocytes.

[0032] Fig. 9C The human hepatocyte stability of compound 101 was demonstrated.

[0033] Fig.9D The stability of testosterone on human hepatocytes was shown.

[0034] Fig.9E The stability of warfarin on human hepatocytes was shown.

[0035] Fig. 10A The pharmacokinetic results of Compound 100 Group 2 dose (83 mg / kg) are shown.

[0036] Fig. 10B The pharmacokinetic results of Compound 100 Group 1 dose (415 mg / kg) are shown.

[0037] Fig.11A The pharmacokinetic results of niacin at the Group 4 dose (40 mg / kg) are shown.

[0038] Fig. 11B Pharmacokinetic results for the Group 3 dose of niacin (200 mg / kg) are shown.

[0039] Fig. 12A The distribution of Compound 100 (415 mg / kg) in the kidney and liver tissues after 24 hours for Group 1 dose is shown.

[0040] Fig. 12B The distribution of Compound 100 (83 mg / kg) in the kidney and liver tissues of Group 2 dose after 24 hours is shown.

[0041] Fig. 12CThe distribution of niacin in the kidney and liver tissues of Group 3 (200 mg / kg) and Group 4 (40 mg / kg) after 24 hours is shown.

[0042] Fig.13 Shown are plasma creatine levels of mice administered control, cisplatin (25 mg / kg), Compound 100 (50 mg / kg) and cisplatin (25 mg / kg), Compound 100 (250 mg / kg) and cisplatin (25 mg / kg), and Compound 100 (500 mg / kg) and cisplatin (25 mg / kg).

[0043] Fig.14 Shown are blood urea nitrogen (BUN) of mice administered control, cisplatin (25 mg / kg), Compound 100 (50 mg / kg) and cisplatin (25 mg / kg), Compound 100 (250 mg / kg) and cisplatin (25 mg / kg), and Compound 100 (500 mg / kg) and cisplatin (25 mg / kg). DETAILED DESCRIPTION

[0044] definition

[0045] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. If multiple definitions of a term exist herein, the definition in this section shall prevail unless otherwise stated. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. If multiple definitions of a term exist herein, the definition in this section shall prevail unless otherwise stated. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. If multiple definitions of a term exist herein, the definition in this section shall prevail unless otherwise stated.

[0046] As used herein, unless otherwise indicated, when used in conjunction with an attribute having a value or a range of values, the terms "about" and "approximately" indicate that the value or range of values ​​may deviate to an extent that is considered reasonable by one of ordinary skill in the art while still describing the particular attribute. Specifically, when the terms "approximately" and "approximately" are used in this context, it means that the value or range of values ​​may vary by 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the value or range of values. In addition, unless the context clearly dictates otherwise, the singular forms "a" and "the" include plural references. Thus, for example, reference to a "compound" includes a plurality of such compounds, and reference to an "assay" includes reference to one or more assays known to those skilled in the art and their equivalents.

[0047] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -C(O)NH 2 Attached through a carbon atom. Dashes at the beginning or end of a chemical group are for convenience; a chemical group may be depicted with or without one or more dashes without losing its usual meaning. A wavy line drawn through a line in a structure indicates the point of attachment of the group. Unless chemically or structurally required, the order in which chemical groups are written or named does not indicate or imply directionality.

[0048] The prefix "C u-v " means that the following group has u to v carbon atoms. It should be understood that u to v carbons include u+1 to v, u+2 to v, u+3 to v, etc. carbons, u+1 to u+3 to v, u+2 to u+4 to v, u+2 to u+4 to v, etc., and covers all possible substitutions of u and v.

[0049] "Alkyl" by itself or as part of another substituent refers to a saturated or unsaturated, branched, straight-chain or cyclic monovalent hydrocarbon radical derived by removing a hydrogen atom from a single carbon atom of a parent alkane. Typical alkyl groups include, but are not limited to, methyl; ethyl; propyl, such as prop-1-yl, prop-2-yl, etc.; butyl, such as but-1-yl, but-2-yl, 2-methylprop-1-yl, 2-methylprop-2-yl, etc.; and the like. In some aspects, the alkyl group contains 1 to 20 carbon atoms (C 1 -C 20 In other aspects, the alkyl group contains 1 to 10 carbon atoms (C 1 -C 10 In other aspects, the alkyl group contains 1 to 6 carbon atoms (C 1 -C 6 alkyl).

[0050] "Alkenyl" by itself or as part of another substituent refers to an unsaturated branched, straight chain or cyclic alkyl radical having at least one carbon-carbon double bond derived by removing a hydrogen atom from a single carbon atom of a parent alkene. The radical may be in the cis or trans configuration about the double bond. Typical alkenyl groups include, but are not limited to, vinyl; propenyl, such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl, cycloprop-1-en-1-yl; cycloprop-2-en-1-yl; butenyl, such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-propyl-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, but-1,3-dien-1-yl, but-1,3-dien-2-yl, cyclo-1-en-1-yl and cyclo-1-en-3-yl, cyclobut-1,3-dien-1-yl, etc. In some aspects, the alkenyl group contains 1 to 20 carbon atoms (C 1 -C 20 In other aspects, the alkenyl group contains 1 to 10 carbon atoms (C 1 -C 10 In other aspects, the alkenyl group contains 1 to 6 carbon atoms (C 1 -C 6 alkenyl).

[0051] "Alkynyl" by itself or as part of another substituent refers to an unsaturated branched, straight chain or cyclic alkyl group having at least one carbon-carbon triple bond, which is derived by removing a hydrogen atom from a single carbon atom of a parent alkyne. Typical alkynyl groups include, but are not limited to, ethynyl; propynyl, such as prop-1-yn-1-yl, prop-1-yn-1-yl, etc.; butynyl, such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc. In some aspects, the alkynyl group contains 1 to 20 carbon atoms (C 1 -C 20 In other aspects, the alkynyl group contains 1 to 10 carbon atoms (C 1 -C 10 In other aspects, the alkynyl group contains 1 to 6 carbon atoms (C 1 -C 6 alkynyl).

[0052] "Aryl" by itself or as part of another substituent refers to a monovalent aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system, as defined herein. Typical aryl groups include, but are not limited to, those derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, pentylene -2,4-diene, penta-2,4-diene, pentalene, pentacene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like. In some aspects, the aryl group contains 6 to 20 carbon atoms (C 6 -C 20 In other aspects, the aryl group contains 6 to 15 carbon atoms (C 6 -C 15 In other aspects, the aryl group contains 6 to 10 carbon atoms (C 6 -C 10 aryl).

[0053] "Arylalkyl" by itself or as part of another substituent refers to an acyclic alkyl group in which the carbon atom (usually a terminal or sp 3 One of the hydrogen atoms bonded to a (C) carbon atom is replaced by an aryl group as defined herein. Typical aralkyl groups include, but are not limited to, benzyl, 2-phenylethane-1-yl, 2-phenylethene-1-yl, naphthylmethyl, 2-naphthylethane-1-yl, 2-naphthylethen-1-yl, naphthylbenzyl, 2-naphthylphenylethane-1-yl, and the like. In some aspects, the aralkyl group is (C 6-C 30 ) aralkyl, for example, the alkyl portion of the aralkyl is (C 1 -C 10 ) alkyl, the aryl part is (C 6 -C 20 In other aspects, the aralkyl group is (C 6 -C 20 ) aralkyl, for example, the alkyl portion of the aralkyl is (C 1 -C 8 ) alkyl, the aryl part is (C 6 -C 12 In other aspects, the aralkyl group is (C 6 -C 15 ) aralkyl, for example, the alkyl portion of the aralkyl is (C 1 -C 5 ) alkyl, the aryl part is (C 6 -C 10 )aryl.

[0054] "Arylalkenyl" by itself or as part of another substituent refers to an acyclic alkenyl group in which one of the hydrogen atoms bonded to a carbon atom is replaced by an aryl group as defined herein. In some aspects, arylalkenyl is (C 6 -C 30 ) arylalkenyl, for example, the alkenyl portion of the arylalkenyl is (C 1 -C 10 ) alkenyl, the aryl part is (C 6 -C 20 In other aspects, the arylalkenyl is (C 6 -C 20 ) arylalkenyl, for example, the alkenyl portion of the arylalkenyl is (C 1 -C 8 ) alkenyl, the aryl part is (C 6 -C 12 In other aspects, the arylalkenyl is (C 6 -C 15 ) arylalkenyl, for example, the alkenyl portion of the arylalkenyl is (C 1 -C 5 ) alkenyl, the aryl part is (C 6 -C 10 )aryl.

[0055] "Arylalkynyl" by itself or as part of another substituent refers to an acyclic alkynyl group in which one of the hydrogen atoms bonded to a carbon atom is replaced by an aryl group as defined herein. In some aspects, arylalkynyl is (C 6 -C 30 ) arylalkyne, for example, the alkynyl portion of arylethynyl is (C1 -C 10 ) alkynyl, the aryl part is "C 6 -C 20 In other aspects, the arylalkynyl group is (C 6 -C 20 )aralkynyl, for example, the alkynyl portion of the aralkynyl is (C 1 -C 5 ) alkynyl, the aryl part is (C 6 -C 10 )aryl.

[0056] "Cycloalkyl" by itself or as part of another substituent refers to a saturated cyclic monovalent hydrocarbon radical derived by removing one hydrogen atom from a single carbon atom of a parent cycloalkane. Typical cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and the like. In some aspects, the cycloalkyl group contains 3 to 20 carbon atoms (C 1 -C 15 In other aspects, the cycloalkyl group contains 3 to 10 carbon atoms (C 1 -C 10 In other aspects, the cycloalkyl group contains 3 to 8 carbon atoms (C 1 -C 8 The term "cyclic monovalent hydrocarbon group" also includes polycyclic hydrocarbon ring systems having a single radical and 3 to 12 carbon atoms. Exemplary polycyclic cycloalkyl rings include, for example, norbornyl, pentyl, and adamantyl.

[0057] "Cycloalkenyl" by itself or as part of another substituent refers to an unsaturated cyclic monovalent hydrocarbon radical derived by removing a hydrogen atom from a single carbon atom of a parent cycloalkene. Typical cycloalkenyl groups include, but are not limited to, cyclopropene, cyclobutene, cyclopentene, and the like. In some aspects, the cycloalkenyl group contains 3 to 20 carbon atoms (C 1 -C 20 In other aspects, the cycloalkenyl group contains 3 to 10 carbon atoms (C 1 -C 10 In some other aspects, the cycloalkenyl group contains 3 to 8 carbon atoms (C 1 -C 8 The term "cyclic monovalent hydrocarbon group" also includes polycyclic hydrocarbon ring systems having single radicals and 3 to 12 carbon atoms.

[0058] "Cycloheteroalkyl" by itself or as part of another substituent refers to a cycloalkyl group as defined herein, wherein one or more carbon atoms (and optionally any associated hydrogen atoms) are each independently replaced with the same or different heteroatoms or heteroatom groups as defined below for "heteroalkyl". In some aspects, the cycloheteroalkyl group comprises 3 to 20 carbon atoms and heteroatoms ( 1-20In other aspects, the cycloheteroalkyl group contains 3 to 10 carbon atoms and heteroatoms ( 1-10 In other aspects, the cycloheteroalkyl group contains 3 to 8 carbon atoms and heteroatoms ( 1-8 The term "cyclic monovalent heteroalkyl" also includes polycyclic heteroalkyl ring systems having a single radical, 3 to 12 carbons and at least one heteroatom.

[0059] "Cycloheteroalkenyl" by itself or as part of another substituent refers to a cycloalkenyl as defined herein, wherein one or more carbon atoms (and optionally any associated hydrogen atoms) are each independently replaced with the same or different heteroatoms or heteroatom groups as defined below for "heteroalkenyl". In some aspects, the cycloheteroalkenyl comprises 3 to 20 carbon atoms and heteroatoms ( 1-20 In other aspects, the cycloheteroalkenyl group contains 3 to 10 carbon atoms and heteroatoms ( 1-10 In other aspects, the cycloheteroalkenyl group contains 3 to 8 carbon atoms and heteroatoms ( 1-8 The term "cyclic monovalent heteroalkenyl" also includes polycyclic heteroalkenyl ring systems having a single radical, 3 to 12 carbons and at least one heteroatom.

[0060] "Compound" refers to a compound contained in the structural formula disclosed herein, including any specific compound in these structural formulas disclosed herein. Compounds can be identified by their chemical structure and / or chemical name. The chemical structure determines the properties of the compound. The compounds described herein may contain one or more chiral centers and / or double bonds, and therefore may exist in the form of stereoisomers, such as double bond isomers (i.e., geometric isomers), enantiomers, or diastereomers. Therefore, the chemical structures described herein include the stereoisomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) shown in the structure. The chemical structures described herein also include enantiomers and stereoisomer derivatives of the compounds. Enantiomers and stereoisomer mixtures can be separated into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to those skilled in the art. These compounds can also exist in several tautomeric forms, including enol forms, keto forms, and mixtures thereof. Therefore, the chemical structures described herein include all possible tautomeric forms of the compounds shown. The compounds also include isotope-labeled compounds in which the atomic mass of one or more atoms is different from the atomic mass commonly found in nature. Examples of isotopes that may be incorporated into the compounds disclosed herein include, but are not limited to 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 18 O. 17O, etc. The compound may exist in an unsolvated form as well as a solvated form, including a hydrated form. In general, the compound may be hydrated or solvated. Certain compounds may exist in a variety of crystalline or amorphous forms. In general, all physical forms are equivalent for the intended uses herein and are intended to fall within the scope of the present disclosure. In addition, it should be understood that when a partial structure of a compound is shown, the brackets represent the point of attachment of the partial structure to the rest of the molecule.

[0061] "Halo" by itself or as part of another substituent refers to the group -F, -Cl, -Br or I.

[0062] "Heteroalkyl" refers to an alkyl group in which one or more carbon atoms (and optionally any associated hydrogen atoms) are each independently replaced by the same or different heteroatoms or heteroatom groups. Typical heteroatoms or heteroatom groups that may replace carbon atoms include, but are not limited to, -O-, -S-, -N-, -Si-, -NH-, -S(O)-, -S-. The heteroatoms or heteroatom groups may be placed at any interior position of the alkyl, alkenyl, or alkynyl group. Typical heteroatom groups that may be included in these groups include, but are not limited to, -O-, -S-, -OO-, -SS-, -OS-, NR 501 R 502 ,=NN=,-N=N-,-N=N-NR 503 R 404 , -PR 505 、-P(O) 2 -、-POR 506 、-OP(O) 2 -、-SO-、-SO 2 -、SnR 507 R 508 etc., where R 501 , R 502 , R 503 , R 504 , R 505 , R 506 , R 507 and R 508 is independently hydrogen, alkyl, aryl, substituted aryl, heteroalkyl, heteroaryl or substituted heteroaryl. In some aspects, the heteroalkyl group contains 1 to 20 carbon atoms and heteroatoms ( 1-20 In other aspects, the heteroalkyl group contains 1 to 10 carbon atoms and heteroatoms ( 1-10 In other aspects, the heteroalkyl group contains 1 to 6 carbon atoms and heteroatoms ( 1-6 heteroalkyl).

[0063] "Heteroalkenyl" refers to an alkenyl group in which one or more carbon atoms (and optionally any associated hydrogen atoms) are each independently replaced by the same or different heteroatoms or heteroatoms. Typical heteroatoms or heteroatom groups that may replace carbon atoms include, but are not limited to, -O-, -S-, -N-, -Si-, -NH-, -S(O)-, -S-. The heteroatoms or heteroatom groups may be placed at any interior position of the alkyl, alkenyl, or alkynyl group. Typical heteroatom groups that may be included in these groups include, but are not limited to, -O-, -S-, -OO-, -SS-, -OS-, -NR 501 R 502 ,=NN=,-N=N-,-N=N-NR 503 R 404 , -PR 505 、-P(O) 2 、-POR 506 、-OP(O) 2 、-SO-、-SO 2 -、-SnR 507 R 508 etc., where R 501 , R 502 , R 503 , R 504 , R 505 , R 506 , R 507 and R 508 is independently hydrogen, alkyl, aryl, substituted aryl, heteroalkyl, heteroaryl, or substituted heteroaryl. In some aspects, the heteroalkenyl group contains 1 to 20 carbon atoms and heteroatoms ( 1-20 In other aspects, the heteroalkenyl group contains 1 to 10 carbon atoms and heteroatoms ( 1-10 In other aspects, the heteroalkenyl group contains 1 to 6 carbon atoms and heteroatoms ( 1-6 heteroalkenyl).

[0064] "Heteroaryl" by itself or as part of another substituent refers to a monovalent heteroaryl derived from a single atom of a parent heteroaromatic ring system by removing one hydrogen atom, as defined herein. Typical heteroaryl groups include, but are not limited to, those derived from acridine, β-carboline, chroman, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perylidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, etc. In some aspects, heteroaryl contains 5 to 20 ring atoms (5-20 membered heteroaryl). In other aspects, the heteroaryl group contains 5 to 10 ring atoms (5-10 membered heteroaryl). Exemplary heteroaryl groups include those derived from furan, thiophene, pyrrole, benzothiophene, benzofuran, benzimidazole, indole, pyridine, pyrazole, quinoline, imidazole, oxazole, isoxazole, and pyrazine.

[0065] "Heteroaralkyl" by itself or as part of another substituent refers to an acyclic alkyl group in which the carbon atom (usually a terminal or sp 3 In some aspects, the heteroarylalkyl group is a 6-21-membered heteroarylalkyl group, for example, the alkyl portion of the heteroarylalkyl group is (C 1 -C 6 ) alkyl, the heteroaryl portion is a 5-15 membered heteroaryl. In other aspects, the heteroaralkyl is a 6-13 membered heteroaralkyl, for example, the alkyl portion is (C 1 -C 3 ) alkyl, the heteroaryl part is a 5-10 membered heteroaryl.

[0066] "Heteroarylalkenyl" by itself or as part of another substituent refers to an acyclic alkenyl group in which one of the hydrogen atoms bonded to a carbon atom is replaced by a heteroaryl group. In some aspects, the heteroarylalkenyl group is a 6-21 membered heteroarylalkyl group, for example, the alkenyl portion of the heteroarylalkenyl group is (C 1 -C 6 ) alkenyl, the heteroaralkyl portion is a 5-15 membered heteroaryl. In other aspects, the heteroarylalkenyl is a 6-13 membered heteroarylalkenyl, for example, the alkenyl portion is (C 1 C 3 ) alkyl, the heteroaryl part is a 5-10 membered heteroaryl.

[0067] "Heteroarylalkynyl" by itself or as part of another substituent refers to an acyclic alkenyl group in which a hydrogen atom bound to a carbon atom is replaced by a heteroaryl group. In some aspects, the heteroarylalkynyl group is a 6-21 membered heteroarylalkyl group, for example, the alkynyl portion of the heteroarylalkynyl group is (C 1 -C6 )alkynyl, and the heteroaryl moiety is a 5-15 membered heteroaryl. In other aspects, the heteroarylalkynyl is a 6-13 membered heteroarylethynyl, for example, the alkynyl moiety is (C 1 -C 3 ) alkyl, the heteroaryl part is a 5-10 membered heteroaryl.

[0068] "Hydrate" refers to the incorporation of water into the crystal lattice of the compound described herein in a stoichiometric ratio to form an adduct. Methods for preparing hydrates include, but are not limited to, storage in an atmosphere containing water vapor, dosage forms containing water, or conventional drug processing steps, such as crystallization (i.e., crystallization from water or mixed aqueous solvents), freeze drying, wet granulation, aqueous film coating, or spray drying. In some cases, when exposed to water vapor or when anhydrous materials are suspended in water, crystalline solvates may also form hydrates. Hydrates may also crystallize in a variety of forms, resulting in hydrate polymorphism. See, for example (GuilloRy, K., Chapter 5, pp. 202-205, Polymorphism in Pharmaceutical Solids, (Brittain, H. ed.), Marcel Dekker, Inc., New York, NY, 1999). The above-mentioned method for preparing hydrates is completely within the scope of those skilled in the art, is completely routine, and does not require any experiments beyond the typical scope of the art. Hydrates can be characterized and / or analyzed by methods well known to those skilled in the art, such as single crystal X-ray diffraction, X-ray powder diffraction, polarized optical microscopy, thermal microscopy, thermogravimetric analysis, differential thermal analysis, differential scanning calorimetry, infrared spectroscopy, Raman spectroscopy, and nuclear magnetic resonance spectroscopy. (Brittain, H., Chapter 6, pages 205-208, Polymorphism in Pharmaceutical Solids, (Brittan, H. ed), Marcel Dekker, Inc., New York, 1999). In addition, many commercial companies often provide services including hydrate preparation and / or characterization, such as HOLODIAG, Pharmaparc II, Voie de l'Innovation, 27 100 Valde reuil, France (http: / / www.holodiag.com).

[0069] "Parent aromatic ring system" refers to an unsaturated cyclic or polycyclic ring system with a conjugated p-electron system. The definition of "parent aromatic ring system" specifically includes fused ring systems in which one or more rings are aromatic and one or more rings are saturated or unsaturated, such as aceanthrene, acenaphthylene, acephenanthrene, anthracene, azulene, benzene, Coronene, fluoranthene, fluorene, hexylene, hexylphene, hexyltriene, asymmetric indene, symmetric indene, indane, indene, naphthalene, octylene, octylphene, octyltriene, ovalene, pentacene, pentylene, pentylphene, perylene, phenanthren, phenanthren, heptacyclopentadiene, phenanthrene, pyrene, pyranthene, rubrene, triphenylene, trinaphthoacene, etc.

[0070] "Parent heteroaromatic ring system" refers to a parent aromatic ring system in which one or more carbon atoms (and optionally any associated hydrogen atoms) are each independently replaced by the same or different heteroatoms. Typical heteroatoms replacing carbon atoms include, but are not limited to, N, P, O, S, Si, etc. Specifically included within the definition of "parent heteroaromatic ring system" are fused ring systems in which one or more rings are aromatic and one or more rings are saturated or unsaturated, such as arsine, carbazole, β-carboline, chroman, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perylidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like.

[0071] "Pharmaceutically acceptable salts" refer to salts of compounds that possess the desired pharmacological activity of the parent compound. These salts include: (1) acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, (1) a salt formed when the acidic proton present in the parent compound is replaced by a metal ion (e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion); or a coordination compound with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, or the like.

[0072] "Preventing" or "prevention" refers to reducing the risk of developing a disease or condition (i.e., preventing a patient who may be exposed to or susceptible to the disease but has not yet experienced or shown symptoms of the disease from developing at least one clinical symptom of the disease). The use of treatment to prevent or prevent a disease or condition is called "prevention". In certain aspects, the compounds provided herein provide a better preventive effect due to lower long-term side effects.

[0073] As used herein, "prodrug" refers to a derivative of a drug molecule that requires transformation in vivo to release the active drug. A prodrug is usually (but not necessarily) inactive until it is converted into the parent drug.

[0074] As used herein, "pro-proliferative" refers to a form of protecting group that, when used to mask a functional group within a drug molecule, converts the drug into a prodrug. Typically, primary cells bind to the drug with a bond that is cleaved by enzymatic or non-enzymatic means in vivo.

[0075] "Protecting group" refers to a group of atoms that, when attached to a reactive functional group in a molecule, masks, reduces or prevents the reactivity of the functional group during chemical synthesis. Examples of protecting groups can be found in "Protective Groups in Organic Chemistry" by Green et al. (Wiley, 2nd Edition, 1991) and "Compendium of Synthetic Organic Methods" by Harrison et al., Vol. 1-8 (John Wiley and Sons, 1971-1996). Representative amino protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl ("CBZ"), tert-butyloxycarbonyl ("Boc"), trimethylsilyl ("TMS"), 2-trimethylsilylethanesulfonyl ("SES"), trityl and substituted trityl, allyloxycarbonyl, 9-fluorenylmethoxycarbonyl ("FMOC"), nitroisopropoxycarbonyl ("NVOC"), and the like. Representative hydroxy protecting groups include, but are not limited to, acylated or alkylated hydroxy protecting groups such as benzyl, trityl ether, and alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers, and allyl ethers.

[0076] "Spirocycloheteroalkyl" by itself or as part of another substituent refers to a bicyclic alkyl structure which shares one atom and contains at least one heteroatom independently selected from N, O and S in the ring(s).

[0077] "Solvation" refers to the incorporation of a solvent into the crystal lattice of a compound described herein in a stoichiometric ratio to form an adduct. Methods for preparing solvates include, but are not limited to, storage in an atmosphere containing a solvent, a dosage form containing a solvent, or conventional drug processing steps, such as crystallization (i.e., crystallization from a solvent or a mixed solvent), vapor diffusion, etc. In some cases, solvates may also be formed by other crystalline solvates or hydrates when exposed to a solvent or a suspended material in a solvent. Solvates may crystallize in a variety of forms, resulting in solvate polymorphism. See, for example (GuilloRy, K., Chapter 5, pp. 202-205, Polymorphism in Pharmaceutical Solids, (Brittain, H. ed.), MaRcel DekkeR, Inc., New York, NY, 1999). The above-mentioned methods for preparing solvates are completely within the scope of those skilled in the art, are completely routine, and do not require any experiments beyond the typical scope of the art. Solvates can be characterized and / or analyzed by methods well known to those skilled in the art, such as single crystal X-ray diffraction, X-ray powder diffraction, polarized optical microscopy, thermal microscopy, thermogravimetric analysis, differential thermal analysis, differential scanning calorimetry, infrared spectroscopy, Raman spectroscopy, and nuclear magnetic resonance spectroscopy. (Brittain, H., Chapter 6, pages 205-208, Polymorphism in Pharmaceutical Solids, (Brittan, H. ed), Marcel Dekke, Inc., New York, 1999). In addition, many commercial companies routinely provide services including the preparation and / or characterization of solvates, such as HOLODIAG, Pharmaparc II, Voie de l'Innovation, 27100 Val de Reuil, France (http: / / www.holodiag.com).

[0078] When used to modify a specific group or radical, "substituted" means that one or more hydrogen atoms of the specific group or radical are independently replaced by the same or different substituents. Substituents used to replace saturated carbon atoms in the specified group or radical include R a , halogen, -O - ,=O,-OR b 、-SR b , -S - , =S, -NR c R c , =NR b , =N-OR b , trihalomethyl, -CF 3 , -CN, -OCN, -SCN, -NO, -NO 2 、-N-ORb 、-N-NR c R c 、-NR b S(O) 2 R b 、=N 2 、-N 3 、-S(O) 2 R b 、-S(O) 2 NR b R b 、-S(O) 2 O - 、-S(O) 2 OR b 、-OS(O) 2 R b 、-OS(O) 2 O - 、-OS(O) 2 OR b 、-OS(O) 2 NR c NR c 、-P(O)(O - ) 2 、-P(O)(OR b )(O - )、-P(O)(OR b )(OR b )、-C(O)R b 、-C(O)NR b -OR b -C(S)R b 、-C(NR b )R b 、-C(O)O - 、-C(O)OR b 、-C(S)OR b 、-C(O)NR c R c 、-C(NR b )NR c R c 、-OC(O)R b 、-OC(S)R b 、-OC(O)O - 、-OC(O)OR b 、-OC(O)NR c R c 、-OC(NCN)NR c R c -OC(S)OR b 、-NR b C(O)Rb 、-NR b C(S)R b 、-NR b C(O)O - 、-NR b C(O)OR b 、-NR b C(NCN)OR b 、-NR b S(O) 2 NR c R c 、-NR b C(S)OR b 、-NR b C(O)NR c R c 、-NR b C(S)NR c R c 、-NR b C(S)NR b C(O)R a 、-NR b S(O) 2 OR b 、-NR b S(O) 2 R b 、-NR b C(NCN)NR c R c 、-NR b C(NR b )R b and-NR b C(NR b )NR c R c , where each R a are independently aryl, substituted aryl, heteroalkyl, substituted heteroalkyl, heteroaryl or substituted heteroaryl; each R b is independently hydrogen, alkyl, heteroalkyl, substituted heteroalkyl, aralkyl, substituted aralkyl, heteroaralkyl, or substituted heteroaralkyl; and each R c Independently for R b , or, two R c Together with the nitrogen atom to which they are bound, they form a 4-, 5-, 6- or 7-membered cycloheteroalkyl, a substituted cycloheteroalkyl or a cycloheteroalkyl fused to an aryl group, which may optionally include 1 to 4 additional heteroatoms selected from O, N and S which may be the same or different. As a specific example, NR c R c Means include -NH 2, -NH-alkyl, N-pyrrolidinyl and N-morpholinyl. In other aspects, substituents that can be used to replace saturated carbon atoms in a given group or radical include R a , halogen, OR b NR c R c , trihalomethyl, -CN, -NR b S(O) 2 R b 、-C(O)R b 、-C(O)NR b -OR b 、-C(O)OR b 、-C(O)NR c R c 、-OC(O)R b 、-OC(O)OR b 、-OS(O) 2 NR c NR c 、-OC(O)NR c R c , and -NR b C(O)OR b , wherein each Ra is independently aryl, substituted aryl, heteroalkyl, and each R b are independently hydrogen, R a , heteroalkyl, aralkyl, heteroaralkyl; and each R c Independently for R b , or alternatively, two R c Together with the nitrogen atom to which they are bound, they form a 4-, 5-, 6-, or 7-membered cycloheteroalkyl ring. In other aspects, substituents that can be used to replace saturated carbon atoms in the specified groups or radicals include R a , halogen, -OR b 、-NR c R c , trihalomethyl, -CN, -C(O)R b 、-C(O)OR b 、-C(O)NR c R c 、-OC(O)R b 、-OC(O)NR c R c and-NR b C(O)OR b ; and each R c Independently for R b , or, two Rc together with the nitrogen atom to which they are bound form a 4-, 5-, 6- or 7-membered cycloheteroalkyl ring.

[0079] Substituents for replacing unsaturated carbon atoms in a given group or radical include -R a , halogen, -O - 、-OR b 、-SR b , -S - 、-NR c R c , trihalomethyl, -CF 3 , -CN, -OCN, -SCN, -NO, -NO 2 、-N 3 、-S(O) 2 O - 、-S(O) 2 OR b 、-OS(O) 2 R b 、-OS(O) 2 OR b 、-OS(O) 2 O - 、-P(O)(O - ) 2 、-P(O)(OR b )(O - )、-P(O)(OR b )(OR b )、-C(O)R b 、-C(S)R b 、-C(NR b )R b 、-C(O)O - 、-C(O)OR b 、-C(S)OR b 、-C(O)NR c R c 、-C(NR b )NR c R c 、-OC(O)R b 、-OC(S)R b 、-OC(O)O - 、-OC(O)OR b 、-OC(S)OR b 、-OC(O)NR c R c 、-OS(O) 2 NR c NR c 、-NR b C(O)R b 、-NR b C(S)R b 、-NR bC(O)O - 、-NR b C(O)OR b 、-NR b S(O) 2 OR a 、-NR b S(O) 2 R a 、-NR b C(S)OR b 、-NR b C(O)NR c R c 、-NR b C(NR b )R b 、-NR b C(NR b )NR c R c and -C(NR b )NR b C(NR b )NR c R c , where R a , R b and R c As described above. In other aspects, substituents that can be used to replace unsaturated carbon atoms in a given group or radical include -R a , halogen, -OR b 、-SR b 、-NR c R c , trihalomethyl, -CN, -S(O) 2 OR b 、-C(O)R b 、-C(O)OR b 、-C(O)NR c R c 、-OC(O)R b 、-OC(O)OR b 、-OS(O) 2 NR c NR c 、-NR b C(O)R b and-NR b C(O)OR b , where R a , R b and R c As described above. In some other aspects, substituents that can be used to replace unsaturated carbon atoms in a given group or free radical include -R a , halogen, -ORb 、-NR c R c , trihalomethyl, -S(O) 2 OR b 、-C(O)R b 、-C(O)OR b 、-C(O)NR c R c 、-OC(O)R b 、-NR b C(O)R b and-NR b C(O)OR b , where R a , R b and R c As mentioned before.

[0080] Substituents that may be used to replace the nitrogen atoms in heteroalkyl and cycloheteroalkyl include, but are not limited to, -R a , -O - 、-OR b 、-SR b , -S - 、-NR c R c , trihalomethyl, -CF 3 、-CN、-NO、-NO 2 、-S(O) 2 R b 、-S(O) 2 O - 、-S(O) 2 OR b 、-OS(O) 2 R b 、-OS(O) 2 O - 、-OS(O) 2 OR b 、-P(O)(O - ) 2 、-P(O)(OR b )(O - )、-P(O)(OR b )(OR b )、-C(O)R b 、-C(S)R b 、-C(NR b )R b 、-C(O)OR b 、-C(S)OR b 、-C(O)NR c R c 、-C(NR b)NR c R c 、-OC(O)R b 、-OC(S)R b 、-OC(O)OR b 、-OC(S)OR b 、-NR b C(O)R b 、-NR b C(S)R b 、-NR b C(O)OR b 、-NR b C(S)OR b 、-NR b C(O)NR c R c 、-NR b C(NR b )R b 、-NR b C(NR b )NR c R c and -C(NR b )NR b C(NR b )NR c R c , where R a , R b and R c As described above. In some aspects, substituents that can be used to replace nitrogen atoms in heteroalkyl and cycloheteroalkyl include R a , halogen, -OR b 、-NR c R c , trihalomethyl, -CN, -S(O) 2 OR b 、-OS(O) 2 R b 、-C(O)R b 、-C(NR b )R b 、-C(O)OR b 、-C(O)NR c R c 、-OC(O)R b 、-OC(O)OR b 、-OS(O) 2 NR c NR c 、-NR b C(O)R b and-NR b C(O)OR b, where R a , R b and R c As described above. In other aspects, substituents that can be used to replace nitrogen atoms in heteroalkyl and cycloheteroalkyl include R a , halogen, -OR b 、-NR c R c , trihalomethyl, -CN, -S(O) 2 OR b 、-C(O)R b 、-C(NR b )R b 、-C(O)OR b 、-C(O)NR c R c 、-OC(O)R b 、-NR b C(O)R b and-NR b C(O)OR b , where R a , R b and R c As mentioned before.

[0081] It will be apparent to one skilled in the art that substituents from the above list may be substituted for other specific groups or atoms.

[0082] Substituents used to replace a particular group may be further substituted, typically with one or more of the same or different groups selected from the various groups described above.

[0083] "Subject," "individual," or "patient" are used interchangeably herein and refer to vertebrates, preferably mammals. Mammals include, but are not limited to, mice, rodents, monkeys, humans, farm animals, sports animals, and pets. In certain aspects, the subject, individual, or patient is a member of the species Homo sapiens. In other aspects, the subject, individual, or patient includes all mammals except Homo sapiens.

[0084] In certain aspects, "treating" or "treatment" of any disease or condition refers to ameliorating the disease or condition (i.e., preventing or reducing the development of the disease or at least one of its clinical symptoms). Treatment may also be considered to include preemptive or prophylactic administration to improve, prevent or prevent the development of the disease or at least one clinical symptom. In another feature, the treatment provided is less likely to produce long-term side effects over many years. In other aspects, "treating" or "treatment" refers to improving at least one physical parameter that the patient may not be able to discern. In other aspects, "treating" or "treatment" refers to inhibiting a disease or condition physically (e.g., stabilization of discernible symptoms), physiologically (e.g., stabilization of physical parameters), or both. In other aspects, "treating" or "treatment" refers to delaying the onset of a disease or condition.

[0085] "Therapeutically effective amount" means the amount of a compound that, when administered to a patient for treating a disease, is sufficient to treat the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, adsorption, distribution, metabolism and excretion of the patient to be treated.

[0086] "Vehicle" refers to a diluent, excipient or carrier for administering a compound to a subject. In certain aspects, the vehicle is pharmaceutically acceptable.

[0087] Compound

[0088] Provided herein are compounds of formula (I): or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein: R 1 Yes - H, R 8 C(O)- R 2 Yes -H or R 9 C(O)-;R 3 Yes -H or R 10 C(O)-;R 4 is -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl, R 11 C(O)- or R 6 is -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl; R 5 , R 7 , R 8 , R 9, R 10 and R 11 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl or substituted heteroaralkyl; provided that R 1 or R 4 At least one of

[0089] In some embodiments, R 4 is -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, R 11 C(O)- or In other embodiments, R 4 is -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, R 11 C(O)- or In other embodiments, R 4 is an alkyl, alkenyl, R 11 C(O)- or

[0090] In some embodiments, R 8 , R 9 , R 10 and R 11 R is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, aralkyl, heteroaryl or heteroaralkyl. 8 and R 11 is alkyl, substituted alkyl, alkenyl, substituted alkenyl or heteroaryl, R 9 and R 10 is independently alkyl, substituted alkyl, alkenyl or substituted alkenyl. In other embodiments, R 8 and R 11 is alkyl, substituted alkyl, alkenyl, substituted alkenyl or heteroaryl, R 9 and R 10 Independently CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH3 ) 2 In some other embodiments, R 8 and R 11 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 or heteroaryl, R 9 and R 10 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 In some other embodiments, R 9 and R 10 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 , or -CH(NH 2 )CH(CH3 ) 2 .

[0091] In some embodiments, R 1 for

[0092] In some embodiments, R 5 is alkyl, alkenyl, aryl, substituted aryl, aralkyl, heteroaryl or heteroaralkyl. In other embodiments, R 5 is alkyl, alkenyl, aryl or substituted aryl. In other embodiments, R 5 It is an aromatic group.

[0093] In some embodiments, R 6 is -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, aralkyl, heteroaryl or heteroaralkyl. 6 is -H, alkyl, substituted alkyl, aralkyl or heteroaralkyl.

[0094] In some embodiments, R 7 is alkyl, alkenyl, aryl, substituted aryl, aralkyl, heteroaryl or heteroaralkyl. In other embodiments, R 7 It is an alkyl group, an alkenyl group or an aralkyl group.

[0095] In some embodiments, R 5 is an alkyl, alkenyl, aryl or substituted aryl group, R 6 is alkyl, substituted alkyl, aralkyl or heteroaralkyl, R 7 is alkyl, alkenyl or aralkyl. In other embodiments, R 5 is an aryl group or an aralkyl group, R 6 is alkyl, substituted alkyl, aralkyl or heteroaralkyl, R 7 It is an alkyl group, an alkenyl group or an aralkyl group.

[0096] In some embodiments, there is provided structural formula (II) In other embodiments, R 9 , R 10 and R 11 is independently alkyl or substituted alkyl. In other embodiments, R 9 , R 10 and R 11 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 , or -CH(NH 2 )CH(CH 3 ) 2 .

[0097] In some embodiments, R 2 YesR 9 C(O)-,R 3 YesR 10 C(O)-,R 4 is -H. In other embodiments, R 9 and R 10 is independently alkyl or substituted alkyl. In other embodiments, R 9 and R 10 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 .

[0098] In some embodiments, R 2 YesR 9 C(O)-,R 3 YesR 10 C(O)-,R 4 YesR 11 C(O)-. In other embodiments, R 9 and R 10 is independently alkyl or substituted alkyl. In other embodiments, R 9 and R 10 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 .

[0099] In some embodiments, R 2 YesR 9 C(O)-,R 3 YesR 10 C(O)-,R 4 YesR 11 C(O)-. In other embodiments, R 9 , R 10 and R 11 is independently alkyl or substituted alkyl. In other embodiments, R 9 , R 10 and R 11 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 .

[0100] In some embodiments, R 2 Yes - H, R 3 YesR 10 C(O)-,R 4 YesR 11 C(O)-. In other embodiments, R 10 and R 11 is independently alkyl or substituted alkyl. In other embodiments, R 10 and R 11 independently -CH 3 , -C2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 .

[0101] In some embodiments, R 2 YesR 9 C(O)-,R 3 Yes - H, R 4 YesR 11 C(O)-. In other embodiments, R 9 and R 11 is independently alkyl or substituted alkyl. In other embodiments, R 9 and R 11 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 .

[0102] In some embodiments, there is provided structural formula (III) In some embodiments, R 8 , R 9 and R 10 is independently alkyl or substituted alkyl. In other embodiments, R 8 , R 9 and R 10 independently -CH 3 , -C 2 H5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 .

[0103] In some embodiments, R 1 YesR 8 C(O)-,R 2 YesR 9 C(O)-,R 3 YesR 10 C(O)-. In other embodiments, wherein R 8 , R 9 and R 10 is independently alkyl or substituted alkyl. In other embodiments, R 8 , R 9 and R 10 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 .

[0104] In some embodiments, R 1 Yes - H, R 2 YesR 2 YesR 9 C(O)-,R 3 YesR 10 C(O)-. In other embodiments, R 9 and R 10is independently alkyl or substituted alkyl. In other embodiments, R 9 and R 10 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 .

[0105] In some embodiments, R 1 YesR 8 C(O)-,R 2 Yes - H, R 3 YesR 10 C(O)-. In other embodiments, R 8 and R 10 is independently alkyl or substituted alkyl. In other embodiments, R 8 and R 10 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 .

[0106] In some embodiments, R 1 YesR 8 C(O)-,R 2 YesR 9 C(O)-,R 3 is -H. In other embodiments, R8 and R 9 is independently alkyl or substituted alkyl. In other embodiments, R 8 and R 9 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 .

[0107] In some embodiments, there is provided a compound of formula (IV) In other embodiments, R 9 and R 10 is independently alkyl or substituted alkyl. In some other embodiments, R 9 and R 10 Each is independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 .

[0108] In some embodiments, R 2 YesR 9 C(O)-,R 3 YesR 10 C(O)-,R 9 and R 10 is independently alkyl or substituted alkyl. 5 is an aryl group or an aralkyl group, R6 is alkyl, substituted alkyl, aralkyl or heteroaralkyl, R 7 is alkyl, alkenyl or aralkyl. In other embodiments, R 9 and R 10 independently -CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 In some other embodiments, R 5 is phenyl, naphthyl or benzyl, R 6 Yes CH 3 , -C 2 H 5 , R 7 Yes-CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 Or cyclopropyl.

[0109] In some embodiments, R 2 Yes - H, R 3 YesR 10 C(O)-,R 10 is alkyl or substituted alkyl. In other embodiments, R 5 is an aryl group or an aralkyl group, R 6 is alkyl, substituted alkyl, aralkyl or heteroaralkyl, R 7 is alkyl, alkenyl or aralkyl. In other embodiments, R 10 Yes-CH 3 , -C 2H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 In some other embodiments, R 5 is an aryl group or an aralkyl group, R 6 is alkyl, substituted alkyl, aralkyl or heteroaralkyl, R 7 is alkyl, alkenyl or aralkyl. In other embodiments, R 5 is phenyl, naphthyl or benzyl, R 6 Yes CH 3 , -C 2 H 5 , R 7 Yes-CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 Or cyclopropyl.

[0110] In some embodiments, R 2 YesR 9 C(O)-,R 3 Yes - H, R 9 is alkyl or substituted alkyl. In other embodiments, R 5 is an aryl group or an aralkyl group, R 6 is alkyl, substituted alkyl, aralkyl or heteroaralkyl, R 7 is alkyl, alkenyl or aralkyl. In other embodiments, R 9 Yes-CH 3 , -C 2 H 5 , -C 3 H7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 or -CH(NH 2 )CH(CH 3 ) 2 In some other embodiments, R 5 is phenyl, naphthyl or benzyl, R 6 Yes CH 3 , -C 2 H 5 , R 7 Yes-CH 3 , -C 2 H 5 , -C 3 H 7 、-CH(CH 3 ) 2 、-CH 2 CH(CH 3 ) 2 、-CH(C 2 H 5 )(CH 2 ) 2 CH 3 Or cyclopropyl.

[0111] Table 1 below provides exemplary compounds.

[0112] Table 1

[0113]

[0114] The above compounds can be prepared by well-known methods, some of which are exemplified in the experimental part.

[0115] Ingredients and administration method

[0116] The compositions provided herein contain an effective therapeutic amount of one or more compounds provided herein and a carrier, which can be used to prevent, treat or improve one or more symptoms of a disease or condition described herein. Carriers suitable for administration of the compounds provided herein include any such carriers known to those skilled in the art to be suitable for a specific mode of administration. In addition, the compound can be formulated as the sole active ingredient in the composition or in combination with other active ingredients.

[0117] The composition comprises one or more compounds provided herein. In some embodiments, the compound is formulated into a suitable preparation, such as a solution, suspension, tablet, dispersible tablet, pill, capsule, powder, sustained-release preparation or elixir, for oral administration, or formulated into a sterile solution or suspension for parenteral administration, as well as topical administration, transdermal administration, intrathecal administration and oral inhalation by a nebulizer, a pressurized metered-dose inhaler and a dry powder inhaler. In some embodiments, the above-mentioned compound is formulated into a composition using techniques and procedures well known in the art (see, for example, Ansel, Introduction to Pharmaceutical Dosage Forms, Seventh Edition (1999)).

[0118] In the composition, an effective concentration of one or more compounds or derivatives thereof is mixed with a suitable carrier. As described above, before preparation, the compound can be derived into a corresponding salt, ester, enol ether or ester, acetal, ketal, orthoester, hemiacetal, hemiketal, acid, base, solvate, ion pair, hydrate or prodrug. The concentration of the compound in the composition can effectively deliver a certain amount of medicine after administration to treat, prevent or improve the symptoms of one or more diseases or conditions described herein. In some embodiments, the composition is formulated for single dose administration. In order to prepare the composition, the weight fraction of the compound is dissolved, suspended, dispersed or otherwise mixed in a selected carrier at an effective concentration to alleviate, prevent or improve one or more symptoms.

[0119] The active compound is contained in a carrier in an amount sufficient to exert a therapeutically useful effect without adverse side effects in the patient being treated. Effective therapeutic concentrations can be predicted empirically by testing the compound in in vitro and in vivo systems well known to those skilled in the art, and then human doses can be extrapolated therefrom. Human doses are then typically fine-tuned in clinical trials and titrated based on response.

[0120] The concentration of the active compound in the composition will depend on the absorption, inactivation and excretion rates of the active compound, the physicochemical properties of the compound, the dosing regimen and the amount of administration, and other factors known to those skilled in the art. For example, the amount delivered is sufficient to improve the symptoms of one or more diseases or disorders described herein.

[0121] In the case where the compound exhibits insufficient solubility, methods for solubilizing the compound can be used, such as the use of liposomes, prodrugs, complexation / chelation, nanoparticles or emulsions or tertiary templates. These methods are known to those skilled in the art and include, but are not limited to, the use of cosolvents, such as dimethyl sulfoxide (DMSO), the use of surfactants or surface modifiers, such as Complexing agents, such as cyclodextrins, or by enhanced ionization solubility (ie, solubilization in aqueous sodium bicarbonate). Derivatives of the compounds, such as prodrugs of the compounds, may also be used to formulate effective compositions.

[0122] After mixing or adding the compounds, the resulting mixture can be a solution, suspension, emulsion, etc. The form of the resulting mixture depends on many factors, including the intended mode of administration and the solubility of the compound in the selected carrier. The effective concentration is sufficient to improve the symptoms of the disease, disorder or condition being treated and can be determined empirically.

[0123] The composition is provided to humans and animals in a dosage form suitable for the indication, such as dry powder inhaler (DPI), pressurized metered dose inhaler (pMDI), nebulizer, tablet, capsule, pill, sublingual tape / bioerodible strip, tablet or capsule, powder, granule, lozenge, emulsion, ointment, suppository, fast dissolving agent, transdermal patch or other transdermal application device / preparation, sterile parenteral solution or suspension, oral solution or suspension, and oil-water emulsion containing an appropriate amount of compound or its derivative. In some embodiments, the therapeutically active compound and its derivative are formulated and administered in unit dosage form or multiple dosage forms. The unit dosage form used herein refers to a physically discrete unit known in the art that is suitable for human and animal subjects and packaged separately. Each unit dose contains a predetermined amount of the therapeutically active compound, sufficient to produce the desired therapeutic effect, and is combined with the desired carrier. Examples of unit dosage forms include ampoules and syringes and individually packaged tablets or capsules. The unit dosage form can be administered in divided doses or multiple doses. Multiple dosage forms are multiple identical unit dosage forms packaged in a single container, administered in separate unit dosage forms. Examples of multiple dose forms include vials, bottles of tablets or capsules, or pint or gallon bottles. Thus, a multiple dose form is a multiple of unit doses that are not isolated in a package.

[0124] For example, liquid compositions can be prepared by dissolving, dispersing or otherwise mixing the active compound as described above and an optional adjuvant in a carrier, such as water, saline, aqueous glucose, glycerol, glycol, ethanol, etc., to form a solution or suspension, colloidal dispersion, emulsion or liposome formulation. If necessary, the composition to be administered may also contain a small amount of non-toxic auxiliary substances, such as wetting agents, emulsifiers, solubilizers, pH buffers, etc., such as acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate and other such agents.

[0125] Actual methods for preparing such dosage forms will be known or apparent to those skilled in the art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 15th edition, 1975 or subsequent editions thereof.

[0126] Dosage forms or compositions containing 0.005% to 100% active ingredient can be prepared, with the balance being made up of carrier or carriers. Methods for preparing these compositions are known to those skilled in the art. The contemplated composition may contain 0.001%-100% active ingredient, in one embodiment 0.1-95%, and in another embodiment 0.4-10%.

[0127] In certain embodiments, the composition is a lactose-free composition containing excipients well known in the art, such as those listed in US Pharmacopeia (USP) 25-NF20 (2002). Generally speaking, a lactose-free composition contains an active ingredient, a binder / filler, and a lubricant in equal amounts. A specific lactose-free dosage form contains an active ingredient, microcrystalline cellulose, pregelatinized starch, and magnesium stearate.

[0128] Anhydrous compositions and dosage forms comprising active ingredients are further provided, because water can promote the degradation of certain compounds. For example, adding water (e.g., 5%) is widely accepted as a means of simulating long-term storage to determine characteristics such as shelf life or stability of formulations over time. For example, see Jens T.Carstensen, Drug Stability:Principles & Practice, 2d.Marcel Dekker, NY, NY, 1995, pages 379-80. In fact, water and heat can accelerate the decomposition of certain compounds. Therefore, the effect of water on the formulation may be of great significance because moisture and / or humidity are often encountered during the manufacture, handling, packaging, storage, shipment, and use of the formulation.

[0129] Anhydrous compositions and dosage forms provided herein can be prepared using anhydrous or low moisture ingredients and low moisture or low humidity conditions.

[0130] Anhydrous compositions should be prepared and stored so as to maintain their anhydrous nature. Accordingly, anhydrous compositions are typically packaged using materials known to prevent exposure to water so that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, sealed foils, plastics, unit dose containers (such as vials), blister packs, and strip packs.

[0131] Oral dosage forms can be solid, gel or liquid. Solid dosage forms are tablets, capsules, granules and bulk powders. Types of oral tablets include compressed chewable lozenges and enteric, sugar-coated or film-coated tablets. Capsules can be hard or soft gelatin capsules, while granules and powders can be provided in non-effervescent or effervescent form in combination with other ingredients known to those skilled in the art.

[0132] In certain embodiments, the preparation is a solid dosage form, such as a capsule or tablet. Tablets, pills, capsules, lozenges, etc. may contain one or more of the following ingredients or compounds of similar nature: binder; lubricant; diluent; glidant; disintegrant; colorant; sweetener; flavoring agent; wetting agent; enteric coating; film coating agent and modified release agent. Examples of binders include microcrystalline cellulose, methylparaben, polyoxyalkylene, tragacanth, glucose solution, gum arabic mucus, gelatin solution, molasses, polyvinylpyrrolidine, povidone, crospovidone, sucrose and starch and starch derivatives. Lubricants include talc, starch, magnesium stearate / calcium, lycopodium and stearic acid. Diluents include, for example, lactose, sucrose, trehalose, lysine, leucine, lecithin, starch, kaolin, salt, mannitol and calcium hydrogen phosphate. Flow aids include but are not limited to colloidal silicon dioxide. Disintegrants include cross-linked sodium carboxymethylcellulose, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose. Colorants include, for example, any approved water-soluble FD and C dyes, and mixtures thereof; and water-insoluble FD and C dyes suspended on alumina hydrate, and advanced coloring or anti-counterfeiting color / milky additives known to those skilled in the art. Sweeteners include sucrose, lactose, mannitol and artificial sweeteners, such as saccharin and any number of spray-dried spices. Flavoring agents include natural flavors extracted from plants such as fruits, and synthetic mixtures of compounds that produce a pleasant sensation or mask unpleasant tastes, such as, but not limited to, mint and methyl salicylate. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol laurate and polyoxyethylene lauryl ether. Enteric coatings include fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate phthalate. Film coating agents include hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Modified release agents include polymers such as Series and cellulose esters.

[0133] The compound or its derivative can be provided in the form of a composition that protects it from the acidic environment of the stomach. For example, the composition can be formulated into an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition can also be formulated in combination with an antacid or other such ingredients.

[0134] When the dosage unit form is a capsule, it may contain, in addition to materials of the types described above, a liquid carrier such as a fatty oil. In addition, the dosage unit form may contain various other materials that modify the physical form of the dosage unit, such as coatings of sugar and other enteric agents. The compounds may also be administered as a component of elixirs, suspensions, syrups, wafers, sprays, chewing gum, and the like. In addition to the active compound, a syrup may contain sucrose as a sweetener and certain preservatives, dyes, colors, and flavors.

[0135] The active material may also be combined with other active materials that do not impair the desired effect or that supplement the desired effect (e.g., antacids, H 2 The active ingredient is a compound as described herein or a derivative thereof. A higher concentration of up to about 98 wt.% of the active ingredient may be included.

[0136] In all embodiments, tablets and capsule formulations may be coated as known to those skilled in the art to modify or sustain the dissolution of the active ingredient. Thus, for example, they may be coated with conventional enteric coatings such as phenyl salicylate, waxes and cellulose acetate phthalate.

[0137] Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and / or suspensions reconstituted from non-effervescent granules, and effervescent preparations reconstituted from effervescent granules. Aqueous solutions include, for example, elixirs and syrups. Emulsions are either oil-in-water or water-in-oil.

[0138] An elixir is a clear, sweetened, hydroalcoholic preparation. Carriers used in elixirs include solvents. A syrup is a concentrated aqueous solution of a sugar, such as sucrose, that may contain a preservative. An emulsion is a two-phase system in which one liquid is dispersed in the form of globules throughout another liquid. Carriers used in emulsions are a non-aqueous liquid, an emulsifier, and a preservative. Suspensions use a suspending agent and a preservative. Acceptable substances used in non-effervescent granules, which can be reconstituted into a liquid oral dosage form, include diluents, sweeteners, and wetting agents. Acceptable substances in effervescent granules, which can be reconstituted into a liquid oral dosage form, include organic acids and a source of carbon dioxide. Colorants and flavoring agents are used in all of the above dosage forms.

[0139] Solvents include glycerol, sorbitol, ethanol and syrup. Examples of preservatives include glycerol, methyl and propyl parabens, benzoic acid, sodium benzoate and ethanol. Examples of non-aqueous liquids used in emulsions include mineral oil and cottonseed oil. Examples of emulsifiers include gelatin, gum arabic, tragacanth, bentonite and surfactants such as polyoxyethylene sorbitan monooleate. Suspending agents include sodium carboxymethylcellulose, pectin, tragacanth, Veegum and gum arabic. Sweeteners include artificial sweeteners such as sucrose, syrup, glycerol and saccharin. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol laurate and polyoxyethylene lauryl ether. Organic acids include citric acid and tartaric acid. Sources of carbon dioxide include sodium bicarbonate and sodium carbonate. Colorants include any approved water-soluble FD and C dyes and mixtures thereof. Flavoring agents include natural flavors extracted from plants such as fruits, as well as synthetic mixtures of compounds that produce a pleasant taste.

[0140] For solid dosage forms, solutions or suspensions, such as propylene carbonate, vegetable oils or triglycerides, are encapsulated in gelatin capsules in some embodiments. Such solutions and their preparation and packaging are disclosed in U.S. Patent Nos. 4,328,245; 4,409,239 and 4,410,545. For liquid dosage forms, solutions, such as solutions in polyethylene glycol, can be diluted with a sufficient amount of a liquid carrier (e.g., water) for easy measurement of dosing.

[0141] Alternatively, liquid or semisolid oral preparations can be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (such as propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells. Other useful formulations include those proposed in U.S. Pat. Nos. RE28,819 and 4,358,603. Briefly, such formulations include, but are not limited to, formulations containing a compound provided herein, a dialkylated mono- or polyalkylene glycol, including but not limited to 1,2-dimethoxyethane, diethylene glycol dimethyl ether, triethylene glycol dimethyl ether, tetraethylene glycol diethyl ether, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, polyvinyl alcohol-750-dimethyl ether, wherein 350, 550 and 750 refer to the approximate average molecular weight of the polyethylene glycol, and one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, thiodipropionic acid and its esters and dithiocarbamates.

[0142] Other preparations include, but are not limited to, aqueous alcohol solutions containing acetals. The alcohol used in these preparations is any water-soluble solvent having one or more hydroxyl groups, including but not limited to propylene glycol and ethanol. Acetals include, but are not limited to, di(lower alkyl) acetals of lower alkyl aldehydes, such as acetaldehyde diethyl acetal.

[0143] In some embodiments characterized by injection, parenteral administration by subcutaneous, intramuscular, intrathecal or intravenous injection is also contemplated herein. Injections can be prepared in conventional forms, can be liquid solutions or suspensions, can be solid forms suitable for dissolving or suspending in liquids before injection, or can be emulsions. Injections, solutions and emulsions also contain one or more excipients. Suitable excipients are, for example, water, saline, glucose, glycerol or ethanol. In addition, if desired, the composition to be administered can also contain a small amount of non-toxic auxiliary substances, such as wetting agents or emulsifiers, pH buffers, stabilizers, solubilizers and other such agents, such as sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.

[0144] Implantation of a slow-release or sustained-release system to maintain a constant dosage level is also contemplated herein (see, e.g., U.S. Pat. No. 3,710,795). Briefly, the compounds provided herein are dispersed in a solid internal matrix, such as polymethyl methacrylate, butyl methacrylate, plasticized or unplasticized polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubber, polydimethylsiloxane, carbonated silicone copolymers, hydrophilic polymers such as hydrogels of acrylates and methacrylates, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate, which is insoluble in the body. The composition is preferably a parenteral composition, wherein the composition is surrounded by an outer polymer membrane of a liquid such as polyethylene, polypropylene, ethylene / propylene copolymer, ethylene / ethyl acrylate copolymer, ethylene / vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, chloroprene rubber, chlorinated polyethylene, polyvinyl chloride, copolymers of vinyl chloride and vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber, epichlorohydrin rubber, ethylene / vinyl alcohol copolymer, ethylene / vinyl acetate / vinyl alcohol terpolymer and ethylene / vinyloxyethanol copolymer. In the release rate controlling step, the compound diffuses through the outer polymer membrane. The percentage of active compound contained in such parenteral compositions is highly dependent on its specific properties, the activity of the compound and the needs of the subject.

[0145] Parenteral administration of the composition includes intravenous, subcutaneous, intrathecal and intramuscular administration. Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products ready to be mixed with solvents before use, such as lyophilized powders, including subcutaneous injection tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be mixed with excipients before use, and sterile emulsions. The solution can be aqueous or non-aqueous.

[0146] If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol and polypropylene glycol, and mixtures thereof.

[0147] Carriers used in parenteral preparations include aqueous carriers, non-aqueous carriers, antibacterial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifiers, chelating agents and other substances.

[0148] Examples of aqueous vehicles include sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringer's injection. Non-aqueous injection vehicles include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil. Antimicrobial agents in bacteriostatic or bacteriostatic concentrations must be added to parenteral preparations packaged in multiple-dose containers, and these include phenols or cresols, mercury, benzyl alcohol, chlorobutanol, methyl and propyl parabens, thimerosal, benzalkonium chloride and phenethonium chloride. Isotonic agents include sodium chloride and dextrose. Buffers include phosphates and citrates. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifiers include polysorbate 80 80). Chelating agents for metal ions include EDTA. Carriers also include ethanol, polyethylene glycol and propylene glycol for water-soluble carriers; and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.

[0149] The concentration of the compound is adjusted so that the injection provides an effective amount to produce the desired pharmacological effect. The exact dose depends on the age, weight, body surface area and condition of the patient or animal as known in the art.

[0150] The unit dose parenteral preparation is packaged in an ampoule, a vial or a syringe with a needle. As is known and practiced in the art, all preparations for parenteral administration must be sterile.

[0151] For example, intravenous or intra-arterial infusion of a sterile aqueous solution containing the active compound is an effective mode of administration. Another embodiment is a sterile aqueous or oily solution or suspension containing the active material, which is injected as needed to produce the desired pharmacological effect.

[0152] Injections are designed for local and systemic administration. In some embodiments, the effective therapeutic dose is formulated to contain a concentration of at least about 0.01% w / w to about 90% w / w or higher, and in certain embodiments greater than 0.1% w / w of active compound to the treated tissue.

[0153] The compound may be suspended in micronized or other suitable form, or may be derivatized to produce a more soluble active product or to produce a prodrug. The form of the resulting mixture depends on many factors, including the intended mode of administration and the solubility of the compound in the selected carrier or carriers. The effective concentration is sufficient to ameliorate the symptoms of the condition and can be determined empirically.

[0154] The active ingredients provided herein can be administered by controlled release means or delivery devices well known to those of ordinary skill in the art. Examples include, but are not limited to, U.S. Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,639,480; 5,733,566; 5,739,108; 5,891,474; Such dosage forms can be used to provide slow or controlled release of one or more active ingredients, for example using hydroxypropylmethylcellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or combinations thereof, to provide the desired release profile in varying proportions. Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients provided herein.

[0155] All controlled-release products share a common goal of improving drug therapy over that of non-controlled products. Ideally, the best-designed controlled-release formulations used in medical treatments are characterized by using the least amount of drug in the shortest amount of time to cure or control a condition. Advantages of controlled-release formulations include prolonged drug activity, reduced dosing frequency, and improved patient compliance. In addition, controlled-release formulations can be used to affect the onset of action or other characteristics, such as blood levels of a drug, and thus the occurrence of side effects, such as adverse reactions.

[0156] Most controlled-release formulations are designed to initially release a certain amount of drug (active ingredient) to rapidly produce the desired therapeutic effect, and to gradually and continuously release additional amounts of drug to maintain this therapeutic or preventive effect over a longer period of time. In order to maintain a constant level of drug in the body, the drug must be released from the dosage form at a certain rate to replace the amount of drug that is metabolized and excreted from the body. Controlled release of the active ingredient can be stimulated by various conditions, including but not limited to pH, temperature, enzymes, water, or other physiological conditions or compounds.

[0157] In certain embodiments, intravenous infusion, implantable osmotic pumps, transdermal patches, liposomes or other modes of administration can be used for administration. In some embodiments, a pump can be used (see Sefton, CRC Crit. Ref. Biomed. Eng. 14: 201 (1987); Buchwald et al., Surgery 88: 507 (1980); Saudek et al., N. Engl. J. Med. 321: 574 (1989)). In other embodiments, polymer materials can be used. In other embodiments, the controlled release system can be placed near the therapeutic target, that is, so only a small part of the systemic dose is required (for example, see Goodson, Medical Applications of Controlled Release, vol. 2, pp. 115-138 (1984)). In some embodiments, the controlled release device is introduced into the vicinity of an inappropriate immune activation site or a tumor in the subject's body. Other controlled release systems are discussed in the review of Langer (Science 249: 15271533 (1990)). The active ingredient can be dispersed in a solid inner matrix, such as polymethyl methacrylate, polybutyl methacrylate, plasticized or unplasticized polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubber, polydimethylsiloxane, silicone carbonate copolymers, hydrophilic polymers such as hydrogels of acrylates and methacrylates, collagen, cross-linked polyvinyl alcohol and cross-linked partially hydrolyzed polyvinyl acetate, which is encapsulated in an outer layer that is insoluble in body fluids. The composition is surrounded by an outer polymer film, such as polyethylene, polypropylene, ethylene / propylene copolymer, ethylene / ethyl acrylate copolymer, ethylene / vinyl acetate copolymer, silicone rubber, polydimethylsiloxane, chloroprene rubber, chlorinated polyethylene, polyvinyl chloride, copolymer of vinyl chloride and vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber, epichlorohydrin rubber, ethylene / vinyl alcohol copolymer, ethylene / vinyl acetate / vinyl alcohol terpolymer and ethylene / ethyleneoxyethanol copolymer. Then, in the release rate controlling step, the active ingredient diffuses through the outer polymer film. The percentage of active ingredient contained in this parenteral composition is highly dependent on its specific properties and the needs of the subject.

[0158] Also of interest herein are lyophilized powders, which can be reconstituted for administration as solutions, emulsions and other mixtures. They can also be reconstituted into solids or gels.

[0159] Sterile lyophilized powder is prepared by dissolving the compound or its derivative provided herein in a suitable solvent. The solvent may contain an excipient that improves the stability of the powder or reconstituted solution prepared from the powder or other pharmacological components. Available excipients include, but are not limited to, antioxidants, buffers, and fillers. In some embodiments, the excipient is selected from glucose, sorbitol, fructose, corn syrup, xylitol, glycerol, glucose, sucrose, and other suitable agents. The solvent may contain a buffer, such as citrate, sodium phosphate or potassium phosphate or other such buffers known to those skilled in the art, with a pH value of about neutral. The solution is then sterile filtered and then freeze-dried under standard conditions known to those skilled in the art, providing the desired preparation. In some embodiments, the resulting solution is distributed into vials for freeze-drying. Each vial will contain a single dose or multiple doses of the compound. The freeze-dried powder can be stored under appropriate conditions, for example, at about 4°C to room temperature.

[0160] Reconstitution of this lyophilized powder with water for injection provides a formulation for parenteral administration. For reconstitution, the lyophilized powder is added to sterile water or other suitable carrier. The exact amount depends on the compound selected. This amount can be determined empirically.

[0161] Topical mixtures are prepared as described for topical and systemic administration. The resulting mixtures may be solutions, suspensions, emulsions, etc., and formulated into creams, gels, ointments, lotions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, rinses, sprays, suppositories, bandages, skin patches, or any other formulation suitable for topical administration.

[0162] The compounds or their derivatives can be formulated as aerosols for topical application, for example by inhalation (see, for example, U.S. Pat. Nos. 4,044,126, 4,414,209 and 4,364,923, which describe aerosols for delivering steroids useful for treating inflammatory diseases, particularly asthma). These formulations for respiratory administration can be in the form of aerosol or nebulizer solutions, or can be ultrafine powders for insufflation, used alone or in combination with an inert carrier such as lactose. In this case, in some embodiments, the mass median geometric diameter of the particles of the formulation will be less than 5 microns, and in other embodiments less than 10 microns.

[0163] Oral inhalation formulations of compounds or derivatives suitable for inhalation include metered dose inhalers, dry powder inhalers, and liquid formulations administered from nebulizers or metered liquid dispensing systems. For metered dose inhalers and dry powder inhalers, the crystalline form of the compound or derivative is the preferred physical form of the drug to impart longer product stability.

[0164] In addition to the particle size reduction methods known to those skilled in the art, supercritical fluid processing can also be used to produce crystalline particles of compounds or derivatives, which has significant advantages in producing such particles for inhalation delivery by producing respirable particles of the desired size in one step. (For example, International Publication No. WO2005 / 025506). The controlled particle size of microcrystals can be selected to ensure that most of the compounds or derivatives are deposited in the lungs. In some embodiments, the mass median aerodynamic diameter of these particles is about 0.1 to about 10 microns, in other embodiments, about 1 to about 5 microns, and in other embodiments, about 1.2 to about 3 microns.

[0165] Inert and non-flammable HFA propellants are selected from HFA 134a (1,1,1,2-tetrafluoroethane) and HFA 227e (1,1,1,2,3,3,3-heptafluoropropane) and are provided either alone or in proportions to match the crystal particle density of the compound or derivative. A proportion is also selected to ensure that the product suspension avoids deleterious precipitation or paste (which would precipitate irreversible agglomerates) and instead promotes a loosely flocculated system that is easily dispersed upon shaking. A loosely flocculated system is believed to provide the best stability for the pMDI canister. Due to the nature of the formulation, the formulation is free of ethanol and surfactants / stabilizers.

[0166] These compounds can be formulated for topical or local application, for example, in the form of gels, creams and lotions for topical application to the skin and mucous membranes, such as the eye, and for ocular or intracisternal or intraspinal application. Topical administration can be used for transdermal administration, and can also be used for administration to the eye or mucous membranes, or for inhalation therapy. Nasal solutions of the active compounds can also be administered alone or in combination with other excipients.

[0167] For nasal administration, the formulation may contain the esterified phosphonate compound dissolved or suspended in a liquid carrier, particularly an aqueous carrier for aerosol application. The carrier may contain a solubilizing or suspending agent, such as propylene glycol, a surfactant, an absorption enhancer, such as lecithin or cyclodextrin, or a preservative.

[0168] Solutions, particularly those for ophthalmic use, can be formulated as 0.01%-10% isotonic solutions, pH about 5-7.4, containing appropriate salts.

[0169] Other routes of administration are also contemplated herein, such as transdermal patches, including iontophoresis and electrophoresis devices, and rectal administration.

[0170] Transdermal patches, including iontophoresis and electrophoresis devices, are well known to those skilled in the art. For example, such patches are disclosed in U.S. Pat. Nos. 6,267,983, 6,261,595, 6,256,533, 6,167,301, 6,024,975, 6,010715, 5,985,317, 5,983,134, 5,948,433, and 5,860,957.

[0171] For example, the dosage form for rectal administration is rectal suppository, capsule and tablet, which is used for systemic effect. Rectal suppository used herein refers to solid inserted into the rectum, which melts or softens at body temperature, releasing one or more pharmacological or therapeutic active ingredients. The material used in the rectal suppository is a matrix or carrier and reagent that improves the melting point. Examples of matrix include cocoa butter (cocoa butter), glycerin gelatin, carbowax (polyoxyethylene glycol) and a suitable mixture of monoglyceride, diglyceride and triglyceride of fatty acid. Various base combinations can be used. Drugs that improve the melting point of suppositories include spermaceti and wax. Rectal suppositories can be prepared by compression or molding. In one embodiment, the weight of the rectal suppository is about 2 to 3 grams. Tablets and capsules for rectal administration are manufactured using the same materials and methods as oral preparations.

[0172] The compounds provided herein or their derivatives can also be formulated into specific tissues, receptors or other areas of the body that target the subject to be treated. Many such targeting methods are well known to those skilled in the art. All of these targeting methods are contemplated herein for use in the present composition. For non-limiting examples of targeting methods, see, for example, U.S. Patent Nos. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071,495, 6,060,082, 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542 and 5,709,874.

[0173] In some embodiments, liposome suspensions, including tissue-targeted liposomes, such as tumor-targeted liposome preparations, may also be suitable as carriers. These can be prepared according to methods known to those skilled in the art. For example, liposome preparations can be prepared as described in U.S. Patent No. 4,522,811. In short, liposomes such as multilamellar vesicles (MLV) can be formed by drying phosphatidylcholine and phosphatidylserine (7:3 molar ratio) inside a flask. A solution of the compound provided herein in phosphate buffered saline (PBS) lacking divalent cations is added, and the flask is shaken until the lipid film is dispersed. The resulting vesicles are washed to remove the unencapsulated compound, precipitated by centrifugation, and then resuspended in PBS.

[0174] The compound or derivative can be packaged as an article of manufacture, which comprises packaging material, a compound or derivative thereof provided herein, which is effective in treating, preventing or ameliorating one or more symptoms of the above-mentioned diseases or conditions within the packaging material, and a label indicating that the compound or composition or derivative thereof is used to treat, prevent or ameliorate one or more symptoms of the above-mentioned diseases.

[0175] Articles provided herein include packaging materials. Packaging materials for packaging products are well known to those skilled in the art. For example, see U.S. Patent Nos. 5,323,907, 5,052,558 and 5,033,252. Examples of packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging materials suitable for selected formulations and intended administration and treatment methods. Various preparations of the compounds and compositions provided herein and various treatment methods for any disease or condition described herein are all contemplated.

[0176] dose

[0177] For the treatment or prevention of infectious diseases, the compounds described herein or their pharmaceutical compositions are administered or applied in an effective therapeutic amount. In human treatment, the doctor will determine the most suitable dosage regimen based on preventive or therapeutic treatment and age, weight, disease stage and other factors specific to the object to be treated. The amount of the active ingredient effectively preventing or treating infectious diseases in the preparations provided herein will vary with the nature and severity of the disease or condition and the route of administration of the active ingredient. Frequency and dosage will also vary according to the specific factors of each subject, depending on the specific therapy (e.g., therapeutic agent or preventive agent) administered, the severity of the infection, the route of administration, and the subject's age, body, weight, reaction and previous medical history.

[0178] Exemplary dosages of the formulations include milligram or microgram amounts of active compound per kilogram of subject (e.g., about 1 microgram / kg to about 50 mg / kg, about 10 microgram / kg to about 30 mg / kg, about 100 microgram / kg to about 10 mg / kg, or about 100 micrograms per kilogram to about 5 mg / kg).

[0179] In some embodiments, the effective therapeutic dose should produce an active ingredient serum concentration of about 0.001 ng / ml to about 50-200 μg / ml. The composition in other embodiments should provide a dosage of about 0.0001 mg to about 70 mg of compound / kg body weight / day. The dosage unit form is prepared to provide a combination of active ingredients or essential ingredients of about 0.01 mg, 0.1 mg or 1 mg to about 500 mg, 1000 mg or 5000 mg per dosage unit form, in some embodiments about 10 mg to about 500 mg.

[0180] The active ingredient can be administered at once or divided into multiple smaller doses, which are administered at intervals. It is understood that the precise dose and duration of treatment is a function of the disease being treated and can be determined empirically using known test protocols or by extrapolation of in vivo or in vitro test data or subsequent clinical testing. It is worth noting that concentrations and dosage values ​​may also vary with the severity of the condition to be alleviated. It should be further understood that for any particular subject, the specific dosage regimen should be adjusted over time according to the individual needs and the professional judgment of the person administering or supervising the administration of the composition, and the concentration ranges described herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.

[0181] In some cases, it may be necessary to use dosages of active ingredients outside the range disclosed herein, which will be apparent to those of ordinary skill in the art. In addition, it is noted that the clinician or treating physician will know how and when to interrupt, adjust or terminate treatment, taking into account the subject's response.

[0182] For systemic administration, the effective therapeutic dose can be estimated initially from in vitro assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC determined in cell culture. 50 (i.e., the concentration of the test compound lethal to 50% of the cell cultures), or the IC determined in cell culture 100 (ie, the concentration of compound that is lethal to 100% of the cell culture.) Such information can be used to more accurately determine useful doses in humans.

[0183] Initial dosages can also be estimated from in vivo data (eg, animal models) using techniques well known in the art. One of ordinary skill in the art can readily optimize dosing for humans based on animal data.

[0184] Alternatively, by using the IC 50 , MIC and / or I 100 IC with known reagents 50 , MIC and / or I 100 Initial doses can be determined from doses of known agents administered, by comparison, and the initial dose adjusted accordingly. Optimal doses can be derived from these initial values ​​by routine optimization.

[0185] In cases of local administration or selective uptake, the effective local concentration of compound used may not be related to plasma concentration. One skilled in the art will be able to optimize the local dose for effective treatment without undue experimentation.

[0186] Ideally, a therapeutically effective dose of the compounds described herein will provide therapeutic benefit without causing substantial toxicity. The toxicity of a compound can be determined using standard pharmaceutical procedures in cell cultures or experimental animals, for example, by determining the LD 50 (dose lethal to 50% of the population) or LD 100 (Concentration lethal to 100% of the population). The dose ratio of toxicity to efficacy is a therapeutic index. Compounds that exhibit a high therapeutic index are preferred. The data obtained from these cell culture tests and animal studies can be used to formulate a dosage range that is non-toxic to the subject. The dosage of the compounds described herein is preferably within a circulating concentration range that includes an effective dose with little or no toxicity. The dosage may vary within this range, depending on the dosage form used and the route of administration used. The exact formulation, route of administration and dosage can be selected by an individual physician based on the patient's condition (see Fingl et al., 1975, The Pharmacological Basis of Therapeutics, Ch. 1, p. 1).

[0187] In some embodiments, the effective therapeutic amount of the compound of structural formula (I) for treating the diseases / disorders disclosed herein or causing a biological effect (e.g., increasing NAD+ levels, enhancing mitochondrial or cellular function, improving metabolic health or cell survival, or providing cellular protection) is about 1-1000 mg, 1-100 mg, 100-500 mg, or 500-1000 mg (e.g., per day or per dose), or as deemed appropriate by the treating physician, it can be administered in a single dose or divided doses. In further embodiments, the effective therapeutic amount of the compound of structural formula (I) is about 1-50 mg, 50-100 mg, 100-200 mg, 200-300 mg, 300-400 mg, 400-500 mg, 500-600 mg, 600-700 mg, 700-800 mg, 800-900 mg, or 900-1000 mg (e.g., per day or per dose). In other embodiments, the therapeutically effective amount of the compound of structural formula (I) is about 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg or 1000 mg (e.g., per day or per dose).

[0188] In some embodiments, the effective therapeutic amount of the compound of formula (I) is about 100-500 mg, 100-200 mg, 200-300 mg, 300-400 mg or 400-500 mg per day, which can be administered in a single dose (e.g., N mg once a day) or divided doses (e.g., N / 2 mg twice a day). In further embodiments, the effective therapeutic amount of the compound of formula (I) is about 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg or 500 mg per day. In certain embodiments, the effective therapeutic amount of the compound of formula (I) is about 200-300 mg per day, or about 200 mg, 250 mg or 300 mg per day.

[0189] Treatment can be repeated intermittently. In certain embodiments, the same formulation provided herein can be repeatedly administered, and administration can be spaced at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months or 6 months.

[0190] Methods of using compounds and compositions

[0191] Disclosed herein are methods for treating, preventing or ameliorating symptoms of medical diseases, such as metabolic diseases, cardiovascular diseases, cerebrovascular diseases, liver diseases, kidney diseases or muscle diseases, using compounds of structural formula (I) and pharmaceutical compositions thereof. In some embodiments, the metabolic disorder is type 1 or type 2 diabetes, impaired glucose tolerance, insulin resistance, obesity, hyperlipidemia, dyslipidemia, hypercholesterolemia or hypertriglyceridemia; cardiovascular disease is cardiomyopathy, heart failure or myocardial ischemia, infarction or ischemia-reperfusion injury (IRI); cerebrovascular disease is stroke or cerebral ischemia, neuroinflammation, multiple sclerosis, hepatic encephalopathy, neurodegenerative diseases, Parkinson's disease or Alzheimer's disease; liver disease refers to non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver disease (NASH), alcoholic liver disease, Alcoholic hepatitis, alcoholic fatty hepatitis, liver fibrosis, liver cirrhosis, liver failure, acute liver failure or chronic liver failure; kidney disease is acute kidney injury or renal ischemia or IRI, chronic kidney injury includes renal failure, glomerulonephritis, diabetic nephropathy; muscle disease includes muscle atrophy, cachexia, sarcopenia, muscular dystrophy, Duchenne muscular dystrophy (DMD), myositis, neuromuscular degeneration, ataxia, spinocerebellar ataxia, adult-onset mitochondrial myopathy, Friedreich ataxia or ataxia telangiectasia. When implementing these methods, an effective therapeutic amount of the compound or pharmaceutical composition described above is administered to a patient suffering from a disease or condition.

[0192] The compounds described herein can increase NAD+ levels in the subject, including levels in cells, tissues and organs, and may also increase levels in the blood. By increasing NAD+ levels, compounds of structural formula (I) can improve mitochondrial and cellular functions (e.g., DNA repair) in target cells, tissues and organs, and increase cell survival. The benefits of improving mitochondrial function include, but are not limited to, enhancing mitochondrial oxidative metabolism, mitochondrial respiration, ATP production, mitochondrial membrane potential, mitochondrial phagocytosis (autophagy of defective mitochondria) and mitochondrial biosynthesis, and reducing reactive oxygen (ROS) levels. For example, higher NAD+ levels increase the activity of mitochondrial NAD-dependent deacetylases longevity protein-1 (SIRT1) and longevity protein-3 (SIRT3). SIRT1 promotes autophagy of defective mitochondria, stimulates mitochondrial biogenesis, inhibits proinflammatory transcription factor NF-κB, increases insulin sensitivity, and simulates the effects of calorie restriction. Stimulation of SIRT3 activity increases mitochondrial biogenesis, increases cellular respiration and energy production, reduces ROS levels (e.g., by stimulating mitochondrial superoxide dismutase 2 [SOD2]), promotes cell survival during genotoxic stress, acts as a mitochondrial tumor suppressor, increases insulin sensitivity, sensitizes cells to glucose uptake, and mimics calorie restriction and exercise. Improved DNA repair can reduce cellular damage and enhance cellular function, health, and lifespan. Furthermore, preventing NAD+ depletion can protect neurons under excitotoxic or ischemic conditions.

[0193] Therefore, compounds of structural formula (I) can be used to treat pellagra, mitochondrial diseases, mitochondrial-related diseases and conditions, diseases and conditions associated with acute NAD+ depletion caused by DNA damage, aging-related diseases and conditions, skin diseases and conditions, and other types of diseases and conditions. In some embodiments, a single compound of structural formula (I) is used to treat a disease / disorder or condition disclosed herein, or to produce a biological effect disclosed herein (e.g., increasing NAD+ levels, enhancing mitochondrial or cellular function, improving metabolic health or cell survival, or providing cell protection). In other embodiments, multiple compounds of structural formula (I) are used to treat a disease / disorder or condition disclosed herein, or to produce a biological effect disclosed herein. The use of multiple compounds of structural formula (I) may have an additive effect or a potential synergistic effect.

[0194] The compounds of structural formula (I) have other beneficial effects. For example, they can enhance the immune function of peripheral blood mononuclear cells (such as T cells, B cells, macrophages and natural killer [NK] cells), which is based on the improvement of antigen recognition and proliferation as immune surveillance functions. For this application, one or more compounds of structural formula (I) can be used alone, as a component of a vaccine, as a component of an ex vivo therapy (such as CAR-T cell therapy), or as a component of some other therapy.

[0195] Mitochondrial diseases include, but are not limited to, mitochondrial myopathy; limb-girdle distribution weakness; Kearns-Sayre syndrome; Pearson syndrome; Leigh syndrome; Barth syndrome; Friedreich ataxia; neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP); mitochondrial DNA depletion syndrome (Alper disease); mitochondrial neurogastrointestinal encephalopathy syndrome; mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome; myoclonic epilepsy with ragged red fibers (MERRF or Fukuhara syndrome); chronic progressive external ophthalmoplegia; Leber hereditary optic dysplasia neuropathy (LHON); inherited blindness and deafness (such as diabetes and deafness); and acquired forms of reversible or permanent hearing loss {e.g., hearing loss associated with type 2 diabetes and hearing loss caused by ototoxic chemicals (such as heavy metals [such as lead], solvents [such as styrene and toluene], and asphyxiants [such as carbon monoxide]) and drugs (such as loop diuretics [such as bumetanide and furosemide], nonsteroidal anti-inflammatory drugs [such as aspirin, celecoxib, diclofenac, ibuprofen, and naproxen], PDE5 inhibitors, macrolide antibiotics, aminoglycosides [such as gentamicin], platinum chemotherapy drugs [such as carboplatin and cisplatin], acetaminophen, and quinine)}.

[0196] Mitochondrial-related diseases and disorders include, but are not limited to, neurodegenerative diseases, neuronal activation diseases, muscle diseases (including eye muscle diseases), fatty acid / beta oxidation diseases, metabolic diseases, inflammatory diseases, vascular diseases (including ocular vascular diseases), kidney diseases, liver diseases, tumors, cancers, male and female infertility, and aging-related diseases.

[0197] Neurodegenerative diseases include, but are not limited to, dementias (e.g., Alzheimer's disease [AD], vascular dementia, dementia with Lewy bodies, and frontotemporal dementia [Pick disease]), motor neuron diseases (e.g., Parkinson's disease, amyotrophic lateral sclerosis [ALS or Lou Gehrig's disease], primary lateral sclerosis [PLS], and spinal muscular atrophy [SMA]), ataxias (e.g., spinocerebellar ataxia / degeneration, Friedreich's ataxia, ataxia telangiectasia [Louis Bar syndrome] and fragile X-associated tremor / ataxia syndrome [FXTAS]), kinesiology disorders (such as cerebral palsy, chorea, dystonia, and essential tremor), cognitive dysfunction movement disorders (such as cortical basal degeneration, Huntington's disease [HD], and Parkinson's disease), chorea acanthocytosis, retinal neuronal degeneration, Batten disease, DNA repair syndromes (such as Cockayne syndrome), and prion diseases (such as Creutzfeldt-Jakob disease).

[0198] Neuronal activation disorders include, but are not limited to, neurodegenerative diseases (such as ALS), neuronal injury (including trauma and mechanical injury to the brain, spinal cord, and peripheral nervous system [PNS], and excitotoxic neuronal injury, such as injury associated with epileptic seizures and local ischemia), neuropathies, neuropathies (such as peripheral neuropathies [such as Charcot-Marie Tooth disease], mononeuropathies [such as those caused by compression, trauma, cumulative trauma, ischemia, inflammation, connective tissue diseases, and tumors], polyneuropathies [such as chronic inflammatory demyelinating polyneuropathy], brachial plexus neuropathy, diabetic neuropathy [such as third nerve palsy, mononeural injury, polyneuropathy, autonomic neuropathy, thoracoabdominal neuropathy, and diabetic amyotrophy], and chemotherapy-induced neuropathy), autoimmune neurological diseases (such as multiple sclerosis, Guillain-Barré syndrome, Lambert-Eaton myasthenic syndrome, and myasthenia gravis), neuroinflammation, delayed ulnar nerve palsy, and toxic myoneuropathies.

[0199] Muscle diseases include, but are not limited to, muscle structure diseases, muscle mass diseases, and muscle fatigue diseases. Muscle structure diseases include, but are not limited to, myopathy (e.g., cardiomyopathy), neuromuscular degeneration, muscular dystrophy (MD), congenital MD, distal MD, Duchenne MD, Becker MD, Emery-Dreifuss MD, limb girdle MD, myotonic MD, facioscapulohumeral MD, oculopharyngeal MD, Bethlehem myopathy, central nuclear disease, congenital fiber type disproportion, hyaline myopathy, muscle sodium channel disease, myotonic dystrophy, myotonic chondrodystrophy, myotubular myopathy, nematode disease, myositis, sarcopenia, rhabdomyolysis, and stress urinary incontinence. Muscle group diseases include, but are not limited to, muscle atrophy, cachexia, cartilage degeneration, cerebral palsy, compartment syndrome, myopathy gravis, inclusion body myositis, sarcopenia, steroid myopathy, and systemic lupus erythematosus (SLE). Muscle fatigue disorders include, but are not limited to, chronic fatigue syndrome, fibromyalgia, thyrotoxic myopathy, lipid storage myopathy, Friedreich's ataxia, glycogen storage diseases (such as Pompe's disease), intermittent claudication, adult-onset mitochondrial myopathy, MELAS, and mucopolysaccharidoses.

[0200] Ocular muscle disorders include, but are not limited to, refractive disorders, accommodative disorders, refractive and accommodative disorders, strabismus, progressive external ophthalmoplegia, internal ophthalmoplegia, esotropia, exotropia, hyperopia, myopia, astigmatism, anisometropia, and presbyopia.

[0201] Fatty acid / beta-oxidation disorders include, but are not limited to, systemic carnitine transporter deficiency, carnitine palmitoyltransferase (CPT) II deficiency, very long chain acyl-CoA dehydrogenase (LCHAD or VLCAD) deficiency, medium chain acyl-CoA dehydrogenase (MCAD) deficiency, short chain acyl-CoA dehydrogenase (SCAD) deficiency, trifunctional enzyme deficiency, and riboflavin responsive beta-oxidation disorder (RR-MADD).

[0202] Metabolic diseases include, but are not limited to, lipodystrophy (inherited and acquired), metabolic syndrome, hyperglycemia, impaired glucose tolerance (including prediabetes and diabetes), insulin resistance, hyperinsulinemia, diabetes (including type 1 and type 2), diabetic complications (such as diabetic neuropathy and diabetic retinopathy), obesity, dyslipidemia, familial hyperlipidemia, hypercholesterolemia, non-high-density lipoprotein (HDL) hypercholesterolemia, low-density lipoprotein cardiomyopathy, heart failure, myocardial infarction, atherosclerosis, thrombotic disease and peripheral vascular disease), inflammatory diseases ( These diseases include arthritis, asthma, and pancreatitis), liver diseases (such as nonalcoholic fatty liver disease [NAFLD] and nonalcoholic steatohepatitis [NASH]), kidney diseases (such as chronic kidney disease), gastrointestinal diseases (such as Crohn's disease, irritable bowel syndrome, ulcerative colitis, and dyspepsia), neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), demyelinating diseases (such as multiple sclerosis), skin diseases (such as acne, dermatitis, psoriasis, and skin aging), hair diseases, adrenoleukodystrophy, edema, ketoacidosis, sexual dysfunction (such as erectile dysfunction), tumors, and cancer.

[0203] In some embodiments, compounds of structural formula (I) are used to treat hyperglycemia, impaired glucose tolerance and insulin resistance and diseases and conditions associated therewith, including prediabetes, type 1 and type 2 diabetes, and obesity-related diseases and conditions. Compounds of structural formula (I) can stimulate SIRT1 and SIRT3 activity, both of which can increase insulin sensitivity, sensitize cells to glucose uptake, and simulate calorie restriction. Increased insulin sensitivity reduces insulin production. Hyperinsulinemia promotes the differentiation of preadipocytes into adipocytes. Therefore, lowering blood insulin levels can inhibit adipocyte differentiation and lipogenesis, thereby having a therapeutic effect on obesity-related diseases and conditions, including but not limited to dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, metabolic syndrome, lipodystrophy, and hypertension.

[0204] ROS stimulate inflammation, in part by activating transcription factors, such as NF-κB, which increases the expression of proinflammatory cytokines. The compounds of structural formula (I) disclosed herein can reduce ROS levels by, for example, stimulating SIRT3 activity. In addition, the compounds of structural formula (I) can increase the activity of the NAD-dependent deacetylase longevity protein-1 (SIRT1) that inhibits NF-κB. NF-κB is the main promoter of gene transcription encoding proinflammatory cytokines. Therefore, the compounds of structural formula (I) can be used to treat inflammatory diseases. Inflammatory diseases include, but are not limited to, neuroinflammation (e.g., neuritis [e.g., ophthalmic neuritis and peripheral neuritis], Alzheimer's disease, and multiple sclerosis), gastrointestinal diseases (e.g., gastritis, necrotizing enterocolitis, mucous colitis, ulcerative colitis, inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, and celiac disease), peritonitis, pancreatitis (acute and chronic), glomerulonephritis, liver diseases (e.g., hepatitis, nonalcoholic and alcoholic steatohepatitis, cirrhosis, and chronic liver disease), multiple organ dysfunction syndrome (e.g., secondary to sepsis or trauma), metabolic diseases (e.g., diabetes [e.g., type 1 and type 2 diabetes and juvenile-onset diabetes] and metabolic syndrome), cardiac diseases (e.g., myocarditis and myocardial infarction, congestive heart failure with preserved or reduced ejection fraction), vascular diseases (e.g., vasculitis, atherosclerosis), sclerosis, stroke, peripheral arterial disease, and shock), reperfusion injury (e.g., due to myocardial ischemia, cerebral ischemia, cardiopulmonary bypass, or renal dialysis), airway diseases (e.g., rhinitis [e.g., allergic rhinitis], esophagitis, asthma, acute respiratory distress syndrome, bronchitis [e.g., chronic bronchitis], pneumonia, and chronic obstructive pulmonary disease [COP]), arthritis (e.g., osteoarthritis [degenerative joint disease], rheumatoid arthritis, psoriatic arthritis, gouty arthritis, axial spondyloarthritis, ankylosing spondylitis, and juvenile arthritis), skin diseases (e.g., dermatitis / eczema, psoriasis, urticaria, skin diseases with an acute inflammatory component, and sunburn), Sjögren's syndrome, eye diseases (e.g., conjunctivitis, retinitis, and AMD), systemic lupus erythematosus, hypertension, and dysmenorrhea (menstrual cramps).

[0205] Inflammation is a major stimulus for fibrosis. Compounds of formula (I) disclosed herein can be used to treat fibrotic diseases, in part by reducing inflammation. Fibrotic diseases include, but are not limited to, cardiomyopathy (such as diabetic cardiomyopathy and uremic cardiomyopathy), cardiac fibrosis, myocardial fibrosis, collagen vascular disease (such as arterial stiffness and vascular fibrosis), atherosclerosis, chronic heart failure, diabetic nephropathy, renal fibrosis, chronic kidney disease (such as chronic renal failure), liver fibrosis, cirrhosis, NASH, chronic liver disease, liver failure (such as chronic liver failure), pulmonary fibrosis (such as idiopathic pulmonary fibrosis and radiation-induced pulmonary fibrosis), cystic fibrosis, and scleroderma (such as localized scleroderma and systemic scleroderma / systemic sclerosis).

[0206] Vascular diseases include, but are not limited to, cardiovascular diseases (e.g., myocardial ischemia, ischemia-reperfusion injury [IRI], atherosclerosis, and atherosclerosis), cerebrovascular diseases (e.g., cerebral ischemia and IRI), peripheral vascular diseases (e.g., peripheral vascular insufficiency, peripheral arterial disease, intermittent / vascular claudication, critical limb ischemia, peripheral atherosclerosis, and occlusive arterial disease), thrombotic / coagulation / hemostatic diseases (e.g., disseminated intravascular coagulation, deep vein thrombosis, thrombosis [e.g., due to antithrombin III deficiency, protein S deficiency, protein C deficiency or resistance to activated protein C], thrombotic thrombocytopenic purpura, heparin-induced thrombocytopenia, fibrinosis, atherosclerotic arteriosclerosis, myocardial ischemia / infarction, angina [such as unstable angina], ischemic stroke, sickle cell disease, myeloproliferative tumors, cancer metastasis, homocystinuria and miscarriage) and embolism (such as thromboembolism, fat embolism, arterial embolism [such as myocardial ischemia, ischemic stroke and acute limb ischemia] and venous embolism [such as pulmonary embolism]). As an illustrative example, one or more compounds of structural formula (I) can be used to treat or prevent thrombosis or thrombotic diseases, including reducing or preventing thrombotic events or reocclusion during and / or after thrombus removal interventions (e.g., procedures such as angioplasty).

[0207] Ocular vascular diseases include, but are not limited to, retinopathy (such as hypertensive retinopathy and diabetic retinopathy), macular degeneration (such as age-related macular degeneration [AMD]), Stargardt's disease, retinal hemorrhage, and glaucoma.

[0208] Renal diseases include, but are not limited to, acute nephritis, chronic nephritis, rapidly progressive nephritis, glomerulonephritis, glomerulosclerosis, hypertensive nephrosclerosis, renal ischemia, IRI, Bartter syndrome, diabetic nephropathy, acute renal failure (acute kidney injury), chronic renal failure, nephrotic syndrome, recurrent hematuria, and persistent hematuria.

[0209] Liver diseases include, but are not limited to, NAFLD, NASH, alcoholic liver disease, hepatitis (such as autoimmune hepatitis, hepatitis B and hepatitis C), cholestatic diseases (such as cholestasis, primary biliary cholangitis / cirrhosis and primary sclerosing cholangitis), liver injury, chronic liver disease, liver failure (acute and chronic), cirrhosis and cancer.

[0210] Tumors (benign and malignant) and cancers include, but are not limited to, brain tumors, spinal cord tumors, germ cell tumors, neuroendocrine tumors, carcinoids, tumors and cancers associated with viral infections (e.g., HIV and HTLV-1), carcinomas, sarcomas and cancers of the digestive / gastrointestinal system, gynecological organs (e.g., breast cancer), genitourinary system, musculoskeletal system, respiratory system, head and neck, eyes, skin (e.g., melanoma), blood (e.g., leukemia, multiple myeloma, Hodgkin's lymphoma and non-Hodgkin's lymphoma), endocrine system (e.g., hormone-dependent cancers such as breast cancer, ovarian cancer, prostate cancer, and testicular cancer), neuroendocrine system, nervous system, and germ cells. In some embodiments, one or more compounds of structural formula (I) are used to treat cancers of the breast, ovary, colon / colon, rectum, pancreas, liver, kidney, lung, prostate, brain, or skin. In a further embodiment, one or more compounds of structural formula (I) are used to treat hematological malignancies, such as acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), non-Hodgkin's lymphoma or multiple myeloma.

[0211] Diseases associated with female infertility include, but are not limited to, polycystic ovary syndrome (PCOS), diminished ovarian reserve, endometriosis, and infertility caused by radiation or chemotherapy. Diseases associated with male infertility include, but are not limited to, drug-induced oligospermia and spermatogenesis.

[0212] Somatic mutations in mitochondrial DNA increase significantly with age, which may lead to mitochondrial defects. In addition, respiratory chain activity decreases with age. Non-limiting examples of aging-related diseases are described below.

[0213] In some embodiments, one or more compounds of structural formula (I) are used to treat mitochondrial-related diseases or disorders selected from hereditary lipodystrophy, metabolic syndrome, obesity, type 1 and type 2 diabetes, NAFLD, NASH, alcoholic liver disease, autoimmune hepatitis, cholestatic liver disease, hemochromatosis, alpha-1 antitrypsin deficiency, other inherited inborn errors of metabolism, and renal ischemia and IRI.

[0214] Diseases and conditions that result in acute NAD+ depletion due to DNA damage include, but are not limited to, exposure to radiation (such as ultraviolet light and ionizing radiation such as X-rays), radiation- or chemotherapy-induced diseases (such as dermatitis, myositis, myocarditis, colitis, prostatitis, hepatitis, pneumonia, neuropathy, and bone marrow failure), burns (including first-degree, second-degree, and third-degree burns), chemical exposure manifested by exfoliative dermatitis, exposure to chemical warfare agents, Stevens-Johnson syndrome, acute respiratory distress syndrome, inhalation lung injury caused by smoke or chemical toxins, trauma-related crush injuries (including fractures), peripheral nerve injuries, spinal cord injuries, and contusions of internal organs (such as the heart, lungs, liver, and kidneys). These diseases and conditions generate large amounts of ROS, such as superoxide, peroxide, and hydroxyl radicals, which cause DNA damage, which can lead to cell damage or cell death. In other words, DNA damage caused by radiation, chemotherapy, or oxidative stress, etc., can lead to acute NAD+ depletion, which can lead to systemic toxicity and systemic diseases (such as dermatitis, pneumonia, bone marrow failure, and neuropathy), as well as local toxicity and local diseases. Exemplary chemical warfare agents include blistering agents (e.g., blistering agents, nitrogen mustards, sulfur mustards, arsenic, and pruritus agents [e.g., phosgene]), blood agents (e.g., cyanide), lung agents (e.g., phosgene), and nerve agents (e.g., G-series agents [e.g., sarin and soman], GV-series agents, and V-series agents).

[0215] Reduced NAD+ levels are associated with aging, which can lead to metabolic dysfunction and diseases associated with aging (such as inflammatory diseases). For example, the expression and activity of CD38, which rapidly degrades NAD+ and its precursor NMN, increases during aging. Therefore, the compounds of structural formula (I) described herein can be used to treat diseases and conditions associated with aging. In addition, the compounds of structural formula (I) described herein can extend the lifespan of cells by, for example, slowing or delaying cellular aging / senescence, promoting cell survival, preventing cell apoptosis, prolonging cell proliferation capacity, increasing cell resistance to stress (such as oxidative stress), simulating the effects of caloric restriction, or promoting wound healing, or any combination thereof. In addition, NAD + Supplementation can improve stem cell function. Diseases and conditions associated with aging include, but are not limited to, aging / senescence, hypertension, eye diseases (such as AMD, cataracts, and keratoconjunctivitis sicca [dry eye syndrome]), hearing loss, osteoporosis, sarcopenia, dementia (such as Alzheimer's disease), metabolic diseases (such as metabolic decline, diabetes [including T1D and T2D], and obesity), cardiovascular diseases (such as arteriosclerosis), inflammatory diseases (such as arthritis and chronic obstructive pulmonary disease), DNA repair syndromes (such as Cockayne syndrome), and tumors and cancer. For example, due to their cytoprotective and antioxidant properties, compounds of structural formula (I) can be used to prevent or alleviate hearing loss, including noise-induced hearing loss, trauma-induced hearing loss, and progressive hearing loss syndromes.

[0216] By enhancing cell viability, providing cell protection, or / and extending cell lifespan, the compounds of structural formula (I) can be used to treat diseases characterized by cell degeneration or death. For example, retinal diseases characterized by cell degeneration or death include, but are not limited to, AMD, retinitis pigmentosa, cone-rod dystrophy / degeneration, diabetic retinopathy, Leber congenital amaurosis, and vision loss.

[0217] The cytoprotective compounds of formula (I) can be used to treat other diseases and conditions characterized by cell degeneration and / or cell death, including but not limited to neuronal diseases (e.g., Alzheimer's disease, Creutzfeldt-Jakob disease, Parkinson's disease, ALS and multiple sclerosis), brain degeneration (e.g., cerebellar degeneration and traumatic brain injury), muscle diseases (e.g., muscular dystrophy, such as Duchenne MD, facioscapulohumeral MD and myotonic dystrophy), ischemic diseases (e.g., myocardial ischemia / infarction and cerebral ischemia [stroke] / infarction), atherosclerosis, bone marrow Dysplastic syndrome (e.g., aplastic anemia), hepatitis (e.g., alcoholic hepatitis, fulminant hepatitis, hepatitis A), hepatitis B, hepatitis C, hepatitis D, and hepatitis E), joint diseases (e.g., osteoarthritis), skin atrophy, lichen planus, UV-induced skin damage, transplant rejection, alopecia, AIDS, and cell damage or / and cell death caused by trauma (e.g., to the brain or spinal cord), surgery, drugs, chemicals, biological and chemical toxins, and radiation (e.g., ionizing radiation such as X-rays). To prevent cell damage or / and cell death that may be caused by medical interventions such as surgery or radiation therapy, one or more compounds of structural formula (I) may be administered to a subject before or shortly after the intervention.

[0218] Due in part to their ability to protect cells from DNA damage and increase cell survival and lifespan, the compounds of structural formula (I) described herein are useful for treating skin diseases and conditions. Skin diseases and conditions may be associated with or caused by natural aging, inflammation, oxidative stress, or sun damage. Such skin diseases and conditions include, but are not limited to, skin wrinkles, dermatitis / eczema (such as atopic dermatitis, contact dermatitis [allergic and irritant], exfoliative dermatitis, and seborrheic dermatitis), psoriasis (such as plaque psoriasis), skin damage caused by sunlight or other light sources (such as sunburn, actinic keratosis, and xeroderma pigmentosum), keratinization disorders, erythema (such as erythema multiforme and erythema nodosum), dermatomyositis, discoid lupus erythematosus, pemphigoid (such as bullous pemphigoid), pemphigus radiation burns, chemical burns, and electrical burns), wounds, and skin cancer.

[0219] Partly due to its cytoprotective properties, the compounds of structural formula (I) disclosed herein can promote the preservation of donor grafts in organ transplantation. Therefore, the compounds of structural formula (I) can be applied to cells, tissues or organs used in transplantation and cell therapy, such as solid tissue transplants, organ transplants, cell suspensions, stem cells and bone marrow cells. The cells, tissues or organs can be autologous transplants, allogeneic transplants, combined transplants or xenografts. Before, simultaneously or / and after the cells, tissues or organs are administered / implanted into the recipient, the cells, tissues and organs can be treated with one or more compounds of structural formula (I). Before removing the cells, tissues or organs from the donor, the cells, tissues and organs can be treated with one or more compounds of structural formula (I), after removing the cells, tissues or organs from the donor, or after administration / implantation into the recipient, the cells, tissues or organs can be treated in vitro. For example, the donor and / or the recipient can be treated systemically with one or more compounds of structural formula (I), or a subset of cells, tissues or organs can be treated locally with one or more compounds of structural formula (I). In certain embodiments, the cells, tissues, or organs (or donors and / or recipients) are treated with additional therapeutic agents that prolong graft survival, such as immunosuppressants, cytokines, or angiogenic factors, or any combination thereof.

[0220] For example, due to NAD + The increase in levels promotes the differentiation of transplanted cells, and the use of one or more compounds of structural formula (I) can improve the implantation of bone marrow transplants, which can minimize cytopenias (including neutropenia, lymphopenia, anemia and thrombocytopenia), the need for growth factors and infectious complications. As another example, the use of one or more compounds of structural formula (I) can prevent graft-versus-host disease (GVHD) in allogeneic transplants.

[0221] In some embodiments, one or more compounds of structural formula (I) are used as components of ex vivo therapy in culture medium, such as chimeric antigen receptor (CAR) T cell therapy. CAR-T cell therapy can be autologous or allogeneic. In certain embodiments, ex vivo therapy utilizes hematopoietic stem cells (HSC), embryonic stem cells (ESC) or pluripotent stem cells (PSC). One or more compounds of structural formula (I) can be used to increase the yield of pancreatic endocrine cells in the final stage of in vitro differentiation of ESC and PSC into islet-like insulin-secreting cells.

[0222] In a further embodiment, the compound of structural formula (I) is used to enhance oocyte or cell function or / and cell energy production before or after in vitro fertilization, or after exposure of ovaries, oocytes, female germline cells after birth or / and preimplantation embryos in vivo. In some embodiments, in assisted reproductive technology (such as in vitro fertilization), one or more compounds of structural formula (I) are used together with a solution selected from cell culture medium, oocyte recovery solution, oocyte nuclear washing solution, egg nuclear in vitro maturation culture medium, follicle in vitro maturation culture fluid, egg nuclear cell in vitro fertilization culture medium, vitrification solution and cryopreservation solution. The present invention includes compositions comprising isolated oocytes, oogonial stem cells (OSC) or OSC offspring and one or more compounds of structural formula (I).

[0223] In some embodiments, the compound of formula (I) can be used as a lipid-lowering agent. The compound of formula (I) may be more effective as a lipid-lowering agent than NA. The lipid-lowering effect of the compound of formula (I) may be mediated by effects on the liver (DGAT1 inhibition, VLDL and HDL metabolism) and adipocytes / adipose tissue (lipolysis inhibition). Long-term pharmacology may provide superior effects in reducing liver fat for the treatment of NAFLD.

[0224] In some embodiments, compounds of formula (I) can be used to improve muscle function. Compounds of formula (I) may have a profound benefit on muscle function over NA. This may be mediated by increasing NAD+ levels and improving oxidative phosphorylation associated with improved mitochondrial function. In particular, compounds of formula (I) may improve the treatment of sarcopenia associated with immobilization-related muscle fatty degeneration, cancer cachexia, chronic malnutrition, cirrhosis, and age-related chronic diseases.

[0225] The effective therapeutic dose of the compound of formula (I) can be administered once, twice or more per day, once every two days, once every three days, twice a week or once a week, or as many times as the treating physician deems appropriate. In certain embodiments, the effective therapeutic dose of the compound of formula (I) is administered once or twice per day. As an illustrative example, if the effective therapeutic dose of the compound of formula (I) is about 300 mg per day, 300 mg of the compound can be taken once per day, or 150 mg of the compound can be taken twice per day.

[0226] When it is necessary to establish the therapeutic level of the compound of formula (I) more quickly, for example, in the treatment of ischemia-reperfusion injury, the compound can be administered according to a dosing regimen in which a loading dose is administered, followed by (i) one or more additional loading doses, followed by one or more effective maintenance doses of treatment, or (ii) one or more effective maintenance doses of treatment without the need for additional loading agents, as deemed appropriate by the treating physician. In this case, the loading dose of the drug is larger (e.g., about 1.5, 2, 3, 4 or 5 times larger) than the subsequent maintenance dose, and is designed to establish the therapeutic level of the drug more quickly. One or more effective maintenance doses of treatment can be any effective therapeutic amount / dose described herein. In certain embodiments, the loading dose is about three times the maintenance dose. In some embodiments, a loading dose of the compound of formula (I) is administered on day 1, and a maintenance dose is administered on day 2 and thereafter during treatment. In other embodiments, a first loading dose of the compound of formula (I) is administered on day 1, a second loading dose is administered on day 2, and a maintenance dose is administered on day 3 and thereafter during treatment. In certain embodiments, the first loading dose is about three times greater than the maintenance dose and the second loading dose is about two times greater than the maintenance dose.

[0227] Combination therapy

[0228] The compounds and compositions disclosed herein may also be used in combination with one or more other active ingredients. In certain embodiments, the compounds may be combined or administered sequentially with another therapeutic agent. Such other therapeutic agents include those known to treat, prevent or improve one or more symptoms associated with the diseases and / or conditions disclosed herein. Other therapeutic agents include, but are not limited to, therapeutic agents known to treat, prevent or improve one or more symptoms of any disease and / or condition disclosed herein.

[0229] It should be understood that any suitable combination of the compounds and compositions provided herein with one or more of the above-mentioned therapeutic agents and optionally one or more other pharmacologically active substances is considered to be within the scope of the present disclosure. In some embodiments, the compounds and compositions provided herein are administered before, simultaneously with, or after one or more additional active ingredients. In other embodiments, the compounds and compositions provided herein are administered with the same or different pharmaceutical compositions of one or more additional active ingredients.

[0230] Other types of therapeutic agents that can be used in combination with the compounds of structural formula (I) include, but are not limited to, sirtuin activators, AMPK activators, CD38 inhibitors, PARP inhibitors, SARM1 inhibitors, ACMSD inhibitors, cellular oxygen consumption stimulators, NMDA receptor antagonists, acetylcholinesterase inhibitors, antidiabetic drugs, antiobesity drugs, antiplatelet drugs, anticoagulants, antihypertensive drugs, antioxidants, anti-inflammatory drugs, analgesics, anesthetics, anticancer drugs, antivirals, antibiotics, antifungals, natural compounds, vitamins and vaccines. Additional therapeutic agents may also include, for example, farnesoid X receptor agonists, liver X receptor inverse agonists and UV protection creams.

[0231] Sirtuin activators include agents that increase the activity, level (e.g., expression) or signaling of sirtuin proteases, such as SIRT1 or SIRT3. The beneficial properties of SIRT1 and SIRT3 are as described above. Longevity protein activators simulate caloric restriction, enhance mitochondrial and cellular function, improve cell viability, extend cell lifespan, increase mitochondrial biogenesis, prevent fatty liver and muscle atrophy, and have anti-inflammatory, anti-diabetic, cardioprotective and anti-aging therapeutic effects. SIRT1 activators include but are not limited to laminin A, methylene blue, resveratrol, SRT-1460, SRT-1720, SRT-2104, SRT-2183 and their analogs, derivatives, fragments and salts. In addition to resveratrol, other polyphenols that activate sirtuins such as SIRT1 include but are not limited to butene, fisetin, isoliquiritigenin, amygdalin, quercetin and its analogs, derivatives and salts. Metformin increases NAD+ levels by activating the NAD+ salvage pathway enzyme nicotinamide phosphoribosyltransferase (NAMPT) and increasing the NAD+ / NADH ratio, thereby increasing the activity of sirtuins such as SIRT1. Other sirtuin activators include branched-chain amino acids and their metabolites, including but not limited to leucine and its metabolites such as hydroxymethylbutyrate and ketoisocaproate / isocaproate. These amino acids increase the levels of sirtuins such as SIRT1 and SIRT3 and stimulate their signaling.

[0232] AMPK activators include agents that increase the activity, level (e.g., expression), or signaling of 5'-AMP-activated protein kinase (AMPK). AMPK plays an important role in cellular energy homeostasis, primarily by stimulating glucose and fatty acid uptake and oxidation when cellular energy is low. AMPK activation stimulates lipolysis, fatty acid oxidation in the liver and skeletal muscle, ketogenesis, and glucose uptake, inhibits cholesterol and triglyceride synthesis and lipogenesis (including adipocyte lipogenesis), and regulates insulin secretion from pancreatic cells. AMPK activation can also increase NAD +AMPK activators include, but are not limited to, sirtuin activators (e.g., resveratrol, quercetin, metformin, and branched-chain amino acids and their metabolites), thiazolidinedione PPAR-γ agonists (hereinafter, such as pioglitazone and rosiglitazone), cannabinoids, 5-aminoimidazole-4-carboxamide-1-D-riboside, berberine, curcumin, dinitrophenol (DNP), epigallocatechin-3-gallate, α-lipoic acid, a-769662, PT-1, adiponectin, ghrelin, leptin, interleukin-6 (IL-6), and analogs, derivatives, fragments, and salts thereof.

[0233] CD38 expression and activity increase during aging, which reduces NAD + Levels, leading to metabolic dysfunction and diseases associated with aging (such as inflammatory diseases). Inhibition of CD38 increases NAD + level, thereby improving mitochondrial and cellular function, and increasing the activity of deacetylases such as SIRT1 and SIRT3. CD38 inhibitors include, but are not limited to, flavonoids (e.g., apigenin and quercetin), thiazoquinolines (thiazoquinazolinones), etc., disclosed in C. Haffner et al., J. Med. Chem., 58: 3548-3571 (2015) (e.g., compounds 76a, 76c, 77a, 77c, 77d, 78a, 78c, 78d, 78e, 79a, 79c and 79d) and their analogs, derivatives and salts.

[0234] Cellular oxygen consumption is a reliable indicator of mitochondrial activity because mitochondrial activity is responsible for almost all of the cell's oxygen use. Mitochondria play a key role in a variety of cellular processes, including energy production and biosynthesis. Drugs that increase mitochondrial activity can be used to treat mitochondrial diseases (such as Leigh syndrome and LHON), mitochondrial-related diseases and conditions (such as metabolic disorders and neurodegenerative diseases [such as Alzheimer's disease, Parkinson's disease, ALS, Friedreich's ataxia, and FXTAS]), help recover from injury (such as traumatic brain injury) or disease, and delay aging. Stimulators of cellular oxygen consumption increase mitochondrial activity by increasing mitochondrial function or / and number. Stimulators of cellular oxygen consumption include, but are not limited to, acarbose, chlormadinone (such as chlormadinone acetate), hydroxymethylprogesterone acetate, diclofenac, enilconazole, flumazenil, quinidine (such as quinidine gluconate), succinylsulfathiazole, toltrazuril and their analogs, derivatives and salts.

[0235] In some embodiments, one or more compounds of formula (I) are used in combination with an N-methyl-D-aspartate receptor (NMDAR) antagonist to treat diseases characterized by neurodegeneration or neurotoxicity, such as dementia (e.g., Alzheimer's disease) or motor neuron disease (e.g., Parkinson's disease). In certain embodiments, the NMDAR antagonist is a non-competitive antagonist (or channel blocker) that activates Mg in NMDAR open ion channels. 2+ The binding site or the vicinity of the dizocilpine (MK-801) / phencyclidine binding site has a medium affinity (e.g., K i or IC 50 The NMDAR non-competitive antagonists include, but are not limited to, alaproclate, amantadine, atomoxetine, budipine, delucemine, dextrallorphan, dextromethorphan, dextromethorphan, dexanabinol, eliprodil, ketamine, lanisamine, minocycline, memantine, nitromemantine, NEFA (a tricyclic small molecule), neramexane, o-phenadrine, procyclidine, ARL / FPL 12495 / 12495AA (the deglycine metabolite of rimacetamide), and analogs, derivatives, and salts thereof. In some embodiments, the NMDAR antagonist is memantine, nitromemantine, amantadine, lanisimine, neramexane, dexnalorphine, dextromethorphan, dextromethorphan (dextromethorphan metabolite) or procyclidine. In certain embodiments, the NMDAR antagonist is memantine, nitromemantine, dexnalorphine, dextromethorphan or dextromethorphan.

[0236] In a further embodiment, one or more compounds of formula (I) are used in combination with an acetylcholinesterase inhibitor (AChEI) to treat cognitive impairment (e.g., dementias such as Alzheimer's disease, Lewy body dementia, or Parkinson's disease) or neuromuscular diseases (e.g., myasthenia gravis). Reversible AChEIs include, but are not limited to, neostigmine, physostigmine, pyridostigmine, rivastigmine, ambenonium, demecarium, donepezil, edrophonium, ladostinil, and analogs, derivatives, and salts thereof.

[0237] Other therapeutic agents that can be used in combination with one or more compounds of structural formula (I) to treat Parkinson's disease include, but are not limited to, levodopa, dopamine agonists (e.g., apomorphine, bromocriptine, cabergoline, serotonin, pergolide, piribedil, pramipexole, ropinirole and rotigotine), catecholamine-O-methyltransferase (COMT) inhibitors (e.g., entacapone, opicapone and tolcapone), monoamine oxidase B (MAO-B) inhibitors (e.g., ladostinil, safinamide, selegiline and rasagiline), peripheral aromatic L-amino acid decarboxylase inhibitors (e.g., carbidopa), and analogs, derivatives and salts thereof.

[0238] In other embodiments, one or more compounds of formula (I) are used in combination with one or more antidiabetic drugs to treat hyperglycemia, insulin resistance or diabetes (e.g., type 1 or type 2), or diseases associated therewith (e.g., NAFLD or NASH). In certain embodiments, one or more antidiabetic drugs are or include biguanides (e.g., metformin), thiazolidinediones (e.g., pioglitazone or rosiglitazone), GLP-1 agonists (e.g., dulaglutide or semaglutide), or SGLT2 inhibitors (e.g., empagliflozin or togliflozin), or any combination thereof.

[0239] Antidiabetic drugs include, but are not limited to: AMP-activated protein kinase (AMPK) agonists, including biguanides (such as buformin, metformin and phenformin); peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists, including thiazolidinediones (such as balaglitazone, ciglitazone, darglitazone, englitazone, roglitazone, nyglitazone, pioglitazone, rivoglitazone, rosiglitazone and troglitazone) and saroglitazar (dual PPAR-α / γ agonist); glucagon-like peptide-1 (GLP-1) receptor agonists, including exendin-4, albiglutide, dulaglutide, exenatide, liraglutide, and tadalafil. glutide, lixisenatide, semaglutide, tasiroglutide, CNTO736, CNTO3649, HM11260C (LAPS exendin), NN9926 (OG9S7GT), TT401 and ZY0G1; dual GLP-1 receptor (GLP-1R) / glucagon receptor (GCGR) agonists, including long-acting gastric acid oxyntomodulin analogs {e.g., lipid-conjugated OXM analogs (e.g., DualAG disclosed in A. Pocai et al., Diabetes, 58:2258-2266

[2009] ), pegylated OXM analogs, cross-linked OXM analogs disclosed in A. Muppidi et al., ACS Chem. Biol., 11:324-328 (2016), and R.OX-SR} disclosed in Scott et al., Peptides, 104:70-77 (2018), HM12525A, JNJ-54728518, LY2944876 (TT-401), MEDI0382, MK-8521, MOD-6031, NN9277, SAR425899, SP-1373 and ZP2929; dual GLP-1R / gastric inhibitory peptide receptor (GIPR) agonists, including Cpd86, LY3298176, NN9709 (MAR709), SAR438335, ZP-DI-70 and ZP-I-98; triple GLP-1R / GIPR / GCGR agonists, including HM15211 and MAR423; dipeptidyl peptidase 4 (DP-4 P-4) inhibitors, including alogliptin, alagliptin, dulagliptin, ipragliptin, gemagliptin, golagliptin, linagliptin, ogliptin, osagliptin, saxagliptin, sepgliptin, sitagliptin, flutixitagliptin (des-fluoro-sitagliptin), teneligliptin, trelagliptin, vildagliptin; α-glucosidase inhibitors, including acarbose, miglitol, and voglibose; ketohexokinase (KHK) inhibitors, including PF-06835919; sodium glucose transporter 2 (SGLT2) inhibitors, including canagliflozin (also inhibits SGLT1), dapagliflozin, empagliflozin, erpagliflozin, ipragliptin, empagliflozin, sogliptin (also inhibits SGLT1), and togliflozin; ATP-dependent K. + (K ATP ) channel blockers, including toluenesulfonyl urea drugs (mitiglinide, nateglinide and repaglinide) and sulfonylurea drugs {including first-generation (such as acetohexamide, amoxicillin (hypoglycemic drug), chlorpropamide, glicyclamide [toluamide], methylcyclamide, toluenesulfonamide, tolbutamide, etc.) and second-generation (such as glibenclamide [glyburide], toluenesulfonamide, toluenesulfonamide, glimepiride, glipizide, gliquidone, glibenclamide, glyburide, etc.)}; insulin and its analogs, including rapid-acting insulin (for example, aspart insulin, glulisine insulin and lispro insulin), intermediate-acting insulin (for example, NPH insulin), long-acting insulin (for example, degludec insulin, detemir insulin and glargine insulin); and their analogs, derivatives and salts.

[0240] In further embodiments, one or more compounds of formula (I) are used in combination with one or more anti-obesity agents to treat obesity or hyperlipidemia or diseases associated therewith, such as metabolic diseases (such as T2D, metabolic syndrome or NAFLD) or cardiovascular diseases (such as atherosclerosis or coronary artery disease). Obesity can also promote inflammatory processes. In certain embodiments, one or more anti-obesity agents are or include lipase inhibitors (such as orlistat) and / or anti-hyperlipidemia agents (such as statins such as atorvastatin, and / or fibrates such as fenofibrate).

[0241] Anti-obesity drugs include, but are not limited to: appetite suppressants (anorexiters), including amphetamine, dextroamphetamine, dimethoprim, clobenzyl, clomiphene, phentermine (with or without topiramate), and lorcaserin; satiety promoters, including ciliary neurotrophic factor (such as axokine) and long-acting analogs of amylin, calcitonin, cholecystokinin (CCK), glucagon (GCG), GLP-1, gastric inhibitory peptide (GIP, also known as glucose-dependent insulinotropic polypeptide), leptin, gastromodulin (OXM), pancreatic polypeptide (PP), peptide YY (PYY), and neuropeptide Y (NPY); lipase inhibitors, including fernleaf, salistat, lipase immunosuppressant A and B, lipase inhibitors, lipostatin, orlistat, percyquinin, panclicin A-E, valinolone, and tenascin; drugs that increase energy expenditure or / and fat burning drugs, including long-acting glucagon analogs, glucagon receptor agonists (such as NN9030) and GLP-1 receptor / glucagon receptor dual agonists (see above); triiodothyronine (T3) and thyroid hormone receptor β (THR-) agonists (e.g., MB07344, MB07811, MGL-3196, MGL-3745, VK0214 and VK2809); and fibroblast growth factor 21 (FGF21) and its analogs and derivatives (e.g., BMS-986036 [PEGylated FGF21]); anti-hyperlipidemic drugs; other drugs that reduce weight and / or fat mass, including dual GLP-1R / GIPR agonists (as described above) and triple GLP-1R / GIMR / GCGR agonists (as described above); and their analogs, derivatives and salts.

[0242] Anti-hyperlipidemic drugs include, but are not limited to: HMG-CoA reductase inhibitors, including statins {e.g., atorvastatin, simvastatin, fluvastatin, mevastatin, statin components, (e.g., monacolin K [lovastatin]), pitavastatin, pravastatin, rosuvastatin, and simvastatin} and flavanones (e.g., naringenin)); squalene synthase inhibitors, including lapastatin, zalaguzic acid, and RPR-107393; acetyl-CoA carboxylase (ACC) inhibitors, including anthocyanidins, avenin, chloroacetylated biotin, cyclodimethylene, dichlorvos-methyl, clofothyl-methyl, sorafenib (sorafen A 1α )、5-(tetradecyloxy)-2-furancarboxylic acid (TOFA), CP-640186, GS-0976, NDI-010976; 7-(4-propoxy-phenylethynyl)-3,3-dimethyl-3,4-dihydro-2H-benzo[b][1,4]dioxepane; N-ethyl-N'-(3-{[4-(3,3-dimethyl-1-oxo-2-oxa-7-azaspiro[4.5]dec-7-yl)piperidin-1-yl]-carbonyl}-1-benzothiophene-2-yl)urea; 5-(3-acetylaminobutyric acid)- 1-(3-{[4-(3,3-dimethyl-1-oxo-2-oxa-7-azaspiro[4.5]dec-7-yl)piperidin-1-yl]-carbonyl}-5-(pyridin-2-yl)-2-thienyl)-3-ethylurea; ATP citrate lyase (ACL) inhibitors, including benzoic acid (ETC-1002), 2-furancarboxylic acid, (-)-hydroxycitric acid, BMS-303141, MEDICA-16, and SB-204990; PPAR-α Agonists, including fibrates (e.g., bezafibrate, ciprofibrate, clinofibrate, clofibric acid, clofibrate, alfibrate, clofibramide, etofibrate, fenofibrate, fenofibrate, gemfibrozil, cloniafibrate, and clofibrate), isoflavones (e.g., daidzein and genistein), and perfluoroalkanoic acids (e.g., perfluorooctanoic acid and perfluorononanoic acid); PPAR-delta agonists, including Elafibranor (a dual PPAR-alpha / delta agonist), Lanilanor (a triple PPAR-alpha / delta / gamma agonist), GFT505 (a PPAR-delta agonist), and phenoxyethanol (a PPAR-delta agonist). PPAR-γ agonists include thiazolidinediones (see above), saroglitazar (PPAR-α / γ dual agonist), 4-oxo-2-thiothiamine (e.g., rhodanine), berberine, honokiol, perfluorononanoic acid, cyclopentenone prostaglandins (e.g., cyclopentenone 15-deoxy-Δ-prostaglandin J 2 [15d-PGJ2])) and isoflavones (such as daidzein and genistein); liver X receptor (LXR) agonists, including endogenous ligands (e.g., oxysterols such as 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 27-hydroxycholesterol, and cholenic acid) and synthetic agonists (e.g., acetylpodophyllotoxin dimer, sulfenamide, N,N-dimethyl-3β-hydroxycholesterolamide [DMHCA], GW3965, and T0901317); retinoid X receptor (RXR) agonists, including endogenous ligands (such as 9-cis retinoic acid) and synthetic agonists (such as bexarotene, AGN 191659, AGN 191701, AGN 192849, BMS649, LG100268, LG100754, and LGD346); triiodothyronine and thyroid hormone receptor beta agonists (see above); ketohexokinase inhibitors (see above); acyl-CoA cholesterol acyltransferase inhibitors (ACAT, also known as sterol O-acyltransferase [SOAT], including ACAT1 [SOAT1] and ACAT2 [SOAT2]), including avasimibe, patimibe, pellitorine, terpenoid indole C, and Flavanones (such as naringenin); inhibitors of stearoyl-CoA desaturase-1 (SCD-1, also known as stearoyl-CoA-delta-9 desaturase) activity or expression, including anandamide cholic acid (arachidamidocholic acid), CAY-10566, CVT-11127, SAR-224, SAR-707, XEN-103; 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and 4-ethylamino- 3-(2-Hydroxymethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide; 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine]; 5-Fluoro-1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] -piperidine]; 6-[5-(cyclopropylmethyl)-4,5-dihydro-1'H,3H-spiro[1,5-benzoxazine-2,4'-piperidin]-1'-yl]-N-(2-hydroxy-2-pyridin-3-ylethyl)pyridazine-3-carboxamide; 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide; 4-(2-chlorophenoxy)-N-[3-(methylcarbamoyl)phenyl]piperidine-1-carboxamide;The cis-9, trans-11 isomers and trans-10, cis-12 isomers of conjugated linoleic acid disclosed in WO 2009 / 129625A1, substituted heteroaromatic compounds, antisense polynucleotides and peptide nucleic acids (PNA) targeting SCD-1 mRNA, and siRNA targeting SCD1; cholesterol transfer protein (CETP) inhibitors, including anacetrapib, dalcetrapib, irasetrapib and torcetrap, and AMG 899 (TA-8995); inhibitors of microsomal triglyceride transfer protein (MTTP) activity or expression, including implitapide, lomitapide, deslotripaide, miritapide, CP-346086, JTT-130, SLx-4090, targeting MTTP mRNA antisense polynucleotides and PNA, micRoRNAs targeting MTSP (such as miRNA-30c) and siRNA targeting MTTP; GLP-1 receptor agonists (see above), glucagon receptor agonists; fibroblast growth factor 21 (FGF21) and its analogs and derivatives, including BMS-986036 (PEGylated FGF21); proprotein convertase subtilisin / kexin PCSK9 activity or expression inhibitors include berberine (reduces PCSK9 levels), annexin A2 (inhibits PCSK9 activity), anti-PCSK9 antibodies (e.g., alirocumab, bococizumab, evolocumab, LGT-209, LY3015014, and RG7652), peptides that mimic the epidermal growth factor-A (EGF-A) domain of the LDL receptor that binds to PCSK9, PCSK9-binding adnectins (e.g., BMS-962476), antisense polynucleotides and PNAs targeting PCSK9 mRNA, and siRNA targeting PCSK9 (e.g., insiliran [ALN-PCS] and ALN-PCS02); FGF21 and its analogs and derivatives (see above). They also include anti-ANGPTL3, anti-ANGTPT4, anti-ANGPTL3 / 8 monoclonal antibodies and siRNA targeting ANGPTL3 under development for the treatment of glucocorticoids.

[0243] Apolipoprotein mimetic peptides include apoA-I mimetic peptides (e.g., 2F, 3F, 3F-1, 3F-2, 3F-14, 4F, 4F-P-4F, 4F-IHS-4F, 4F2, 5F, 6F, 7F, 18F, 5A, 5A-C1, 5A-CH1, 5A-CH2, 5A-H1, 18A, 37pA [18A-P-18A], ELK [name], ELK-1A, ELK-1F, ELK-1A1E, ELK-1L1K, ELK-1W, ELK-2A, E LK-2A2K2E, ELK-2E2K, ELK-2F, ELK-3E3EK, ELK-3E3K3A, ELK-3E3LK, ELK-PA, ELK-P2A, ELKA[name], ELKA-CH2, ATI-5261, CS-6253, ETC-642, FAMP[name], FREL[name], and KRES[name]]) and apoE mimetics (e.g., Ac-hE18A-NH2[AEM-28], Ac-[R]hE18A-NH 2 , AEM-28-14, EpK, hEp, mR18L, COG-112, COG-133 and COG-1410); omega-3 fatty acids, including docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), eicosapentaenoic acid, alpha-linolenic acid (ALA), fish oils (containing, for example, DHA and EPA) and esters thereof (e.g., glycerides and ethyl esters); and analogs, derivatives and salts thereof.

[0244] In other embodiments, one or more compounds of formula (I) are used in combination with an antiplatelet agent or / and an anticoagulant to treat thrombotic or hemostatic diseases, such as cardiovascular diseases (such as myocardial ischemia / infarction) or cerebrovascular diseases (such as ischemic stroke). In certain embodiments, the antiplatelet agent is or includes a COX-1 inhibitor (e.g., aspirin) or / and a P2Y 12 The anticoagulant is or includes a direct factor Xa inhibitor (eg, apixaban or rivaroxaban) or / and a direct thrombin inhibitor (eg, dabigatran).

[0245] Antiplatelet drugs include, but are not limited to, cyclooxygenase (COX-1) inhibitors, including bispyribac, naproxen, triflusal, and 2-hydroxy-4-trifluoromethylbenzoic acid (the major metabolite of triflusal); and thromboxanes (e.g., A 2 ) synthase inhibitors, including dipyridamole, ifetroban, ibogrel, picotamide, ramatroban, ridogrel, smixogrel, terbogrel, truroban, and EV-077; thromboxanes (such as A 2) receptor antagonists, including cangrelor, clopidogrel, prasugrel, ticagrelor and ticlopidine; adenosine reuptake inhibitors, including cilostazol and dipyridamole; GPⅡb / Ⅲa inhibitors, including abciximab, eptifibatide, tirofiban, TRA-418, prostacyclin and its analogs; phosphodiesterase (e.g., PDE3 or / and PDE5) inhibitors, including cilostazol and dipyridamole; protease activated receptor 1 (PAR1) antagonists, including vorapaxar; prostacyclin and its analogs, including aprost, beraprost, (e.g., uberprost), 5,6,7-trinor-4,8-m-phenyl-9-fluoro-PGI 2 , carbetocin, isocarbetocin, clinprostil (isocarbetocin methyl ester), ciprostene, eptaprost, cicarprostil (a metabolite of eptaprost), iloprost, pyraprostil, SM-10906 (desmethylpyraprostil), nasaprost, tacrolimus, treprostinil, CS-570, OP-2507, TY-11223; and their analogs, derivatives and salts.

[0246] Anticoagulants include, but are not limited to, vitamin K antagonists, including 4-hydroxycoumarins (e.g., acenocoumarol, brodifacoum, coumatetralin, dicoumarol, phenprocoumon, ticlomol, and warfarin) and 1,3-indanediones (e.g., chloranil, benzoquinone, fluridone, and phenidyldione); indirect factor Xa inhibitors, including heparin (regular), low molecular weight heparin (e.g., Low molar heparin derivatives (e.g., bemiparin, certoparin, dalteparin, enoxaparin, nadroparin, parparin, reviparin and tinzaparin), heparin analogs (e.g., fondaparinux and idroparinux) and heparinoids (e.g., danaparatide, sulodexide, dermatan sulfate); direct factor Xa inhibitors, including apixaban, betrixaban, darexaban, edoxaban, edoxaban, lenaxaban, omixaban, lazaxaban, rivaroxaban, LY-517717 and YM-466; direct thrombin (factor IIa) inhibitors (DTIs), including monovalent DTIs (e.g., argatroban, dabigatran, enogatran, melagatran and ximelagatran) and divalent DTIs (e.g., hirudin and hirudin analogs [e.g., bivalirudin, desirudin and lepirudin]); and analogs, derivatives and salts thereof.

[0247] In another embodiment, one or more compounds of formula (I) are used in combination with one or more antihypertensive agents. Hypertension is a clinical feature or major risk factor for a variety of diseases. Hypertension-related diseases include, but are not limited to, cardiovascular disease (such as cardiomyopathy, heart failure, atherosclerosis, arteriosclerosis, coronary artery disease [such as myocardial ischemia / infarction] and peripheral vascular disease [such as peripheral arterial disease]), cerebrovascular disease (such as stroke and cerebral infarction), metabolic disease (such as metabolic syndrome and T2D), kidney disease (such as diabetic nephropathy, glomerulonephritis, renal ischemia, nephrotic syndrome and renal failure [such as acute renal injury and chronic kidney disease]), liver failure (such as cirrhosis) and eye disease (such as retinopathy, ocular vascular damage and vision loss).

[0248] Antihypertensive drugs include, but are not limited to, renin-angiotensin-aldosterone system (RAAS) antagonists, including renin inhibitors (such as aliskiren), angiotensin-converting enzyme (ACE) inhibitors (such as benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and tredopril), angiotensin II receptor type 1 (AT1), and ACE inhibitors. 1 ) antagonists (such as azilsartan, candesartan, eprosartan, fimasartan, irbesartan, losartan, olmesartan medoxomil, olmesartan, telmisartan, and valsartan) and aldosterone receptor antagonists (such as eplerenone and spironolactone); diuretics, including loop diuretics (such as bumetanide, ethacrynic acid, furosemide, and torsemide), thiazide diuretics (such as bendrofluazide, hydrochlorothiazide, hydrochlorothiazide, epithiazide, methylclomethiazide, and polythiazide), thiazide diuretics (for example, chlorthalidone, indole, Calcium channel blockers, including dihydropyridines (e.g., amlodipine, levamlodipine, cilnidipine, clevidipine, felodipine, isradipine, lercanidipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, etc.) and non-dihydropyridines (e.g., diltiazem and verapamil); 2 -Adrenergic receptor agonists, including clonidine, guanabenz, guanfacine, methyldopa, and moxonidine; alpha 1Adrenergic receptor antagonists (alpha blockers), including doxazosin, indolaamine, nicergoline, phenoxybenzamine, phentolamine, prazosin, terazosin, tolazoline; beta-adrenergic receptor (1 or / and 2) antagonists (beta blockers), including atenolol, betaxolol, bisoprolol, carteolol, carvedilol, labetalol, metoprolol, naproxenolol, nebivolol, propranolol, penbutolol, propranolol, timolol; mixed alpha / beta blockers, including bucinolol, carvedilol, and labetalol; endothelin receptor antagonists, including selective ET A Receptor antagonists (such as ambrisentan, atrasentan, edonatan, sitaxsentan, zibotentan, BQ-123, etc.) and ETA / ETB dual antagonists (such as bosentan, macitentan, tezosentan, etc.); other vasodilators include hydralazine, minoxidil, theobromine, sodium nitroprusside, organic nitrates (for example, isosorbide mononitrate, isosorbide dinitrate and nitroglycerin, which are in nitric oxide (NO) is converted to nitric oxide in the body), endothelial nitric oxide synthase (eNOS) stimulators (e.g., cilclotanide), soluble guanylate cyclase activators (e.g., cinaciguat and riociguat), phosphodiesterase 5 (PDE5) inhibitors (avanafil, benzophenone, dasafil, dynamic heat stress, lodenafil, milonafil, sildenafil, tadalafil, udenafil, vardenafil, Dipyridamole, papaverine, propentofylline, melphalan, T-1032), prostaglandin E1 (alprostadil) and its analogs (e.g., limaprost and misoprostol), prostacyclin and its analogs (above), non-prostaglandin prostacyclin receptor agonists (e.g., ocrelate (1-phthalazinol), ralinepag, selexipag, ACT-333679 [MRE-269, the active metabolite of selexipag], and TRA-418), phospholipase C (PLC) inhibitors and protein kinase C (PKC) inhibitors (e.g., BIM-1, BIM-2, BIM-3, BIM-8, chelerythrine, cilostane, gossypol, caesalpinol, myricetin, rubustard, verbascoside); minerals, including magnesium and magnesium sulfate; and their analogs, derivatives and salts.

[0249] In certain embodiments, the one or more antihypertensive drugs are or include a thiazide or thiazide-like diuretic (e.g., hydrochlorothiazide or chlorthalidone), a calcium channel blocker (e.g., amlodipine or nifedipine), an ACE inhibitor (e.g., benazepril, captopril, or perindopril), or an angiotensin II receptor antagonist (e.g., olmesartan medoxomil, olmesartan, telmisartan, or valsartan), or any combination thereof.

[0250] In a further embodiment, one or more compounds of formula (I) are used in combination with one or more antioxidants to treat diseases whose pathogenesis or pathophysiology involves oxidative stress and / or oxidative damage / injury. Such oxidative diseases include, but are not limited to, neurodegenerative diseases (such as Alzheimer's, Huntington's and Parkinson's diseases, ALS and multiple sclerosis), metabolic diseases (such as type 1 and type 2 diabetes and metabolic syndrome), cardiovascular diseases (such as atherosclerosis, heart failure, myocardial ischemia / infarction and IRI), cerebrovascular diseases (such as stroke and IRI, kidney diseases (such as diabetic nephropathy), liver diseases (such as cirrhosis) and eye diseases (such as AMD). In addition, oxidants (such as ROS) and oxidized molecules (such as oxidized lipids) may be highly inflammatory.

[0251] Antioxidants include but are not limited to: vitamins and their analogs, including vitamin A, vitamin B 3(e.g., niacin and niacinamide), vitamin C (ascorbic acid), vitamin E (including tocopherols [e.g., alpha-tocopherol] and tocotrienols) and vitamin E analogs (e.g., trolox [water-soluble]); carotenoids, including carotenes (e.g., beta-carotene), xanthophylls (e.g., lutein, zeaxanthin, and mesozeaxanthin), and carotenoids from saffron (e.g., crocin and crocin); sulfur-containing antioxidants, including glutathione (GSH), N-acetyl-L-cysteine ​​( NAC), bupivacaine, S-nitroso-N-acetyl-L-cystine (SNAC), S-allyl L-cysteine ​​(SAC), S-adenosyl-L-methionine (SAM), alpha-lipoic acid, and taurine; scavengers of ROS and free radicals, including carnosine, N-acetyl carnosine, curcuminoids (such as curcumin, demethoxycurcumin, and tetrahydrocurcumin), cysteamine, ebselen, glutathione, hydroxycinnamic acids and their derivatives (such as esters and amides) (such as caffeic acid, rosmarinic acid, and tranilast), melatonin and its metabolites products, nitronates (e.g., sodium disulphonate [NXY-059]), nitrogen oxides (e.g., XJB-5-131), polyphenols (e.g., flavonoids [e.g., apigenin, genistein, luteolin, naringenin, and quercetin]), superoxide dismutase mimetics (hereinafter), tirilazad, vitamin C, vitamin E and its analogs (e.g., α-tocopherol and quinoline dimethacrylate), and xanthine derivatives (e.g., pentoxifylline); inhibitors of enzymes that generate ROS, including NADPH oxidase (NOX) inhibitors (e.g., apocynin, pursedrin and pursedrin angelate [both inhibit the activity and expression of NOX-1, NOX-2, and NOX-4], diphenyliodonium and GKT-831 [formerly GKT-137831, a dual NOX1 / 4 inhibitor]), NADH:ubiquinone oxidoreductase (complex I) inhibitors (e.g., metformin and rotenone), and myeloperoxidase inhibitors (e.g., azide and 4-aminobenzoic acid hydrazide, as well as apoE mimetics such as AEM-28 and AEM-28-14);Substances that mimic or increase the activity or production of antioxidant enzymes, including superoxide dismutase (SOD) {e.g., SOD mimetics, such as manganese (III) and zinc (III)-porphyrin complexes (e.g., MnTBAP, MnTMPyP, and ZnTBAP), manganese (II) pentaazamacrocyclic complexes (e.g., M40401 and M40403), manganese (III)-salen complexes [e.g., US 7,122,537]] and OT-551 (a cyclopropyl ester prodrug of bisphenol hydroxylamine), resveratrol and apoA-I mimetics such as 4F (both increase expression)}, catalase, catalase (such as catalase mimetics such as manganese (III)-salen complex [e.g., disclosed in U.S. Pat. No. 7,122,537] and zinc [increase activity]), glutathione peroxidase (GPx) (e.g., apomorphine and zinc [both increase activity], and β-catenin, etoposide and resveratrol [both increase expression]), increased expression]), reduced glutathione reductase (e.g., 4-tert-butylcatechol and redox cofactors such as flavin adenine dinucleotide [FAD] and NADPH [all increased activity]), glutathione S-transferase (GST) (e.g., phenylalkyl isothiocyanate cysteine ​​conjugates {e.g., S-[N-benzyl(thiocarbamoyl)]-L-cysteine}, luminal, rosemary extract, and carnosine [all enhanced activity]), thioredoxin (TRx) (e.g., geranylgeranylacetone, prostaglandin E; 1and sulforaphane [both increased expression]), NADPH-quinone oxidoreductase 1 (NQO1) {e.g., flavonoids [e.g., β-naphthoflavone (5,6-benzoflavone)] and triterpenes [e.g., oleanolic acid analogs such as TP-151 (CDDO), TP-155 (CDDO methyl ester), TP-190, TP-218, TP-222, TP-223 (CDDO carboxamide), TP-224 (CDDO monocarboxamide), TP-225, TP-226 ( CDDO dimethylamide), TP-230, TP-235 (CDDO imidazole), TP-241, CDDO monoethylamide, CDDO mono(trifluoroethyl)amide, and (+)-TBE-B], all of which increase expression by activating Nrf2}, heme oxygenase 1 (HO-1) For example, curcuminoids (e.g., curcumin), triterpenoids (e.g., oleanolic acid analogs [as above, such as TP-225]), and apoA-I mimetics (as above, such as 4F), all of which increase increase expression}, and paraoxonase 1 (PON-1) (e.g., apoE mimetics [above, such as AEM-28 and AEM-28-14] and apoA-I analogs [above, such as 4F], both of which increase activity); activators of transcription factors that upregulate expression of antioxidant enzymes, including activators of nuclear factor (erythroid-derived 2)-like 2 (NFE2L2 or Nrf2) {e.g., bardoxolone methyl, OT-551, fumarates (e.g., dimethyl fumarate and monomethyl fumarate) ), dithiothiones (e.g., oltipraz), flavonoids (e.g., β-naphthoflavone), isoflavones (e.g., genistein), sulforaphane, trichostatin A, triterpenoids (e.g., oleanolic acid analogs [above, such as TP-225]), and melatonin (which increases Nrf2 expression); mitochondrial-targeted antioxidants, including MitoE and MitoQ; other classes of antioxidants, including anthocyanidins, benzoic acid abutilon diterpenes (e.g., carnosic acid), cyclopentenone prostaglandins (e.g., 15d-PGJ 2 ), flavonoids {such as those in Ginkgo biloba (such as myricetin and quercetin [which increase levels of glutathione, superoxide dismutase, catalase, GPx, and GST]), prenylated flavonoids (such as isoxanthohumol), flavonoids (such as apigenin), isoflavones (such as genistein), flavanones (such as naringenin), and flavanols (such as catechins and epigallocatechin-3-gallate)}, omega-3 fatty acids and their esters (see above), phenethyl alcohols (such as tyrosol and hydroxytyrosol), retinoids (such as all-trans-retinol [vitamin A]), stilbenes (such as resveratrol), uric acid, apoA-I mimetics (such as 4F), apoE mimetics (such as AEM-28 and AEM-28-14), and minerals (such as selenium and zinc [such as zinc monocysteine]); and their analogs, derivatives, and salts.

[0252] In certain embodiments, the one or more antioxidants are or include vitamins or their analogs (e.g., vitamin E or its analogs, such as α-tocopherol or quinoline dimethacrylate) or / and ROS or free radical scavengers (e.g., melatonin or / and glutathione). In other embodiments, the antioxidant or / and natural compound is selected from resveratrol, pterostilbene, ellagic acid, urolithin A, quercetin, coenzyme Q, glutathione, N-acetyl-L-cysteine, α-lipoic acid, melatonin, creatine, S-adenosylmethionine, leucine, pyruvate / pyruvic acid and combinations thereof.

[0253] In some embodiments, one or more compounds of formula (I) are combined with thiamine (B 1 ), riboflavin (B 2 ), niacin (B 3 ), pantothenic acid (B 5 ), pyridoxine (B 6 ), biotin (B 7 ), folic acid (B 9 ) and cobalamin (B 12 ) is used in combination with one or more B vitamins. In certain embodiments, one or more compounds of formula (I) are used in combination with vitamin B 1 , B 2 , B 3 or B 6 or any combination thereof.

[0254] In other embodiments, one or more compounds of formula (I) are used in combination with one or more anti-inflammatory agents to treat inflammatory diseases. Inflammation contributes to the pathogenesis or pathophysiology of a variety of diseases. In addition, inflammation is a major stimulus for fibrosis. In certain embodiments, one or more anti-inflammatory agents are or include NSAIDs or / and inhibitors of proinflammatory cytokines or their receptors or their production (e.g., TNF-α, IL-4, IL-6, or IL-23, or any combination thereof).

[0255] Anti-inflammatory drugs include, but are not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs), including those listed below; immunomodulators, including imides (such as thalidomide, lenalidomide, pomalidomide, and apremilast) and xanthine derivatives (such as lisofylline, pentoxifylline, and propentofylline); immunosuppressants, including interferon beta (IFN-β), glucocorticoids (described below), antimetabolites (such as hydroxyurea [hydroxyurea], antifolates [such as methotrexate], and purine analogs [such as azathioprine, mercaptopurine, and thioguanine]), pyrimidine synthesis inhibitors (such as leflunomide and teriflunomide), calcineurin inhibitors (such as cyclosporine [cyclosporine A], pimecrolimus, and tacrolimus), inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors (such as mycophenolic acid and its derivatives [such as mycophenolate sodium and mycophenolate mofetil]), rapamycin ( Mechanistic / mammalian target of sirolimus (mTOR) inhibitors (e.g., sirolimus, rufolimus, everolimus, temsirolimus, umimios, zotarolimus, and RTP-801), sphingosine-1-phosphate receptor modulators (e.g., S1PR1) (e.g., fingolimod), and serine C-palmitoyltransferase inhibitors (e.g., myricetin); anti-inflammatory cytokines and compounds that increase their production, including IL-10 and compounds that increase IL-10 production {e.g., S-adenosyl-L-methionine, melatonin, metformin, rotenone, curcuminoids (e.g., curcumin), prostacyclins and their analogs (as described above), triterpenes (e.g., oleanolic acid analogs [as described above, such as TP-225]), and apoA-I mimetics (as described above, such as 4F);Inhibitors of proinflammatory cytokines or their receptors, including (e.g., inhibitors of antibodies or fragments thereof targeting tumor necrosis factor alpha (TNF-α) (e.g., adalimumab, certolizumab pegol, imumab, infliximab, etanercept, bupropion, curcumin, catechins, and ART-621) or its receptor (TNFR1), inhibitors of thymic stromal lymphopoietin (e.g., anti-TSLP antibodies and fragments thereof [e.g., tezepelumab and M702] and immunoconjugates comprising the extracellular domain of TSLPR) or its receptor (TSLPR), inhibitors (e.g., antibodies or fragments thereof targeting) proinflammatory interferons (e.g., interferon alpha [IFN-α]) or its receptors, inhibitors of proinflammatory interleukins or their receptors (e.g., antibodies or fragments thereof targeting) {e.g., IL-1 (e.g., IL-1α and IL- 1β (e.g., canakinumab and levofloxacin) or IL-1R (e.g., anakinra and isunakinra [EBI-005]), IL-2 or IL-2R (e.g., basiliximab and daclizumab), IL-4 or IL-4R (e.g., dupilumab), IL-5 (e.g., mepolizumab and reslizumab) or IL-5R, IL-6 (e.g., clazakinumab, icilizumab, olizumab, cetuximab) , IL-13 or IL-13R, IL-15 or IL-15R, IL-17 (e.g., ixekizumab and secukinumab) or IL-17R (e.g., bodalumab), IL-18 (e.g., GSK; 1070806) or IL-18R, IL-20 (e.g., antibody 7E) or IL-20R, IL-22 (e.g., fizakumab), or IL-22R, IL-23 (e.g., Brienuka, guselkumab, liscenzumab, tetracycline [SCH-90022], ustenumab, and BI-655066) or IL-23R, IL-31 (e.g., disclosed in US9822177) and monocyte chemoattractant protein 1 (MCP-1) inhibitors {e.g., bindali, anti-MCP1 antibodies (e.g., 5D3-F7 and 10F7), MCP1 binding peptides (e.g., HSWRHFHTLGGG (SEQ ID NO: 136), HSWRHFHTLGGG (SEQ ID NO: 137), ... NO:2)) and MCP1 binding RNA aptamers (e.g., ADR22 and mNOX-E36 [spiegelmer])} or their receptors (e.g., CCR2 antagonists such as spiropiperidines [e.g., RS-29634, RS-102895, and RS-504393]); inhibitors of proinflammatory cytokine or receptor production, including TNF-α {e.g., N-acetyl-L-cysteine, S-adenosyl-L-methionine, L-carnitine, hydroxychloroquine, melatonin, parthenolide, pirfenidone, sulfasalazine, mesalamine (5-aminosalicylic acid), taurine, flavonoids (e.g., epigallocatechin-3-gallate [EGCG], naringenin, and quercetin), omega-3 fatty acids and their esters, glucocorticoids, immunomodulatory imide and xanthine derivatives, PDE4 inhibitors, serine protease inhibitors (e.g., gabexate and nafamostat), inhibitors of prostacyclin and its analogs, SOCS1 mimetics (see below), myxoma virus M013 protein, Yersinia YopM protein, apoA-I mimetics (e.g., 4F) and apoE mimetics (e.g., AEM-28 and hEp)}, IFN-α (e.g., afacept), IL-1 (e.g., IL-1α and IL-1β) (e.g., chloroquine, hydroxychloroquine, nafamostat, pirfenidone, sulfasalazine, mesalamine, prostacyclin and its analogs, glucocorticoids, TNF-α inhibitors, PAR1 antagonists [e.g., vorapaxel], M013 protein, YopM protein and apoA-I mimetics [e.g., 4F], IL-1 (e.g., melatonin, metformin, rotenone, flavonoids [e.g., EGCG and naringenin]), annexin A 1 mimetics and caspase-1 inhibitors [such as belnacasan, pralnacasan, and parthenolide]), IL-2 (e.g., glucocorticoids, calcineurin inhibitors, and PDE 4inhibitors), IL-4 (e.g., glucocorticoids and serine protease inhibitors [e.g., gabexate and nafamostat]), IL-5 glucocorticoids), IL-12 (e.g., apimod, PDE4 inhibitors and YopM proteins), IL-15 (e.g., YopM proteins), IL-17 (e.g., protein kinase C inhibitors such as sotadarin), IL-18 (e.g., M013 proteins, YopM proteases and caspase-1 inhibitors), and IL-23 (e.g., apimod, alexicept and PDE4 inhibitors) and MCP-1 (e.g., EGCG, melatonin and tranilast); pro-inflammatory transcription factors or Inhibitors of its activation or expression, including inhibitors of NF-κB or its activation and expression {e.g., aliskiren, melatonin, minocycline and parthenolide (all inhibiting NF-κB nuclear translocation), nafamostat, niclosamide, (-)-DHMEQ, IT-603, IT-901, PBS-1086, flavonoids (e.g., EGCG and quercetin), hydroxycinnamic acid and its esters (e.g., caffeic acid ethyl ester), lipoxins (e.g., 15-epi-LXA4 and LXB4), ω-3 fatty acids and their esters, stilbenes (e.g., resveratrol), statins (e.g., rosuvastatin), triterpenes (e.g., oleanolic acid analogs, such as TP-225), TNF-α inhibitors, apoE mimetics (such as AEM-28), M013 proteins, penetratin and longevity protein 1 activators (SIRT1, inhibiting NF-κB) (such as flavonoids [such as luteolin], phenylethanols [such as tyrosol, inducing SIRT1 expression], stilbenes [such as resveratrol, increasing SIRT1 activity and expression] and laminin A)}, and inhibitors of STAT (signal transducer and activator of transcription) proteins or their activation or expression {e.g., Janus kinase 1 (JAK1) inhibitors (e.g., itatinib, upadacitinib, GLPG0634 and GSK2586184), JAK2 inhibitors (e.g., lestaurtinib, paclitinib, CYT387, TG101348, SOCS1 mimetics and SOCS3 mimetics), JAK3 inhibitors (e.g., ASP-015K, R348, and VX-509), JAK1 / JAK2 dual inhibitors SOCS1-KIR, NewSOCS1-KIR, PS-5, and Tkip] and SOCS3 mimetics), niclosamide, hydroxycinnamic acids and their esters (e.g., rosmarinic acid), and lipoxins (e.g., 15-epi-LXA4 and LXB4); proinflammatory prostaglandins (e.g., prostaglandin E 2 [PGE 2]) or its receptors (such as EP3) or inhibitors of their production, including cyclooxygenase inhibitors (such as nonsteroidal anti-inflammatory drugs [including non-selective COX-1 / COX-2 inhibitors such as aspirin and selective COX-2 inhibitors such as coxib], glucocorticoids [inhibit COX activity and expression], ω-3 fatty acids and their esters, curcuminoids [such as curcumin], stilbenes [such as resveratrol, inhibit COX-1 and COX-2 activity and expression], vitamin E and its analogs [such as α-tocopherol and quinolone dimethacrylate], cyclopentenone prostaglandins (such as prostaglandin J 2 [PGJ 2 ], Δ12-PGJ 2 and 15-deoxy-Δ12,14-PGJ 2), hydroxycinnamic acids and their esters (e.g., caffeic acid ethyl ester, which inhibits COX-2 expression), and triterpenoids (e.g., oleanolic acid analogs, such as TP-225, which inhibits COX-2 expression); inhibitors of leukotrienes or their receptors or their production, including cysteinyl leukotriene receptor 1 (cysLTR1) antagonists (e.g., cilostazol, gemilukast [a dual cysLTR1 / cysLTR2 antagonist], ilikast, montelukast, procalcitonin, tadalafil, tadalafil, sirolimus ... lenkast, tolukast, velukast, and zafirlukast), CP-195494, CP-199330, ICI-198615, MK-571, and lipoxins [e.g., LXA4 and 15-epi-LXA4]), cysLTR2 antagonists (e.g., HAMI-3379), 5-lipoxygenase (5-LOX) inhibitors (e.g., baicalin, caffeic acid, curcumin, hyperforin, gamma-linolenic acid [GLA], meclofenamic acid, meclofenamic acid), sodium fenamate, minocycline, zileuton, MK-886, and omega-3 fatty acids and their esters), and immunomodulatory xanthine derivatives; phospholipase A2 inhibitors (e.g., secretory and cytosolic PLA2), including glucocorticoids, arachidonic acid trifluoromethyl ketone, bromoenol lactone, chloroquine, cytidine 5-diphosphamide, darelatin, quinacrine, vitamin E, RO-061606, ZPL-521, lipocorticoids (annexins, such as annexin A1), and annexin peptidomimetics (e.g., annexin A1 mimetics [e.g., Ac2-26 and CGEN-855A]); inhibitors of C-reactive protein (CRP) activity or levels, including statins (e.g., rosuvastatin), thiazolidinediones (as described above), DPP-4 inhibitors (as described above), stilbenes (e.g., resveratrol), epigallocatechin gallate, and CRP-i2; mast cell stabilizers, including cromoglycine. acid) (cromolyn), methylpyrrolidone, methylxanthines, nedocromil, nicotinamide, olopatadine, omalizumab, pemirolast, quercetin, and zinc sulfate; phosphodiesterase inhibitors, including PDE4 inhibitors (e.g., aprilistat, cilomilast, ibudilast, piramilalast, roflumilast, crisaborole, diazepam, digitoxan, mesembryant, rolipram, AN2728, and E6005);Specialized pro-resolving mediators (SPMs) include metabolites of polyunsaturated fatty acids (PUFAs), such as lipoxins (e.g., LXA4, 15-epi-LXA4, LXB4, and 15-epi-LXB4), resolvins (e.g., resolvins derived from 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic acid [EPA], resolvins derived from 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid [DHA], and resolvins derived from 7Z,10Z,13Z,16Z,19Z-hexacosahexanoic acid [n-3DPA]), and lipoxins (e.g., resolvins derived from 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic acid [EPA], resolvins derived from 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid [DHA], and resolvins derived from 7Z,10Z,13Z,16Z,19Z-hexacosahexanoic acid [n-3DPA]). ] of the resolvins), protectins / neuroprotectins (such as DHA-derived protectins / neuroprotectins and n-3DPA-derived protectins / neuroprotectins), maresins (such as DHA-derived maresin and n-3-DPA-derived maresin), n-3DPA-metabolites, n-6DPA (4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid) metabolites, oxy-DHA metabolites, oxy-DPA metabolites, docosahexaenoylethanolamide metabolites, cyclopentenone prostaglandins (such as Δ12-PGJ; 2 and 15-deoxy-Δ12,14-PGJ 2 ) and cyclopentenone isoprostanes (such as 5,6-epoxyisoprostaglandin A2 and 5,6-epoxyisoprostaglandin E 2 ); other types of anti-inflammatory drugs, including pirfenidone, nintedanib, vitamin A, omega-3 fatty acids and their esters, apoA-I mimetics (such as 4F), apoE mimetics (such as AEM-28 and AEM-28-14) and antioxidants (such as sulfur-containing antioxidants); and their analogs, derivatives, fragments and salts.

[0256] Nonsteroidal anti-inflammatory drugs (NSAIDs) include, but are not limited to, acetic acid derivatives such as aceclofenac, bromfenac, diclofenac, etodolac, indomethacin, ketorolac, nabumetone, sulindac, sulindac sulfide, sulindac sulfone, and tolpyridine acetic acid; anthranilic acid derivatives (benzoates) such as flubenzoic acid, meclofenamic acid, mefenamic acid, and tolfenamic acid; enolic acid derivatives (oxicams) such as droxicam, isoxicam, lornoxicam, meloxicam, piroxicam, and tenoxicam; propionic acid derivatives such as fenoprofen, flurbiprofen, ibuprofen, dexibuprofen, ketoprofen, dexketoprofen, loxoprofen, naproxen, and oxpromazine; salicylates such as diflunisal, salicylate, and salicyclic acid. Acid, acetylsalicylic acid (aspirin), choline magnesium trisalicylate, salicylates, and mesalamine; COX-2 selective inhibitors such as aproxil, celecoxib, etoricoxib, firocoxib, flucoxib (such as flucoxib AC), lumiracoxib, movacoxib, parecoxib, rofecoxib, temacoxib (JTE-522), valdecoxib, 4-O-methylhonokiol, niflumic acid, DuP-697, CG100649, GW406381, NS-398, SC-236, SC-58125, benzothieno[3,2-d]pyrimidin-4-one sulfonamide sulfur derivatives, and sulfonamides derived from Tribulus terrestris terrestris); other types of nonsteroidal anti-inflammatory drugs, such as monoterpenes (such as eucalyptol and phenols [such as carvacrol]), anilinopyridine carboxylic acids (such as clonidine), sulfonanilides (such as nimesulide), and dual inhibitors of lipoxygenase (such as 5-LOX) and cyclooxygenase (such as COX-2) {such as myrobalan, lexapro, 2-(3,4,5-trimethoxyphenyl)-4-(N-methylindol-3-yl)thiophene and di-tert-butylphenol compounds (such as DTPBHZ, DTPINH, DTPNHZ and DTPSAL)}; and their analogs, derivatives and salts.

[0257] Glucocorticoids Corticosteroids have anti-inflammatory and immunosuppressive properties. Glucocorticoids include, but are not limited to, hydrocortisone types (e.g., cortisone and its derivatives [e.g., cortisone acetate], hydrocortisone and its derivatives (e.g., hydrocortisone acetate, 17-levulinic acid hydrocortisone, 17-butenoic acid hydrocortisone, 17-butyric acid hydrocortisone and 17-valerate hydrocortisone), prednisolone, methylprednisolone and its derivatives [e.g., methylprednisolone propionate], prednisone and tixocortolone and its derivatives (e.g., tixocortolone pivalate)), beta-hydroxybutyrate, hydroxyethyl ester ... betamethasone-type (e.g., betamethasone and its derivatives [e.g., betamethasone dipropionate, betamethasone sodium phosphate, and betamethasone valerate)], dexamethasone and its derivatives [e.g., dexamethasone sodium phosphate], and fluocortolone and its derivatives [e.g., fluocortolone caproate and fluocortolone pivalate]), halogenated steroids (e.g., alclomethasone and its derivatives [e.g., alclomethasone dipropionate], beclomethasone and its derivatives [e.g., beclomethasone dipropionate], clobetasol and its derivatives [e.g., clobetasol- 17-propionate], clobetasone and its derivatives [e.g., clobetasone-17-butyrate], deoxymethasone and its derivatives [e.g., deoxymethasone acetate], diflorasone and its derivatives [e.g., diflorasone diacetate], diflucortolone and its derivatives [e.g., diflucortolone valerate], fluoromethidene and its derivatives [e.g., fluoromethidene acetate], fluticasone and its derivatives [e.g., fluticasone propionate], halobetasol [ubetasol] and its derivatives [e.g., halobetasol [halometasone acetate], halometasone and its derivatives [halometasone acetate], mometasone and its derivatives ([e.g., mometasone furoate]), amcinolone and related substances ((e.g., amcinolone acetonide, cyclopent[one] triamcinolone acetate, budesonide, ciclesonide, desonide, fluocinolone acetonide, fluocinolone acetate, flurandrenolide [flurane acetonide or flurandrenolide], halcinonide, triamcinolone acetonide and triamcinolone acetonide alcohol)), carbonates (e.g., prednicarbate) and analogs, their derivatives and salts.

[0258] In other embodiments, one or more compounds of formula (I) are used in combination with one or more anti-fibrotic agents to treat fibrotic diseases. In some embodiments, one or more anti-fibrotic agents are or include anti-inflammatory agents or / and antioxidants (e.g., vitamin E or its analogs [e.g., α-tocopherol or quinoline dimethacrylate], sulfur-containing antioxidants or ROS or free radical scavengers [e.g., melatonin], or any combination thereof). In certain embodiments, one or more anti-fibrotic agents are or include pirfenidone (which can also reduce fibroblast proliferation in various anti-fibrotic and anti-inflammatory properties described herein) or / and nintedanib (which blocks the signaling of fibroblast growth factor receptors [FGFR], platelet-derived growth factor receptors [PDGFR], and vascular endothelial growth factor receptors [VEGFR] involved in fibroblast proliferation, migration, and transformation).

[0259] In a further embodiment, the one or more anti-fibrotic drugs are or include one or more drugs with anti-hyperglycemic and / or insulin sensitizing activity for the treatment of fibrotic diseases in which hyperglycemia, diabetes or insulin resistance lead to the development of fibrosis. Examples of such diseases include diabetic nephropathy, which is characterized by renal fibrosis, and NASH and cirrhosis, both of which are characterized by liver fibrosis. The use of anti-hyperglycemic and / or insulin sensitizers can reduce or prevent, for example, renal inflammation and fibrosis or liver inflammation and fibrosis. In certain embodiments, one or more anti-fibrotic agents are or include PPAR-γ agonists (e.g., thiazolidinediones [as described above], such as pioglitazone or rosiglitazone). PPARγ activates thiazolidinediones with anti-hyperglycemic and insulin sensitizing properties.

[0260] Antifibrotic agents include, but are not limited to, inhibitors of collagen accumulation, including protein kinase C (PKC) inhibitors (which, as described above, inhibit collagen production), colchicine and its metabolite colchicine (both inhibit collagen synthesis and deposition), diphenylol oleoylphosphatidylcholine (inhibits transforming growth factor β1 [TGF-β1]-induced collagen production), luteolin (reduces fibrosis in part by increasing expression of matrix metalloproteinase 9 [M-9] and metallothioneins, which degrade the extracellular matrix [ECM]), malate (reduces procollagen Iα2 [Col1a2] expression), melatonin (inhibits expression of procollagens I and III), S-nitroso-N-acetyl-L-cysteine ​​(reduces the amount of type I collagen in part by activating MMP-13 and inhibiting tissue inhibitor of metalloproteinase 2 [TIMP-2]), oxymatrine {reduces type I procollagen α 1(Col1a1) (and α-smooth muscle actin [α-SMA]) expression}, pioglitazone (reduces type I collagen [and α-SAM] production), pirfenidone (reduces type I procollagen and type II procollagen production, inhibits TGF-β-stimulated collagen production), quercetin (reduces Col1a1 and type III procollagen α1 [Col3a1] expression), resveratrol (reduces type I collagen [and α-SMA] production), RGD mimetics and analogs (hereinafter, reduce type I collagen accumulation in part by increasing collagenase secretion), safilonide (reduces type I collagen [and α-SAM] production), statins (such as atorvastatin, lovastatin, and simvastatin [all three drugs both reduce collagen production]), tranilast (inhibits procollagen expression and fibroblast proliferation), valproic acid (reduces collagen deposition), collagen cross-linking inhibitors {e.g., D-penicillamine and lysyl oxidase-like 2 (LOXL2, which promote collagen cross-linking) inhibitors (e.g., -aminopropionitrile and anti-LOXL2 antibodies [e.g., cintuzumab and AB-0023])}, procollagen proline dioxygenase (or prolyl 4-hydroxylase, which forms more stable hydroxylated collagen) inhibitors (e.g., malotiate, HOE-077, S-0885, and S-4682), and procollagen glucosyltransferase (or galactosylhydroxylysine glucosyltransferase, which is important for collagen fibril formation) inhibitors (e.g., malotiate);inhibitors of profibrotic growth factors (e.g., transforming growth factor β [including TGF-1], connective tissue growth factor [CTGF], and platelet-derived growth factor [including PDGF-B, PDGF-C, and PDGF-D]) or their production, activation, or signaling, including TGF-inhibitors {e.g., anti-TGF-antibodies (e.g., fisutuzumab [GC1008] and CAT-192) and soluble TGF-receptors (e.g., sTGFR1, sTGFR2, and sTGFR3)}, TGFR antagonists antagonists {e.g., TGFR1 (ALK5) antagonists (e.g., galunisterib [LY-2157299], EW-7197, GW-788388, LY-2109761, SB-431542, SB-525334, SKI-2162, SM-16, and inhibitory Smads [e.g., Smad6 and Smad7])}, anti-CTGF antibodies (e.g., FG-3019), PDGF inhibitors (e.g., squalamine, PP1, anti-PDGF inhibitors ligands [e.g. E10030], anti-PDGF-antibodies [e.g. targeting PDGF-B, PDGF-C and PDGF-D] and soluble PDGF receptors [e.g. sPDGFRα and sPDGFRβ]), PDGFR (e.g. PDGFRα or / and PDGFRβ) antagonists (e.g. anti-PDGFR antibodies [e.g. REGN2176-3]), bone morphogenetic protein-7 (BMP-7) (directly antagonizes TGF-1 signaling and Smad3 activation, and promotes mesenchymal-epithelial transition) ), N-acetyl-L-cysteine ​​(inhibits TGF-β expression and activation by monomerization of biologically active TGF-β dimers), S-nitroso-N-acetyl-L-cystine (inhibits TGF-β1), L-carnitine (reduces PDGF-B expression), epigallocatechin-3-gallate (inhibits activation of Smad2 and Smad3 [and Akt]), galectin-7 (binds to and inhibits phosphorylated Smad2 [and Smad3]), Leu-SeR-Lys-Leu (SEQ ID NO:3) (inhibits TGF-γ1 activation), α-lipoic acid (inhibits TGF-β signaling by inhibiting Smad3 and AP-1), luteolin (inhibits TGF-α and PDGF signaling), melatonin (inhibits TGF- and CTGF expression and Smad3 activation), naringenin (inhibits Smad3 expression and activation), niacin (reduces TGF-β expression), pirfenidone (reduces TGF-β production), quercetin, vitamin E and its analogs (e.g., α-tocopherol and quinoline dimethoate, both of which inhibit TGF-β expression), and αV6 integrin (activates TGF-β1) inhibitors (e.g., anti-αV6 antibodies, such as STX-100);receptor tyrosine kinase (TK) inhibitors, including epidermal growth factor receptor (EGFR) inhibitors such as nintedanib and pazopanib); anti-EGFR antibodies such as cetuximab, matuzumab, nimotuzumab, panitumumab, and zaluzumab; anti-inflammatory agents, including those listed above, such as anti-inflammatory cytokines (such as IL-10), pro-inflammatory cytokines or their receptors or inhibitors of their production (such as TNF-α [such as anti-TNF-α antibodies such as infliximab or immunomodulators such as pentoxifylline], IL-1β, IL-6, and MCP-1), colchicine, curcumin (such as curcumin), marotetate, nintedanib, pirfenidone, and tranilast; antioxidants, including those listed above, such as vitamins and their analogs (such as vitamin E and its analogs such as alpha-tocopherol and quinolones), sulfur-containing antioxidants antagonists of the renin-angiotensin-aldosterone system (RAAS), including those listed above, such as renin inhibitors (e.g., aliskiren [reduces hepatic steatosis, oxidative stress, inflammation, and fibrosis]), ACE inhibitors (e.g., captopril [inhibits fibroblast proliferation and reduces fibrotic lung responses] and perindopril [inhibits liver fibrosis]), and angiotensin II receptor type 1 (AT; 1 ) antagonists (e.g., candesartan [inhibits hepatic fibrosis], irbesartan, and losartan) (angiotensin II activation of AT1 activates PLC, leading to cytosolic Ca 2+concentrations, thereby stimulating PKC, which also activates tyrosine kinases and promotes ECM formation); inhibitors of the accumulation or action of advanced glycation end products (AGEs, which, among other things, increase arterial stiffness and stimulate mesangial matrix expansion), including inhibitors of AGE formation (such as aminoguanidine, aspirin, benflutiamine, carnosine, alpha-lipoic acid, metformin, pentoxifylline, pimaguanide, pioglitazone, pyridoxamine, taurine, and vitamin C), cleavage agents of AGE cross-links (such as aminoguanidine, N-benzoylthiazolidine bromide, rosmarinic acid, cytarabine [ALT-711], ALT-462, ALT-486, and ALT-946), and AGE action. inhibitors used (e.g., natural phenols such as curcumin and resveratrol); this is because; other types of anti-fibrotic drugs, including RGD mimetics and analogs (inhibit fibroblast and immune cell adhesion to ECM glycoproteins) (such as NS-11, SF-6,5 and GRGDS), galectin-3 (essential for liver fibrosis) inhibitors (such as GM-CT-01 and GR-MD-02), marine biotin inhibitors (such as resibufogenin, spironolactone and canrenone), trichostatin A (inhibits TGFβ1-induced epithelial-mesenchymal transition) and PPAR-γ agonists (such as thiazolidinediones [see above]); and their analogs, derivatives, fragments and salts.

[0261] Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in developed countries and is characterized by fatty liver, which occurs when fat, especially free fatty acids and triglycerides, accumulate in hepatocytes (hepatic steatosis) due to reasons other than excessive alcohol consumption, such as nutrient overload, high caloric intake, and metabolic dysfunction (such as hyperlipidemia and impaired glucose control). The liver can remain fatty without affecting liver function, but fatty liver can progress to nonalcoholic steatohepatitis (NASH), a disease in which steatosis is accompanied by inflammation, ballooning of hepatocytes, and cellular damage, with or without liver fibrosis. Fibrosis is the strongest predictor of mortality in NASH. NASH is the most extreme form of NAFLD. NASH is a progressive disease with approximately 20% of patients developing cirrhosis and approximately 10% of patients dying from liver disease, such as cirrhosis or cancer (such as hepatocellular carcinoma).

[0262] NAFLD, including NASH, is associated with obesity, metabolic syndrome, and insulin resistance. For example, insulin resistance causes fatty liver to progress to liver inflammation and fibrosis, which leads to NASH. In addition, obesity promotes and exacerbates NASH, and weight loss can alleviate NASH.

[0263] In some embodiments, one or more compounds of formula (I) are used in combination with one or more additional therapeutic agents to treat NAFLD, such as NASH. In some embodiments, the one or more additional therapeutic agents are selected from antidiabetic agents, antiobesity agents, anti-inflammatory agents, antifibrotic agents, antioxidants, and combinations thereof.

[0264] Therapeutic agents that can be used to treat NAFLD (such as NASH) include, but are not limited to: PPAR agonists, including PPAR-δ agonists (such as MBX-8025, elafibranor [PPAR-α / δ dual agonist], lanilanor [PPAR-α-δ / γ triple agonist], and GW501516 [PPAR- / δ dual agonist]) and PPAR-γ agonists (e.g., thiazolidinediones, such as pioglitazone and rosiglitazone, and saroglitazar [PPARα / γ dual agonist] steatosis and PPAR-δ agonism inhibit the activation of macrophages and Kupffer cells; GLP-1 inhibitors. -1R agonists (such as exenatide, liraglutide, and semaglutide), GLP-1R / GCGR dual agonists (such as MEDI0382 and SP-1373), and GLP-1R / GIPR dual agonists - these agonists can reduce hepatic steatosis, inflammation, and fibrosis; farnesoid X receptor (FXR) agonists, such as obeticholic acid, EDP-305, GS-9674, LJN452, and TERN-101 - FXR agonists, which can reduce hepatic gluconeogenesis, lipogenesis, steatosis, and fibrosis; thyroid hormone receptor β agonists, such as MGL-3196 and VK2809 - THR-agonists fibroblast growth factor 19 (FGF19) and its analogs and derivatives, such as NGM-282-FGF19 analogs, can reduce hepatic gluconeogenesis and steatosis; fibroblast growth factor 21 (FGF21) and its analogs and derivatives, such as BMS-986036 and PF-05231023-FGF21 analogs, can reduce hepatic steatosis, cell damage and fibrosis; HMG-CoA reductase inhibitors, including statins (such as atorvastatin, pitavastatin and rosuvastatin)-statins can reduce steatohepatitis and fibrosis; ACC inhibitors, such as ND I-010976 (liver-targeted) and GS-0976-ACC inhibitors reduce de novo lipogenesis and hepatic steatosis; SCD-1 inhibitors, such as anandamide cholic acid-SCD-1 inhibitors, reduce hepatic steatosis and increase insulin sensitivity; ATP citrate lyase inhibitors, such as bepedic acid-ACL inhibitors, reduce hepatic steatosis; ketohexokinase inhibitors, such as PF-06835919-KHK inhibitors, reduce hepatic lipogenesis and inflammation; SGLT2 inhibitors, such as canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, and rupagliflozin, reduce body weight, hepatic ALT levels, and fibrosis;Vascular adhesion protein-1 (VAP-1) inhibitors, such as N-[4-(2-{4-[(2-amino-1H-imidazol-4-yl)methyl]phenyl}ethyl)thiazol-2-yl]acetamide hydrochloride, 2-bromoethylamine, semicarbazide, ASP8232, BI-1467335 (PXS-4728A), PXS-4681A, PRX-167700, and TERN-201-VAP-1 inhibitors can increase insulin sensitivity and reduce liver inflammation and fibrosis; CCR2 or / and CCR5 antagonists, such as siniplatin Livero - antagonists of CCR2 (binds CCL2 [MCP1]) and CCR5 (binds CCL5 [RANTES]) inhibit activation and migration of inflammatory cells (such as macrophages) to the liver and reduce liver fibrosis; apoptosis inhibitors, including apoptosis signal-regulating kinase 1 (ASK1) inhibitors (such as selonsertib) and caspase inhibitors (such as enlicasin [pan-caspase inhibitor]) - apoptosis inhibitors reduce hepatic steatosis and fibrosis; transforming growth factor inhibitors (such as fesutuzumab) and transforming growth factor receptor antagonists (such as galunisterib) - they can reduce liver fibrosis; lysyl oxidase-like 2 (LOXL2) inhibitors, such as cintuzumab - LOXL2 is a key matrix enzyme in collagen formation and is highly expressed in the liver; galectin-3 inhibitors, such as GR-MD-02 and TD139 - galectin-3 is essential for the development of liver fibrosis; inhibitors of lysophosphatidic acid (LPA) or its receptors (such as LPAR1) or its production, such as autocrine toxin inhibitors (such as GLPG1690) , HA-130, ONO-8430506, PF-8380, S-32826) and anti-autocrine toxin DNA aptamers (e.g., RB011 and RB014) – these inhibitors inhibit myofibroblast proliferation and thus liver fibrosis; antioxidants, including vitamin E (e.g., α-tocopherol) and ROS and free radical scavengers (e.g., cysteamine, glutathione, melatonin, and pentoxifylline [which also acts as an anti-inflammatory by inhibiting TNF-α and phosphodiesterase]) – vitamin E reduces hepatic steatosis, hepatocyte ballooning, and lobular inflammation;and their analogs, derivatives and salts. Other NASH compounds include LXR inverse agonists, ACMSD inhibitors, VAP1 inhibitors, IBAT inhibitors, DGAT inhibitors, ACC2 inhibitors, HSD17b13 inhibitors (Roal and siRNA), PNPLA3 siRNA, THRb agonists (Resmetirol, TERN, Viking), FGF21 (Efruxfermin, Pegozafermin), TLC-3595 (ACC2 inhibitor), mitochondrial prokaryotic proteins (TLC-6740, Rivus HU6, TLC-1235, NASH-siRNA (such as PNPLA3, HSD17b13, GPAM, mARC1 and CIDEB) and mitochondrial uncouplers. Liver failure drugs include terlipressin, octreotide and tolvaptan.;

[0265] In some embodiments, one or more additional therapeutic agents for treating NAFLD (e.g., NASH) are or include PPAR agonists (e.g., PPAR-δ agonists, such as elafilbrum or / and PPAR-γ agonists, such as pioglitazone), HMG-CoA reductase inhibitors (e.g., statins, such as rosuvastatin), FXR agonists or antioxidants (e.g., vitamin E), or any combination thereof. In certain embodiments, one or more additional therapeutic agents for treating NAFLD (e.g., NASH) are or include vitamin E or / and pioglitazone.

[0266] In other embodiments, one or more compounds of formula (I) are used in combination with one or more anticancer agents to treat tumors (benign or malignant) or cancer. For brevity, the term "anticancer agent" as used herein includes antitumor agents. In some embodiments, one or more anticancer agents are or include radiotherapy, chemotherapy or cancer immunotherapy, or any combination or all thereof.

[0267] In some embodiments, the chemotherapeutic agent is or includes a PARP inhibitor, a TGF-β inhibitor, or a cytotoxic agent, or any combination or all thereof. Examples of PARP inhibitors are described above. In certain embodiments, the PARP inhibitor is Olaparib.

[0268] Transforming growth factor beta (TGF-β) is a cytokine that promotes precancerous and cancer cell growth, angiogenesis, and cancer cell invasion. TGF-β also converts effector T cells that normally attack cancer cells through inflammatory (immune) responses into regulatory T cells that suppress immune responses. Increased expression of TGF-β is often associated with the malignancy of many cancers. Therefore, inhibitors of TGF-β or its production, activation, or signaling can be used to treat tumors and cancer. Since TGF-β (including TGF-β1) is also a major driver of collagen production and fibrosis, inhibitors of TGF-β or its production, activation, or signaling are listed as anti-fibrotic drugs above.

[0269] Anticancer toxic drugs include, but are not limited to, alkylating agents, including aziridines (such as desconar, mitomycin, and thiotepa), nitrogen mustards (such as mannitol mustard, mustard [dichloromethyl diethylamine or dichloroethyl methylamine], aniline mustard, bendamustine, benzoic acid mustard, chlorambucil, chlorambucil C6-galactosyl mustard, melphalan, methoxychlor hydrochloride [oxygen mustard], chlorambucil, uracil mustard, nitrogen mustard carbamates [such as estradiol mustard], and oxaphosphobenzophenones [such as cyclophosphamide, ifosfamide, mafosfamide, and trofosfamide]), nitrosoureas (such as carmustine, fotemustine, lomustine and nimustine, N-nitroso-N-methylurea, ranimustine, semustine, and streptozotocin), platinum compounds (such as cisplatin, carboplatin, and oxaliplatin), alkyl sulfonates (such as busulfan, mannitol mesylate, and threosulfan), hydrazines (such as dacarbazine and procarbazine), imidazotetrazines (such as mitozolomide and temozolomide), triazines (such as atroxymethylmelamine [atroxamide]); cytotoxic antibiotics, including anthracyclines (such as aclarubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, pirarubicin, and valrubicin), actinomycins (such as actinomycin D), bleomycins (such as bleomycin A 2 and B 2), mitomycins (such as mitomycin C) and mithramycins; antimetabolites, including antifolates (such as aminopterin, methotrexate, pemetrexed, and pralatrexed), deoxynucleoside analogs (such as 5-azacytidine [azacitidine], 5-aza-2'-deoxycytidine [decitabine], cladribine, clofarabine, cytarabine, decitabine, fludarabine, gemcitabine, nelarabine, and pentostatin), Fluorouracils (e.g., 5-fluorouracil, capecitabine, 5-fluoro-5'-deoxyuridine [polyfluridine], and trifluridine) and thiopurines (e.g., thioguanine, thioazaprine, and mercaptopurine); antimicrotubule drugs, including dostatins (e.g., dostatin 15), epothilones (e.g., epothilone AF), halichondrins (e.g., halichondrin B) and their analogs (e.g., eribulin), maytansine, maytansine oxadiazine (e.g., ansamicin, emtansine, mertansine, ravtansine, and ravtansine), taxanes (e.g., paclitaxel, docetaxel, and cabazitaxel), vinca alkaloids (e.g., vinblastine, vincristine, vindesine, and vinorelbine), colchicine, nocodazole, podophyllotoxin, and rhizostatin; histone deacetylase inhibitors, including trichostatins (e.g., trichostatin A), romidepsin, pamistatin, and vorinostat; kinase inhibitors, including bortezomib, erlotinib, gefitinib, imatinib, vemurafenib, vismodegib, curcumin, cyclocreatine, deguelin, phosphothricin, smilaxone, staurosporine and its derivatives (e.g., midostaurin), and tyrosine phosphorylation inhibitors (e.g., tyrosine phosphorylation inhibitors AG 34 and AG 879); topoisomerase I inhibitors, including camptothecin, irinotecan, and topotecan; topoisomerase II targeted agents, including topoisomerase II poisons (e.g., etoposide, taflutoposide, teniposide, doxorubicin, and mitoxantrone) and topoisomerase II inhibitors (e.g., novobiocin, mepallone, and aclarubicin); DNA or RNA synthesis inhibitors, including 3-amino-1,2,4-benzotriazine 1,4-dioxide, cytosine β-D-arabinofuranoside, 5,6-dichlorobenzimidazole 1-β-D-ribofuranoside , ganciclovir and hydroxyurea; protein synthesis inhibitors, including homoharringtonine; cell growth and differentiation regulators, including retinoids (e.g., all-trans retinol [vitamin A], 11-cis retinal, all-trans retinal [vitamin A aldehyde], 11-cis retinal, all-trans retinoic acid [retinoic acid], 9-cis retinoyl [alitretin], 11-cis retinoic acid, 13-cis retinoic acid [isotretinoin]), all-trans retinol esters, etretinoin, acitretin, adapalene, bexarotene and tazarotene);Cell proliferation inhibitors, including mTOR inhibitors (such as everolimus, novolimus, lidaformolimus, sirolimus [rapamycin], temsirolimus, umimios [biotin A9], and zotarolimus), apigenin, cholecalciferol (vitamin D3), and sex hormone binding globulin; apoptosis inducers, including 17-allylamino-17-demethoxygeldanamycin, melatonin, movinoline, psoralen, thapsigargin, troglitazone, histone deacetylase inhibitors (such as romidepsin), and RXR agonists (such as retinoids [such as bexarotene], as described above); and their analogs, derivatives, and salts. ;

[0270] Cancer immunotherapeutics include drugs that block immune checkpoints and drugs that stimulate the immune system. In certain embodiments, the cancer immunotherapeutic agent is or includes an anti-PD-1 antibody or an anti-PD-L 1 Antibodies, or / and anti-CTLA-4 antibodies.

[0271] Anticancer drugs that block immune checkpoints include, but are not limited to, inhibitors of the programmed cell death 1 (PD-1) receptor or its ligands (e.g., PD-L1 and PD-L2), including anti-PD-1 antibodies (e.g., cemiplimab, nivolumab, pembrolizumab, pilizumab, and MEDI-0680 [AMP-514]), anti-PD-1 fusion proteins (e.g., AMP-224 [containing an FcAb domain and PD-L2]), anti-PD-L1 antibodies (e.g., (e.g., avelumab, atezolizumab, durvalumab, and BMS-936559 [MDX-1105]) and small molecule inhibitors of PD-L1 (e.g., BMS-1001 and BMS-1166); inhibitors of the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) receptor or its ligands, including anti-CTLA-4 antibodies (e.g., ipilimumab and tremelimumab); inhibitors of killer cell immunoglobulin-like receptors (KIR) or their ligands, including anti-KIR antibodies inhibitors of the lymphocyte activation gene 3 (LAG-3) receptor or its ligands, including anti-LAG-3 antibodies (e.g., BMS-986016 and GSK2831781); inhibitors of T-cell immunoglobulin and mucin domain-containing 3 (TIM-3, also known as hepatitis A virus cellular receptor 2 [HAVCR2]), including anti-TIM3 antibodies (e.g., LY3321367, MBG453, and TSR-022); indoleamine 2, 3-dioxygenase (IDO or IDO1) inhibitors, including indolizumab (1-methyl-D-tryptophan), navoximod, α-methyltryptophan, β-carboline (9H-pyrido[3,4-b]indole or norharman), icaridostat (INCB024360), BMS-986205, NLG-919, and COX-2 inhibitors (e.g., coxibs that downregulate IDO expression [see above]); and analogs, derivatives, fragments, and salts thereof.

[0272] Anticancer drugs that stimulate the immune system include, but are not limited to: agonists of tumor necrosis factor receptor superfamily member 4 (TNFRSF4, OX40, or CD134), including antibodies targeting OX40 (e.g., MEDI-6469 and 9B12) and ligands of OX40 (e.g., OX40L); agonists of TNFRSF member 5 (TNFRSF5 or CD40), including antibodies targeting CD40 (e.g., dallimab and CP-870893) and ligands of CD40 (e.g., CD40L [CD154]); agonists of TNFRSF member 9 (TNFRSF9, 4-1BB, or CD137), including antibodies targeting 4-1BB (e.g., useluzumab and PF-050 82566) and ligands of 4-1BB (such as 4-1BBL); agonists of TNFRSF member 18 (TNFRSF18, glucocorticoid-induced TNFR-related protein [GITR], or CD357), including GITR-targeting antibodies (such as DTA-1 and TRX518) and GITR ligands (such as GITRL); agonists of toll-like receptors (TLRs), including ligands of TLR9 (e.g., unmethylated CpG oligodeoxynucleotides [CpG-ODNs], such as agatolimod); cytokines and hormones that stimulate immune cells, including IL-6 and epinephrine (a stimulator of natural killer cells); and their analogs, derivatives, fragments, and salts.

[0273] Angiogenesis is important for the metastasis of benign tumors to malignant tumors (i.e., cancer) and the metastasis of cancer. Therefore, anticancer drugs include angiogenesis inhibitors. Angiogenesis inhibitors include, but are not limited to, inhibitors of vascular endothelial growth factor (VEGF) {e.g., squalamine, ACU-6151, LHA-510, PAN-90806, decorin, anti-VEGF antibodies and fragments thereof (e.g., bevacizumab, ranibizumab, brucelluzumab, ENV1305, ESBA903, and ESBA1008), anti-VEGF immunoconjugates (e.g., KSI-301), anti-VEGF aptamers (e.g., pegaptanib), anti-VEGF-designed ankyrin repeat proteins (DARPins) (e.g., abicip arpegol), soluble VEGFR (e.g., sVEGFR1), and soluble fusion proteins containing one or more extracellular domains of one or more VEGFR (e.g., VEGFR1, VEGFR2, and VEGFR3) (e.g., aflibercept, conbercept, and OPT-302), VEGF receptor inhibitors (e.g., EGFR1 and VEGFR2) (e.g., axitinib, fruquintinib, pazopanib, regorafenib, sorafenib, sunitinib, tivozanib, isoxanthohumol, prismaticol, KPI-285, PF-33721 0, PP1, TG100572, X-82, D-(LPR), core protein and anti-VEGFR antibodies and fragments thereof [e.g., ramucirumab]), platelet-derived inhibitor growth factor {e.g., squalamine, PP1, decorin, anti-PDGF aptamers (e.g., E10030 and pegaptanib), anti-PDGF-antibodies and fragments thereof (e.g., linusumab), and soluble PDGFR} or its receptor (PDGFR) (e.g., axitinib, imatinib, nilotinib, pazopanib, sorafenib, sunitinib, X-82, and anti-PDGF R antibodies and fragments thereof [e.g., REGN2176-3]), fibroblast growth factor inhibitors (FGF) (e.g., squalamine, decorin, anti-FGF antibodies and fragments thereof, anti-FGF aptamers, and soluble FGFR) or its receptors (e.g., erdafitinib, pazopanib, and anti-FGFR antibodies and fragments thereof), angiogenin inhibitors (e.g., decorin, anti-angiogenin antibodies and fragments thereof, such as nevacuzumab and REGN910-3, and soluble angiogenin receptors) or their receptors (e.g., anti-angiogenin receptor antibodies and fragments thereof,Integrin inhibitors (e.g. ALG-1001, JSM-6427, SF0166 and anti-integrin antibodies and fragments thereof), tissue factor (TF) inhibitors (e.g. anti-TF antibodies and fragments thereof and fusion proteins [e.g. ICON-1]), kallikrein inhibitors (e.g. avostat, ecallantide, BCX7353, KVD001 and anti-kallikrein antibodies and fragments thereof [e.g. DX-2930]), serine / arginine protein kinase 1 (SRPK1) inhibitors (e.g. SPHINX31), SRc kinase inhibitors (e.g. SKI-606 and TG100572), anecortave (anecortave acetate), angiostatins (e.g., angiostatin K1-3), αVβ3 inhibitors (e.g., idarucizumab), apoA-I mimetics (e.g., L-4F and L-5F), apoE mimetics (e.g., apoEdp), azurin (50-77) (page 28), berberine, bleomycin, borrelidin, carboxyamidotriazole, cartilage-derived angiogenesis inhibitors (e.g., chondroitin I and troponin I), iminoglycoside castaneospermide, CM101, corticosteroids (including glucocorticoids), cyclopropene fatty acids ( stearic acid), α-difluoromethylornithine, endostatin, everolimus, fumagillin, genistein, heparin, interferon-α, interleukin-12, interleukin-18, itraconazole, KV11, linomide, 2-methoxyestradiol, pigment epithelium-derived factor (PEDF), platelet factor-4, PPAR-α agonists (such as fibrates), PPAR-γ agonists (such as thiazolidinediones), prolactin, rapamycin (sirolimus), sphingosine-1-phosphate inhibitors (such as sonelizumab), squalene, staurosporine, angiostatic steroids (such as tetrahydrocortisol), plus Heparin, stilbenes, suramin, SU5416, tasquinimod, tecogalan, tetrathiomolybdate, thalidomide and its derivatives (e.g., lenalidomide and pomalidomide), thiabendazole, thrombospondin (e.g., thrombospondin 1), TNP-470, tranilast, triterpenoids (e.g., oleanolic acid analogs [see above], such as TP-225), (+)-TBE-B, tumstatin and its fusion proteins (e.g., OCU200), angiostatin, angiostatin 48, withaferin A and its analogs, derivatives, fragments and salts.

[0274] Other classes of anticancer drugs include, but are not limited to: drug efflux pump inhibitors, including P-glycoprotein inhibitors (such as mifepristone and verapamil); cell adhesion inhibitors, such as cimetidine; Golgi disruptors, such as brefeldin (e.g., brefeldin A); ionizing radiation, such as X-rays; radiopharmaceuticals, such as 131 I-iodide, 131 I-MIBG (meta-iodobenzylguanidine), 223Ra dichloride, 153 Sm-EDTMP (ethylenediaminetetramethylenephosphonic acid) and 89 SR chloride; sensitizers for cancer cells to radiation, including PARP inhibitors (see below), berberine, and indomethacin; enhancers of cell survival after cytotoxic drugs or radiation treatment, such as pifithrin-α; vaccines, including vaccines that stimulate the immune system to recognize proteins produced by tumor / cancer cells and thereby attack tumor / cancer cells; and their analogs, derivatives, and salts.

[0275] When used in combination with antiviral, antibacterial or antifungal drugs, the compounds of formula (I) can enhance the immune response to acute or chronic viral, bacterial or fungal infections. In certain embodiments, the antibiotic is ethionamide and optionally SMARt-420, for the treatment of, for example, tuberculosis. Acetamide has antibacterial properties against mycobacteria such as Mycobacterium tuberculosis. SMARt-420 reverses the resistance of Mycobacterium tuberculosis to ethionamide and increases the sensitivity of bacteria to ethionamide.

[0276] The compounds of formula (I) can also enhance and direct the adaptive immune response to vaccine antigens, thereby improving the effectiveness of the vaccine. The compounds of formula (I) can be used as components of vaccine adjuvants. In certain embodiments, the compounds of formula (I) are administered to a subject in combination with a vaccine to improve the effectiveness of the vaccine.

[0277] When activated by DNA damage, poly ADP ribose polymerase (PARP) recruits other proteins to repair single-strand DNA breaks ("nicks"). PARP activity is required for the repair of DNA nicks. PARP expression and activity are upregulated under a variety of conditions that lead to DNA damage and ultimately cell damage or cell death, including hypoxia. However, PARP is a key NAD + The major consumer of NAD, significantly increased PARP activity will deplete NAD + , leading to severe mitochondrial and cellular dysfunction. Therefore, PARP inhibition can increase NAD + Levels (e.g., in mitochondria, cytoplasm, and / or nucleus, such as total cellular NAD + levels), which can enhance mitochondrial function (e.g., oxidative metabolism), mitochondrial biogenesis, and cellular function (e.g., increase the activity of sirtuins such as SIRT1 and SIRT3).

[0278] PARP inhibitors are currently approved as anti-tumor / anti-cancer drugs. DNA damage occurs numerous times during each cell cycle, and failure to repair damaged DNA leads to the death of tumor / cancer cells. Some PARP inhibitors primarily block PARP enzyme activity and do not trap PARP on DNA, while other PARP inhibitors both block PARP activity and act as PARP poisons. In the latter case, PARP bound to the PARP inhibitor is trapped at DNA gaps, and this trapped PARP-DNA complex (PARP toxin) is more toxic to cells than unrepaired single-stranded DNA breaks that accumulate in the absence of PARP activity because it blocks DNA replication. PARP inhibitors include, but are not limited to, niraparib, olaparib, pamiparib (BGB290), rucaparib, talazopanib, veliparib, 4-amino-1,8-naphthalimide, CEP9722, E7016, PJ34, and their analogs, derivatives, and salts.

[0279] The compound of formula (I) can synergistically increase NAD by combining with olaparib at a dose much lower than its chemotherapy dose. + Levels (e.g., in mitochondria, cytoplasm, and / or nucleus, such as total cellular NAD + levels) and provide cytoprotection (reduced cytotoxicity) under DNA damage-inducing conditions. Without wishing to be bound by theory, low-level PARP inhibition by low-dose PARP inhibitors (such as olaparib) may reduce PARP consumption of NAD + The rate at which NAD is increased + Levels of PARP can be reduced, thereby enhancing mitochondrial and cellular function and providing cellular protection. In addition, low-level PARP inhibition can avoid PARP being trapped at DNA gaps, thereby enabling cellular DNA repair mechanisms to repair damaged DNA.

[0280] In some embodiments, one or more compounds of formula (I) in combination with a PARP inhibitor can be used to increase NAD + Levels (e.g., total cellular NAD + In some embodiments, one or more compounds of formula (I) in combination with a PARP inhibitor increase NAD in vitro, ex vivo or in vivo. + Levels (e.g., total cellular NAD+ levels, such as levels in target cells) are increased by at least about 50%, 100% (2-fold), 3-fold, or 5-fold.

[0281] In further embodiments, one or more compounds of Structural Formula (I) in combination with a PARP inhibitor increase the number of viable cells (e.g., target cells) in vitro, ex vivo, or in vivo by at least about 10%, 20%, 30%, 50%, 100% (2-fold), 150%, 200% (3-fold), 4-fold, or 5-fold. In certain embodiments, the combination of a compound of Structural Formula (I) and a PARP inhibitor increases the number of viable cells (e.g., target cells) in vitro, ex vivo, or in vivo by at least about 20%, 50%, 100%, or 200%.

[0282] In some embodiments, the compound of structural formula (I) is used in combination with a PARP inhibitor at a dose significantly lower than its recommended dose as an anti-tumor / anti-cancer agent to treat a non-tumor / non-cancer disease / disorder or condition disclosed herein, or to produce a biological effect disclosed herein (e.g., increasing NAD+ levels or / and providing cytoprotection). The PARP inhibitor may inhibit one or more members of the PARP family, such as PARP-1 or / and PARP-2. In certain embodiments, the PARP inhibitor is a selective or non-selective inhibitor of PARP-1. The non-tumor / non-cancerous disease or condition may be, for example, any mitochondrial disease, mitochondrial-related disease or condition, or a condition characterized by acute NAD+ due to DNA damage as described herein. + In some embodiments, the disease or condition is a metabolic disorder (e.g., obesity or type 2 diabetes). One or more other therapeutic agents described herein may optionally be used in combination with a compound of formula (I) and a PARP inhibitor. The use of one or more compounds of formula (I) in combination with a PARP inhibitor (e.g., olaparib) at a significant sub-chemotherapeutic dose may synergistically increase NAD + levels (e.g., in the mitochondria, cytoplasm, and / or nucleus, such as total cellular NAD+ levels) or / and provide cellular protection (e.g., reduce cell damage, injury, or death), or may have a synergistic therapeutic effect.

[0283] PARP inhibitors at doses significantly lower than chemotherapeutic doses can be used in combination with one or more compounds of formula (I) to treat any non-tumor / non-cancer disease / disorder or condition associated with DNA damage. DNA damage may be caused by any cause, such as radiation (such as ultraviolet light or ionizing radiation, such as X-rays), chemicals, chemotherapeutic agents, oxidative stress or hypoxia. The disease / disorder or condition may be acute or chronic and may be associated with NAD + depletion and / or associated with cell damage, injury, degeneration or death. Such diseases / disorders and conditions include, but are not limited to, acute NAD depletion due to DNA damage. +Diseases and disorders characterized by depletion, as described above. In certain embodiments, the disease / disorder or condition is an acute life-threatening cardiovascular (e.g., myocardial ischemia / infarction / IRI) or cerebrovascular (e.g., cerebral ischemia / infarction / IRI) disease, or a neurodegenerative disease.

[0284] In some embodiments, the dosage of the PARP inhibitor to treat a non-tumor / non-cancer disease / disorder or condition disclosed herein, or to produce a biological effect disclosed herein, in combination with one or more nicotinyl ribosyl side chain compounds, does not exceed about 10%, 5%, 1%, 0.5%, or 0.1% of the recommended dosage of the PARP inhibitor as an anti-tumor / anti-cancer agent. In certain embodiments, the dosage of the PARP inhibitor for such use does not exceed about 1% of the recommended dosage of the PARP inhibitor as an anti-tumor / anti-cancer agent. In some embodiments, the PARP inhibitor is olaparib, and the dose (e.g., per day or per dose) of olaparib in combination with one or more nicotinic riboside compounds for treating a non-tumor / non-cancerous disease / disorder or condition disclosed herein, or for producing a biological effect disclosed herein, is no greater than about 10 mg, 5 mg, 1 mg, 0.5 mg, or 0.1 mg; or about 0.01 or 0.1 mg to about 10 mg, about 0.01 or 0.1 mm to about 1 mg, or about 1 mg to about 10 mg / ; or about 0.01-0.1 mg, 0.1-0.5 mg, 0.5-1 mg, 1-5 mg, or 5-10 mg; or about 10 μg, 50 μg, 0.1 mg, 0.5 mg, 1 mg, 5 mg, or 10 mg. In certain embodiments, the dose (e.g., per day or per dose) of olaparib for such use does not exceed about 1 mg.

[0285] The PARP inhibitor can be administered at any suitable frequency. In certain embodiments, the PARP inhibitor is administered once or twice daily.

[0286] The dosage or therapeutically effective amount, dosing frequency and administration route of the compound of formula (I) used in combination with a low-dose PARP inhibitor can be, for example, any dosage or therapeutically ineffective amount, any dosing frequency and any administration route described herein. In some embodiments, the dosage of the compound of formula (I) is about 1, 50 or 100 mg to about 500 or 1000 mg per day, which can be administered (e.g., orally) in a single dose (e.g., once a day, N mg) or divided doses (e.g., twice a day, N / 2 mg). In certain embodiments, the dosage of the compound of formula (I) is about 1-100 mg, 100-500 mg or 500-1000 mg per day, or about 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg or 1000 mg per day. In further embodiments, the dosage of the compound of formula (I) is about 1-50 mg, 50-100 mg, 100-200 mg, 200-300 mg, 300-400 mg or 400-500 mg per day. In certain embodiments, the dosage of the compound of formula (I) is about 10, 50 or 100 mg to about 200 or 300 mg per day. In some embodiments, lower doses of the compound of formula (I) are used to treat less severe non-tumor / non-cancerous diseases / disorders or conditions, while higher doses of the compound of formula (I) are used to treat more severe non-tumor / non-cancerous diseases / disorders / conditions.

[0287] The synergistic effect of the combination of one or more compounds of formula (I) and a low dose of a PARP inhibitor, for example in increasing NAD + In terms of reducing levels and enhancing cell protection, it can be used prophylactically to prevent non-tumor / non-cancer diseases / disorders or conditions, or potentially to prevent tumors or cancer. For example, one or more compounds of structural formula (I) and a low dose of a PARP inhibitor can be administered before surgery to reduce the incidence caused by cytotoxicity induced by general anesthesia or hypoxia or hypotension. For example, before cardiac surgery (such as angioplasty or valve surgery), one or more compounds of structural formula (I) and a low dose of a PARP inhibitor can be administered to reduce the morbidity and mortality caused by hypotension or bleeding episodes. As another example, one or more compounds of structural formula (I) and a low dose of a PARP inhibitor can be applied to the skin to prevent skin damage caused by sunlight.

[0288] In some embodiments, one or more compounds of structural formula (I) and / or a PARP inhibitor are administered as a complex with a dendrimer (e.g., PAMAM) or via a composition containing a dendrimer. The dendrimer may optionally have one or more moieties for targeting a specific organ, tissue, cell type, or organelle, such as one or more N-acetylgalactosamine moieties for liver-directed treatment, such as liver or metabolic disorders.

[0289] In other embodiments, one or more compounds of formula (I) or / and PARP inhibitors are used for ex vivo treatment, including any ex vivo treatment described herein. In other embodiments, one or more compounds of formula (I) and PARP inhibitors are used to enhance DNA editing, such as using CRISPR, transcription activator-like effector nucleases (TALENs) or Arcus nucleases to promote non-homologous end joining (NHEJ) or homology-directed repair (HDR). Low levels of PARP inhibition by low-dose PARP inhibitors allow repair of single-stranded DNA breaks.

[0290] Other synergistic approaches include ACMSD inhibitors, NR, NMN, NRH, CD38 inhibitors, SARM1 inhibitors, uncouplers, and other lipid / TG lowering approaches.

[0291] In other embodiments, one or more compounds of structural formula (I) can be used simultaneously with drugs that can cause acute kidney injury (AKI) or prevent the deterioration of chronic kidney injury. Common drugs associated with acute kidney injury are antibiotics: aminoglycosides, cephalosporins, amphotericin B, bacitracin and vancomycin. All classes of ACE inhibitors and angiotensin receptor blockers (candesartan and valsartan). Drugs used for cancer chemotherapy: cisplatin, carboplatin and methotrexate. Dyes (contrast agents) used in medical imaging tests, especially in patients with coronary artery disease or patients with impaired renal function after coronary artery bypass grafting. Another major category is nonsteroidal anti-inflammatory drugs - ibuprofen, uroprofen and naproxen.

[0292] In other embodiments, one or more compounds of structural formula (I) can be used simultaneously with drugs such as mitochondrial stress response regulators such as tetracycline, including non-microbial compounds such as 9TB, to enhance host tolerance, prevent and treat acute and chronic severe viral infections, bacterial sepsis and ischemia-reperfusion injury states.

[0293] In other embodiments, one or more compounds of formula (I) may be combined with a drug such as SPT 1 Inhibitors are used concurrently to treat myopathies, including inclusion body myositis, sarcopenia, DMD, and other genetic causes of myopathies.

[0294] Finally, it should be noted that there are alternative ways of implementing the invention. The present embodiments are therefore to be considered as illustrative and not restrictive, and the invention is not to be limited to the details given herein, but may be modified within the scope and equivalents of the appended claims.

[0295] All publications and patents cited herein are incorporated by reference in their entirety.

[0296] The following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

[0297] Example

[0298] Abbreviations used in the experimental procedures.

[0299] Aq aqueous solution

[0300] RT Room temperature

[0301] MeOH Methanol

[0302] THF Tetrahydrofuran

[0303] DMF Dimethylformamide

[0304] TLC Thin layer chromatography using silica gel plates

[0305] EtOAc Ethyl acetate

[0306] HCl

[0307] TBDMS tert-Butyldimethylsilyl chloride

[0308] TFA Trifluoroacetic acid

[0309] E 3 N.3HF Triethylamine Trihydrogen Fluoride

[0310] DMAP N,N-Dimethylaminopyridine

[0311] Py Pyridine

[0312] Scheme 1 illustrates the preparation of compounds 100 and 101.

[0313]

[0314] ((3R,4R,5R)-5-((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2,3,4-triyl)tri(oxy)tris(tert-butyldimethylsilane)(1)

[0315]

[0316] To a stirred solution of ribose (50 g, 0.33 mol) in DMF (120 mL) was added imidazole (90.6 g, 1.33 mol) at 0°C, followed by TBDMSCl (200 g, 1.33 mmol). The resulting mixture was stirred at room temperature for 24 hours. TLC of the reaction mixture showed complete conversion of the starting material, and a new nonpolar spot was observed. The reaction mixture was purified by HPLC with NaHCO 3 The reaction mixture was quenched with aqueous solution and extracted with ethyl acetate. The combined organic layers were washed with anhydrous Na 2 SO 4 Drying, filtration and concentration under reduced pressure afforded the crude compound. The crude material was purified by column chromatography to afford compound 1 (125 g, 62%) as a pale yellow liquid. 1 H NMR (400MHz, DMSO): δ5.09 (d, J=1.6Hz, 1H), 4.04-4.05 (m, 1H), 3.92-3.91 ( m,1H),3.73(d,J=3.2Hz,2H),3.58-3.59(m,1H),0.9(s,36H),0.6(s,24H).R f :0.8. Mobile phase: 5% EA / hexane.

[0317] (3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-((tert-butyldimethylsilyl)oxymethyl)tetrahydrofuran-2-ol (2)

[0318]

[0319] To a stirred solution of compound 1 (150 g, 0.24 mol) in DCM (2.5 L) was added TFA (452 ​​g, 3.4 mol) at 0°C. The resulting mixture was stirred at the same temperature for 2-3 minutes (note: immediate quenching is required). After 3 minutes, the reaction mixture was poured into NaHCO 3 The organic layer was separated and washed with anhydrous Na 2 SO 4 Drying, filtration and concentration under reduced pressure afforded the crude compound. The crude material was purified by column chromatography to afford compound 2 (40 g, 33%) as a pale yellow gum. 1 H NMR (400 MHz, CDCl 3 ): δ5.011-5.017(m,1H),4.206-4.234(m,1H),4.051-4.062(m,3H),3.65-3.658(m,1H),3.529-3.541(m,1H),0.9(s,27H),0.6(s,18H).R f :0.4 (mobile phase: 5% EA / hexane).

[0320] (3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-((tert-butyldimethylsilyl)oxymethyl)tetrahydrofuran-2-ylnicotinate (3)

[0321]

[0322] To a stirred solution of compound 2 (80 g, 0.16 mol) in DMF (320 mL) was added dropwise a solution of nicotine chloride (34 g, 0.19 mol) in pyridine (80 mL) at 0°C. The resulting mixture was stirred at room temperature for 12 hours. TLC showed complete conversion of the starting material and a new polar spot was observed. The reaction mixture was quenched with NaHCO 3 The reaction mixture was quenched with aqueous solution and extracted with ethyl acetate. The combined organic layers were washed with 1N HCl (500 mL) and washed with anhydrous Na 2 SO 4 The mixture was dried, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude compound. The crude material was purified by column chromatography to obtain a light yellow gummy liquid compound 3 (80 g, 82%). 1 H NMR (400 MHz, CDCl 3 ): δ9.2(m,1H),8.78(d,J=1.6Hz,1H),8.27(t,J=2Hz,1H),7.39(q,J=4.8Hz,1H),6.14(d,J=1.2Hz,1H),4.36(q,J=4.4Hz, R f :0.4. Mobile phase: 10% EA / hexane.

[0323] Example 1: (3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-ylnicotinate (100)

[0324]

[0325] To a stirred solution of compound 3 (40 g, 0.06 mol) in THF (160 mL) was added Et 3N.3HF (38 g, 0.2 mol; manufactured by SpectRochem; 97% purity). The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was then cooled to -40°C, the THF layer was removed without any water treatment, the gummy compound was washed with ether (3x100 mL), and purified by column chromatography using 100-200 mesh (neutralized with triethylamine) and eluted with 2-5% methanol in DCM to give an off-white sticky solid (9 g, 53%). LCMS showed 80% of the desired mass, and re-purification by RP-C18 gave (4 g, 24%) of compound 100 with a purity of 98%. 1 H NMR (400MHz, CD 3 OD): δ9.11(s,1H),8.75(d,J=1.6Hz,1H),8.40(m,1H),7.58(d,1H),6.24(s,1H) ,4.35(q,1H),4.18(d,1H),4.04-4.05(m,1H),3.82-3.79(d,1H),3.63(dd,1H). LCMS:m / z:256.11[M+H] + ,91.49%(0.89min,0.76min). Chromatographic column: Aquity BEH C18 (2.1x 100mm, 1.7μm). Mobile phase: A-0.01% FA aqueous solution; B-0.01% FA content in ACN (T / %B:0.01 / 10, 0.5 / 10, 4 / 90, 8 / 90). Flow rate: 0.4mL / min. R f : 0.4. Mobile phase: 10% methanol in DCM.

[0326] Example 2: (3R,4S,5R)-3,4-dihydroxy-5-(1-methoxy-1-oxopropan-2-yl)amino)(phenoxy)phosphoryl)oxy)methyl)tetrahydrofuran-2-ylnicotinate (101)

[0327]

[0328] To a stirred solution of compound 100 (8 g, 0.03 mol, 80% pure material) in THF (80 mL) was added dropwise N-methylimidazole (12 g, 0.15 mol) for 5 minutes at room temperature. The reaction mixture was stirred for 15 minutes and then compound 4 (26 g, 0.09 mol) in THF (diastereomers) was added and detected by LCMS. The material was repurified by C-18 RP preparative HPLC and the portions were lyophilized to give compound 101 (800 mg, ~5%) as an off-white gummy solid. 1 H NMR [400MHz, CD 3OD]: δ9.11 (dd, 1H), 8.75 (d, J = 1.6 Hz, 1H), 8.38 (m, 1H), 7.50 (dd, Hz, 1H), 7.29 (m, 2H), 7.15 (t, 2H), 7.10 (d, 1H) 6.24 (s, 1H), 4.41 (m, 2H), 4.20 (m, 3H), 3.375 (m, 1H), 3.56 (d, 3H), 1.25 (d, 3H). LCMS purity: (44.46% and 48.09% of diastereoisomer mixture). Chromatographic column: Acquity Halo C18 (2.1 x 100 mm, 2.7 μm). Mobile phase: A-0.1% ammonia; B-ACN, (T / %B: 0.01 / 10, 0.5 / 10, 5 / 40, 10 / 90). Flow rate: 0.4 mL / min. f : 0.5. Mobile phase: 10% MeOH / DCM.

[0329] Methyl (2S)-2-((Chloro(phenoxy)phosphoryl)amino)propanoate (4)

[0330]

[0331] To a stirred solution of compound 5 (60 g, 0.43 mol) and compound 6 (90 g, 0.44 mol) in DCM (200 mL) was added dropwise Et 3 N (87g, 0.86mol) in DCM (100mL). The reaction mixture was stirred at room temperature for 4 hours. TLC showed that the starting material was completely converted, and new non-polar spots were observed. The reactant was directly concentrated under reduced pressure to obtain a white solid. Ether was added to the solid compound and the suspension was stirred for 30 minutes. The solid was removed by filtration and the filtrate was concentrated under reduced pressure to obtain a crude compound. The crude material was purified by column chromatography and eluted with a hexane solution of 10% to 30% ethyl acetate to obtain a light yellow gummy compound 4 (50g, 28%). 1 H NMR (400 MHz, CDCl 3 ):δ7.2(m,5H),4.0(m,1H),3.8(s,3H),1.37(dd,3H).LCMS:m / z:260.05(chloro is replaced by hydroxyl)[M+H] + ,90% (1.87min.). Chromatographic column: AcquityBEH C18 (2.1x 100mm, 1.7μm). Mobile phase: A-0.01% FA aqueous solution; B-0.01% FA content in ACN (T / %B: 0.01 / 10, 0.5 / 10, 4 / 90, 8 / 90). Flow rate: 0.4mL / min. Rf: 0.5. Mobile phase: 40% EA / hexane.

[0332] Scheme 2 illustrates the preparation of compound 102.

[0333]

[0334] 6-(Hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxolane-4-ol(2)(7)

[0335]

[0336] A solution of ribose (10.0 g, 66.6 mmol) in anhydrous acetone (100 mL) was cooled to 0°C, and then pTSA (80 mg, 2.1 mmol) was added, followed by DMP (9 mL, 73.3 mmol). The resulting mixture was stirred at room temperature for 2 hours. The clarified reactant was neutralized with anhydrous sodium bicarbonate, filtered through a diatomaceous earth bed, and the filtrate was concentrated under reduced pressure to give a crude gummy compound. The crude compound was purified by column chromatography using 100-200 silica gel (eluted in 30% EtOAc: hexane) to give a colorless liquid compound 2 (7.4 g, 59%). The product was purified by column chromatography using 100-200 silica gel (eluted in 30% EtOAc: hexane) to give a colorless liquid compound 2 (7.4 g, 59%). 1 H NMR confirmed. 1 H NMR (400 MHz, DMSO) δ 6.49 (d, 1H), 5.18 (m, 1H), 4.9 (m, 1Hs), 4.7 (t, 1H) and 4.42 (m, 1H), 4.0 (m, 1hs), 3.42 (m, 24=H), 1.38 (m, 3H) and 1.28 (s, 3H). f =0.3 (mobile phase: 40% ethyl acetate:hexane).

[0337] (3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-((tert-butyldimethylsilyl)oxymethyl)tetrahydrofuran-2-ylnicotinate (9)

[0338]

[0339] To a stirred solution of compound 7 (80 g, 0.16 mol) in DMF (320 mL) was added dropwise a solution of nicotine chloride (8) (34 g, 0.19 mol) in pyridine (80 mL) at 0°C. The resulting mixture was stirred at room temperature for 12 hours. TLC showed complete conversion of the starting material and a new polar spot was observed. The reaction mixture was quenched with NaHCO 3 The reaction mixture was quenched with aqueous solution and extracted with ethyl acetate. The combined organic layers were washed with 1N HCl (500 mL) and washed with anhydrous Na 2 SO 4The mixture was dried, filtered, and the filtrate was concentrated under reduced pressure to give crude compound 9. The crude material was purified by column chromatography to give compound 9 (80 g, 82%) as a pale yellow gummy liquid. 1 H NMR [400MHz, CDCl 3 ]: δ9.2(m,1H),8.78(d,J=1.6Hz,1H),8.27(t,J=2Hz,1H),7.39(q,J=4.8Hz,1H),6.14(d,J=1.2Hz,1H),4.36(q,J=4.4Hz, R f :0.4. Mobile phase: 10% EA / hexane.

[0340] Example 3: (3,4,5-Trihydroxytetrahydrofuran-2-yl)methylpicolinate (102)

[0341]

[0342] Compound 9 (9.0 g, 22.5 mmol) was dissolved in TFA:H 2 O, then stirred at room temperature for 16 hours. The solvent was evaporated to provide a crude product, which was purified by column chromatography using 100-200 silica gel (eluted in 5% MeOH:DCM) to give compound 102 (800 mg, 14%) as a light yellow liquid. 1 H NMR[400MHz, CDCl3]: δ9.15(s,1H),8.75-8.74(d,J=1.6Hz,1H),8.49-8.46(d,1H),7.60-7.56(m,1H),5.20(s,1H),4.65(m,1 H), 4.4 (m, 1H), 4.30 (m, 1H), 4.28 (m, 1H), 4.18-4.15 (m, 1H), 3.85-3.80 (d, 1H). LCMS: m / z: 256.19[M+H]+, 96.65% (8.28min.). Column: LUNA 5μC18 (4.6x 100mm). Mobile phase: 0.1% TFA in water; 0.1% TFA in B-ACN, (T / %B: 0.01 / 10, 5 / 10, 20 / 90, 25 / 90). Flow rate: 0.7 mL / min. Rf: 0.3 (mobile phase: 10% methanol: DCM).

[0343] Scheme 3 illustrates the preparation of compounds 103 and 104.

[0344]

[0345] Example 4: (2S,3R,4S,4S,5R)-3,4-dihydroxy-5-(S)-((((S)-1-methoxy-1-oxopropan-2-yl)amino)(phenoxy)phosphorylphosphoryl)oxy)methyl)tetrahydrofuran-2-ylnicotinate (103) and (2S,3R,4S,5R)-3,4-dihydroxy-5-((((R)-(((S)-1-methoxy-1-oxopropan-2-yl)amino)(phenoxy)phosphoryl)oxy)methyl)tetrahydrofuran-2-ylnicotinate (104)

[0346]

[0347] Compound 101 (2.5 g, LC-MS purity 75%) was purified by chiral HPLC (CHIRALPAK IG, 250 x 4.6 mm, 5μ (mobile phase: n-hexane:IPA:MeOH (75:05:20)) to give 450 mg of Compound 103 and 450 ng of Compound 104.

[0348] Compound 103: 1 H NMR [400MHz, CD 3 OD]: δ9.09-9.08(m,1H),8.69-8.68(m,1H),8.38-8.35(m,1H),7.58-7.48(m,1H),7.28(m,J=8.0Hz,2H),7.14-7.09(m,3H),6 .24(s,1H),4.41-4.33(m,2H),4.24-4.15(m,3H),3.88-3.84(m,1H),3.61(s,3H),1.28-1.24(m,3H).LCMS:m / z:497.18[M+H] + ,98.51%(2.80min.); Chromatographic column: Kinetex EVO C18 (2.1x 50mm, 1.7μm), Mobile phase: A-0.1% ammonia solution; B-ACN, (T / %B:0.01 / 10, 0.5 / 10, 5 / 40, 10 / 90); Flow rate: 0.4mL / min.

[0349] Compound 104: 1 H NMR [400MHz, CD 3OD]: δ9.107-9.104(m,1H),8.68(dd,J=1.2,4.8Hz,1H),8.38-8.35(m,1 H),7.47-7.43(m,1H),7.27(t,J=7.6Hz,2H),7.12(t,J=7.6Hz,1H),7.03 (d,J=8.4Hz,2H),6.24(s,1H),4.47-4.39(m,2H),4.25-4.19(m,3H),3. 83-3.79(m,1H),3.56(s,3H),1.28-1.23(m,3H).LCMS:m / z:497.18[M+H] + ,98.51%(2.80min.); Chromatographic column: Kinetex EVO C18 (2.1x 50mm, 1.7μm), Mobile phase: 0.1%NH 3 Aqueous solution; B-ACN, (T / %B: 0.01 / 10, 0.5 / 10, 5 / 40, 10 / 90); flow rate: 0.4 mL / min.

[0350] Scheme 4 illustrates the preparation of compound 105.

[0351]

[0352] Example 5: ((2S, 3R, 4S, 5R)-3,4-dihydroxy-5-(((S)-(((S)-1-isopropoxy-1-oxopropyl)

[0353] Preparation of (105) tetrahydrofuran-2-yl)amino (phenoxy)phosphoryl)oxy)methyl)tetrahydrofuran-2-yl nicotinate

[0354] To a stirred solution of (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-ylnicotinate (100) (100 mg, 1.33 mmol) in THF (1 mL) was added MgCl 2 (20 mg, 0.204 mmol), and the reaction mixture was stirred at room temperature for 15 minutes. Then (S)-2-((((S)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propionic acid isopropyl ester (10) (110 mg, 0.243 mmol) and DIPEA (0.1 mL, 0.608 mmol) were added at room temperature. Two batches were run simultaneously to provide two batches. The two batches were mixed and the volatiles were evaporated under reduced pressure to provide a crude compound. The crude compound was purified by column chromatography (100-200 mesh silica gel, 10% MeOH-DCM as eluent) to give 105 (35 mg, 12% LCMS). LCMS: m / z: 525.16 [M+H] +, (2.11min.). Chromatographic column: EVO C18 (2.1x 50mm, 1.7μM). Mobile phase: A-0.01% FA in water; B-0.01% FA in ACN, (T / %B: 0.01 / 10, 0.5 / 10, 4 / 90, 7 / 90). Flow rate: 0.4mL / min.

[0355] Example 6: Solid-state stability of compounds 100, 101 and 102

[0356] To evaluate the solid state stability at room temperature, refrigerated conditions, and deep freeze conditions, compounds 100, 101, and 102 were stored in glass vials at three different locations at -25°C, 2-8°C, and -20°C, respectively. The purity of the compounds in these vials was evaluated by UPLC at three different time points of 0 hours, 24 hours, and 48 hours. Table 2 describes the results of solid state stability at 25°C, 2-8°C, and -20°C, respectively. Purity measurements were performed at 0 hours, 24 hours, and 48 hours.

[0357] Table 2

[0358]

[0359] Example 7: Solution stability (simulated gastric fluid, simulated intestinal fluid and pH stability)

[0360] 1 mg / ml solutions of compounds 101 and 102 were prepared in each buffer and analyzed as follows: Column: Acquity Halo C18 (2.1 x 100 mm, 2.7 μm), Mobile phase: A-0.1% NH 3 ; B-ACN, (T / %B: 0.01 / 10, 0.5 / 10, 5 / 40, 10 / 90) flow rate: 0.4mL / min; column: Luna C18 (4.6x 150mm, 5μm), mobile phase: A-0.1% TFA aqueous solution; B-0.1% TFA in ACN, (T / %B: 0.01 / 0, 5 / 0.20 / 90, 25 / 90), flow rate: 0.7mL / min.

[0361] A 1 mg / ml solution of compound 100 was prepared in each buffer, diluted to 0.1 mg / ml with methanol at each time point and analyzed as follows: Gemini C-18, 250 x 4.6 mm, 5 μm, mobile phase: methanol, isocratic flow rate: 0.4 ml / min.

[0362] Table 3 shows the pH values ​​and buffers used.

[0363] Table 3

[0364]

[0365]

[0366] Table 4 describes the stability of Compound 100 in solution, simulated gastric fluid, and intestinal fluid over a range of pH.

[0367] Table 4

[0368]

[0369] Table 5 describes the stability of Compound 101 in solution, simulated gastric fluid, and intestinal fluid over a range of pH.

[0370] Table 5

[0371]

[0372]

[0373] Table 6 describes the stability of Compound 102 in solution, simulated gastric fluid, and intestinal fluid over a range of pH.

[0374] Table 6

[0375]

[0376] Preparation of stock solutions for cell-based assays

[0377] Compounds 100, 101 and 102 were weighed and 60 μM stock solutions were prepared in RPMI medium. A 200 ng / mL Rac tenofovir d6 (Vivan Life Sciences) solution was prepared in methanol (MeOH) and kept at -20°C until use.

[0378] Example 8: Effects of Compounds on Cellular NAD+ Levels in Jurkat Cells

[0379] Jurkat cells from NCCS Pune were cultured in RPMI medium containing FBS and antibiotics. Cells from different flasks (90% confluence) were combined into a 15 mL conical tube and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded and replaced with 5 mL of sterile PBS (without Ca). 2+ and Mg 2+) Wash the precipitate. The tubes were then centrifuged at 1200 rpm for 5 minutes and the supernatant was discarded. The cell pellet was resuspended in 7 mL of RPMI medium and 10 uL of the cell solution was used for cell counting. 1.5 million cells from the cell solution were inoculated into a 1.5 mL microcentrifuge tube. Compounds (100, 101, 102 and niacin) were added together with RPMI medium without PBS to a total volume of 1 mL and a final concentration of 30 μM. The tubes were placed on a rack and gently rotated to mix the compounds into the medium containing the cells. The tubes were then incubated at 37°C, 5% CO 2 incubator for 4 hours. After 4 hours of incubation, the cells were spun at 1000 rpm for 10 minutes, the supernatant was carefully discarded, and the cells were snap frozen in liquid nitrogen. When the samples were run, the extraction of the cells was performed on ice, using 20uL of deionized water to lyse the cells, followed by the addition of ice-cold 80% methanol containing the internal standard Rac Tenofovir D. The tubes were then vortexed at 2500rpm for 8 minutes and then centrifuged at 125000rpm for 10 minutes. 150uL of the supernatant was carefully transferred to an HPLC vial and analyzed for NAD+ on an Abscised 4000QTrap LCMS / MS system. A C18, 3.5μm, 2.1x100 mm bridge column was used in the liquid chromatography. The mobile phase consisted of 10mM ammonium acetate and 0.1% acetic acid and 0.1% hexylamine as solvent A, 10mM ammonium acetate and 0.1% acetic acid and 0.1% hexylamine salt in 95 / 5MeOH / H 2 O as solvent B. The gradient used was 0 min - 0.0% B, 0.5 min - 100% B, 1.5 min - 100% B., 3.0 min - 100% B. 3.1 min - 0.0% B., 7.0 - STOP. The column flow rate was 0.5 mL / min and the injection volume was 3 μL.

[0380] All four compounds (100, 101, 102, and niacin) showed statistically significant increases in NAD+ levels after four hours of incubation compared to untreated cells. Figure 1 As shown, the greatest increase was observed in cells treated with compound 101.

[0381] Example 9: Effects of Compounds on Cellular NAD in Huh-7 Cells + The impact of level

[0382] Huh-7 cells from NCCS Pune were cultured in RPMI medium containing FBS and antibiotics. Cells from different flasks (80-90% confluence) were combined into a 15 mL conical tube and centrifuged at 1200 rpm for 5 minutes. The supernatant was discarded and replaced with 5 mL of sterile PBS (without Ca). 2 + and Mg2 +) Wash the precipitate. The tube was then centrifuged at 1200 rpm for 5 minutes and the supernatant was discarded. The cell pellet was resuspended in 7 mL of RPMI medium and 10 uL of the cell solution was used for cell counting. 1.5 million cells from the cell solution were inoculated into a 1.5 mL microcentrifuge tube. Compounds (100, 101, 102 and niacin) were added together with RPMI medium without PBS to a total volume of 1 mL and a final concentration of 30 μM. The tubes were placed on a rack and gently rotated to mix the compounds into the medium containing the cells. The tubes were then incubated at 37°C, 5% CO 2 incubator for 4 hours. After 4 hours of incubation, the cells were spun at 1000 rpm for 10 minutes, the supernatant was carefully discarded, and the cells were snap frozen in liquid nitrogen. When the samples were run, the extraction of the cells was performed on ice, using 20uL of deionized water to lyse the cells, followed by the addition of ice-cold 80% methanol containing the internal standard Rac Tenofovir D. The tubes were then vortexed at 2500rpm for 8 minutes and then centrifuged at 125000rpm for 10 minutes. 150uL of the supernatant was carefully transferred to an HPLC vial and analyzed for NAD+ on an Abscised 4000QTrap LCMS / MS system. A C18, 3.5μm, 2.1x100 mm bridge column was used in the liquid chromatography. The mobile phase consisted of 10mM ammonium acetate with 0.1% acetic acid and 0.1% hexylamine as solvent A, 10mM ammonium acetate with 0.1% acetic acid and 0.1% hexylamine salt in 95 / 5MeOH / H 2 O as solvent B. The gradient used was 0 min - 0.0% B, 0.5 min - 100% B, 1.5 min - 100% B., 3.0 min - 100% B. 3.1 min - 0.0% B., 7.0 - stop. The column flow rate was 0.5 mL / min and the injection volume was 3 μL.

[0383] Figure 2 Depicted is the increase in NAD+ in HEPG2 cells. All four compounds (100, 101, 102 and niacin) at 125 μM increased NAD+ levels after four hours of incubation compared to untreated cells.

[0384] Example 10: Effects of 250 μM Compounds 103 and 104 on Primary Human Hepatocytes

[0385] Cryopreserved primary human hepatocytes were obtained from Lonza, cultured, and seeded into 6-well culture dishes with 500,000 cells per well. Compounds 103 and 104 were added in duplicate and incubated in an incubator at 37°C for 4 hours. The cells were then spun down and extracted. NAD+ in the supernatant was detected by LCMS / MS.

[0386] The results are as follows Figures 3A-3D In primary human hepatocytes, compounds 103, 104, and niacin significantly increased NAD+ levels after four hours of incubation at 250 μM compared to untreated cells.

[0387] Example 11: Effects of Compounds on Cellular NAD+ Levels in HEPG2 Cells - NAD Cycle Assay

[0388] HEPG2 cells were seeded in 6-well plates at a density of 1 million cells per well. The next day, cells were treated with test compounds for 4 h and harvested using the following protocol. Each well was washed once with 2 mL of ice-cold PBS, PBS was removed, and 400 μL of 2 M HClO was added to each well. 4 (perchloric acid), scrape off, transfer the residue to a 1.5 mL test tube and centrifuge. Transfer 100 μL of supernatant to a clean 1.5 mL vial, add 150 μL of KOH / MOPS2M / 0.6M (neutralization buffer) to each vial under vortexing, and spin. Measure pH according to the NAD cycle protocol.

[0389] According to Table 7, NAD standards were prepared in water from 0 to 0.5 μM.

[0390] Table 7

[0391]

[0392]

[0393] The cycling reactions were prepared as follows. 10 μl of sample was added, then water was added to bring the volume to 25 μl. 25 μl of each standard was used for the reaction in duplicate. 50 μl of mixture A (cycling mixture) was then added to the sample and standards. Mixture A contained the following components:

[0394]

[0395] The reaction was initiated using 25 μL of enzyme mixture (15 U / ml alcohol dehydrogenase + 15 U / ml malate dehydrogenase). The sample was incubated in a water bath at 37°C for 30 minutes and terminated by heating in a bath at 80°C for 5 minutes. 25 μL of sample was then used in the detection step. 100 μL of mixture B containing the following ingredients was added to the sample.

[0396] Mixture B2X (Indicator) μl 100mM Bis-Tris pH 9.0 (1M) 500 1mM NAD(5mM) 1000 10mM L-glutamate (100mM) 500 QUR 3000 Make up 5000

[0397] The reaction was initiated using the starting reagent (prepared by mixing 10 μl of malate dehydrogenase and 10 μl of glutamate oxaloacetate transaminase in 1 ml of water). The reading was measured at 340 nm in an Envision microplate reader. The results are shown in Figures 4A-4D shown.

[0398] All five compounds (100-105 and niacin at 10 μM, 50 μM, 100 μM, and 250 μM) increased NAD+ levels in 101, 103, and 104 with statistical significance in MP compared to untreated cells after four hours of incubation. Compounds 103 and 104 showed statistically significant increases even at the lowest concentration of 10 μM. Compound 104 also showed a statistically significant increase compared to all concentrations of niacin.

[0399] Example 12: Effects of Compounds 103 and 104 in Primary Human Hepatocytes

[0400] Cryopreserved primary human hepatocytes from Lonza were cultured and seeded into 6-well dishes with 500,000 cells per well. Compounds 103 and 104 were added in duplicate and incubated in an incubator at 37°C for 4 hours. The cells were then spun down and extracted. NAD+ in the supernatant was detected by LCMS / MS.

[0401] The results are as follows Figure 5 As shown in Figure 6. In primary human hepatocytes with 10 μM compounds 103, 104, and niacin, NAD+ levels increased significantly after 4 hours of incubation compared to untreated cells.

[0402] Example 13: In vitro cytotoxicity of compounds 100, 101 and 102 on HEPG2 cells

[0403] HEPG2 cells were cultured and used to test the in vitro cytotoxic effects of compounds 100, 101, and 102. Cell Titer purchased from Promega was used. The assay was performed using a luminescent cell viability assay kit. The concentrations of compounds 100, 101, and 102 were 0.3, 1, 3, 10, 30, 100, 300, and 1000 μM, respectively. 1000 cells per well were plated and incubated for 72 hours with each of these concentrations. Cisplatin (6.5 μM) and nicotinamide riboside (NR) (100 μM) were used as controls. The generation of a luminescent signal proportional to the amount of ATP present was measured on a microplate reader as luminescence (RLU). The amount of ATP is proportional to the number of cells present in the culture. The results are shown in Figure 2. Figure 7 shown.

[0404] Example 14: CACO2 Permeability of Compounds 100, 101 and 102

[0405] A Caco-2 permeability assay was performed to measure the permeability of compounds 100, 101, and 102 across the human intestinal epithelial cell barrier. The endpoint measured was intestinal permeability expressed as the apparent permeability - Papp value. All permeability values ​​were expressed as x10 -6 The permeability was ranked according to the following criteria shown in Table 8.

[0406] Table 8

[0407]

[0408] Low: Papp AB <2.5×10 -6 cm / s. High: Papp AB ≥ 2.5×10 -6 Cm / sec. Compounds 100 and 102 had low pumping rates, while compound 101 had an effective pumping rate.

[0409] Example 15: Kinetic Solubility of Compounds 100, 101 and 102

[0410] Table 9

[0411]

[0412] The kinetic solubility of the test compounds was measured in aqueous buffer when added from an existing stock solution of DMSO (50 μL of 10 mM DMSO stock). The target compound concentration was 100 μM (kinetic), the assay buffer was 0.1 M phosphate buffered saline pH 7.4, and the mixing time was 1.5 hours (kinetic). Samples were prepared by centrifugation or filtration, and the detection methods used were HPLC and UV-vis spectroscopy.

[0413] As shown in Table 9 above, all tested compounds had solubility greater than 95% at 100 μM. The data for Albendazole and Flurbiprofen (QC compounds) were consistent with historical data.

[0414] Example 16: Human Hepatocyte Clearance of Compounds 100-104

[0415] Table 10

[0416]

[0417] Remove the hepatocyte vial from the liquid nitrogen tank and thaw in a 37°C water bath. The thawed cell suspension is transferred to a torque tube containing 50mL thawing medium (Xenotech). The thawing medium containing the hepatocytes is centrifuged at 1000rpm for 5 minutes, the supernatant is discarded, and the precipitate is resuspended in 2ml Xenotech OptiIncubate medium. After mixing the aliquoted cell suspension with an equal volume of trypan blue, the cells are counted using a hemocytometer. The cell suspension is diluted to a working density of 2 million cells with DMEM medium without FBS. A 10mM test compound stock solution is prepared in DMSO and diluted to a concentration of 1mM with DMSO. A working concentration of 2μM is prepared by further diluting with PBS.

[0418] The assay was performed twice (n=2). 150 μL of a 2 million cell working stock of hepatocyte suspension was added to a 24-well plate and incubated at 500 RPM for 10 minutes in a 37°C incubator. 150 μL of a 2 μM working stock of the test compound was incubated alone. The reaction was stopped at 0, 15, 30, 60, and 90 minutes by precipitating 20 μL of the incubation mixture with 200 μL of an internal standard containing acetonitrile. The samples were vortexed at 1200 rpm for 5 minutes and centrifuged at 4000 rpm for 10 minutes. The supernatant was separated, diluted 1:1 with water, and then injected into LC-MS / MS analysis. Testosterone and warfarin were used as assay controls.

[0419] Compounds 100, 102 and 104 showed moderate clearance, while compounds 101 and 109 showed high clearance in human hepatocytes, as shown above in Table 10. Testosterone and warfarin (QC compound) data were consistent with the reference data.

[0420] title Human hepatocyte stability Test concentration (μM) 1μM Incubation time (min) 0,15,30,60 and 90 Number of repetitions 2 Number of cells in the experiment 1 million cells / mL Analytical methods LC-MS / MS

[0421] Example 17: Human Hepatocyte Stability of Compounds 100, 101, 103 and 104

[0422] Table 11

[0423]

[0424] Prepare 10mM test compound stock solution in DMSO and dilute to 1mM concentration with DMSO. Prepare 2μM working concentration by further dilution with PBS. Add 150μL of the pre-incubation mixture of hepatocyte suspension (1000000 cells / mL, INVITROGRO HT culture medium buffer) to a vial and pre-incubate for 10 minutes at 37°C.

[0425] 150 μL of 2 μM test compound working stock was added to the cell suspension and incubated at 37 ° C, 500 rpm. The reaction was stopped at 0, 15, 30, 60 and 90 minutes by precipitating 50 μL of the incubation mixture with 150 μL of acetonitrile. The sample was vortexed at 1200 rpm for 5 minutes and centrifuged at 4000 rpm for 10 minutes. 150 μL of supernatant was diluted with 150 μL of water and injected into an MS system (SCIEX, API 4500Q Trap) for analysis.

[0426] Compounds 100, 102 and 104 showed moderate clearance, while compounds 101 and 109 showed high clearance in human hepatocytes, as shown above in Table 11. Testosterone and warfarin (QC compound) data were consistent with the reference data. Fig.9A -E shows the results for compounds 101, 103, 104, testosterone, and warfarin in graphical form.

[0427] Example 18: Human plasma protein binding of compounds 100, 101 and 102

[0428] Weigh the test compounds and prepare them as 10 mM stock solutions in 100% DMSO. 10 μM is the final test concentration for all compounds. The substrate of the RED chamber is rinsed with 20% ethanol for 10 minutes, rinsed twice with water, dried and used immediately or covered according to the manufacturer's recommended protocol.

[0429] Samples were prepared by adding test compounds to plasma at a final concentration of 10 μM. 200 μL of plasma containing test compounds was added to the donor well (RED chamber) of the insert. At the same time, 350 μL of dialysis buffer (1X PBS) was added to the receiver well (white chamber). Two measurements were performed for each test compound. The plate was covered with a sealant and incubated at 37°C for 5 hours at 500 rpm on an orbital shaker.

[0430] After incubation, 25 μl plasma (RED chamber) and 25 μl buffer (white chamber) samples were collected into separate centrifuge tubes. Plasma and buffer samples were precipitated with 200 μL of 100% acetonitrile containing internal standard. 25 μl T 0 (T Zero) Plasma samples (samples before 5 hours of incubation) (T 0 Samples were processed immediately after preparation of plasma working stock solutions. These samples were used as indicators for calculating the recovery of test compounds and were precipitated using an internal standard containing 100% acetonitrile). Samples were vortexed at 1000 rpm for 5 minutes and centrifuged at 4000 rpm for 10 minutes. The supernatant was diluted 2-fold with water and injected into LC-MS / MS. Reference compounds were atenolol and warfarin.

[0431] The percentage of plasma bound / unbound fraction was calculated by the following equations: Unbound or free percentage = 100*(Fc / Tc); % recovery = 100(Fc+Tc) / Tc, where Tc = total compound concentration determined by the concentration calculated on the plasma side of the membrane (concentration in the plasma compartment), Fc = free compound concentration determined by the concentration calculated on the buffer side of the membrane (concentration in the buffer compartment), Tc = total compound concentration determined by the concentration calculated on the buffer side of the membrane (concentration in the buffer compartment), 0 = total complex concentration determined before dialysis.

[0432] Table 12

[0433]

[0434]

[0435] As shown in Table 12 above, compounds 100 and 102 were not detected, indicating no protein binding. The atenolol and warfarin data were consistent with the reference data.

[0436] Example 19: Plasma Stability of Compounds 101, 102, 103 and 104

[0437] Fresh plasma was incubated at 37°C for 10 minutes, mixed and centrifuged to remove any aggregated proteins. The clarified supernatant was aliquoted into assay plates. Plasma was equilibrated to 37°C and biotransformation was initiated by adding compound solution (1 μL of 200x compound was added to 200 μL of plasma and mixed thoroughly (final concentration was -1 μM)).

[0438] T was collected immediately after mixing the compounds. 0 Samples. The assay plate was placed on a shaker at 37°C and samples were collected at 15, 30, 60, and 120 minutes. At each time point, 20 μl of sample was added to 300 μl of acetonitrile containing internal standard. The samples were vortexed at 1200 rpm for 5 minutes, centrifuged at 4000 rpm for 10 minutes, and the supernatant was diluted with water and injected into LC-MS / MS for analysis.

[0439] % Remaining = 100*(peak area ratio at time point / T 0 Peak area ratio = analyte peak area / internal standard plasma half-life peak area (T 1 / 2)=0.693 / K, where K is the slope of the linear fit of the natural logarithm of the remaining portion of the parent compound versus incubation time.

[0440] Table 13

[0441]

[0442]

[0443] Table 14

[0444]

[0445] The results are as follows Figures 8A-8E As shown, Tables 13 and 14 are shown in tabular form. The human plasma stability of compounds 100-104 and nicotinic acid (NA) at 5 μM for 0-2 hours was evaluated. Compounds 101-104 showed slow degradation of the parent molecule, indicating stability for more than 2 hours. All four compounds were converted to nicotinic acid over a 2-hour time course. Compound 100 and nicotinic acid were measured to determine the decomposition of the compounds. The compound 101 measurement represents compounds 103 and 104 because the LCMS assay is the same for determining the compound 101 isomer.

[0446] Example 20: PK study of compound 100 in rats

[0447]

[0448] Rats were divided into 4 groups, Group 1 and Group 4 (n=3). Compound 100 was administered to Group 1 and Group 2 (Group 1 was orally administered 415 mg / kg and Group 2 was intravenously administered 83 mg / kg). Groups 3 and 4 were given niacin (Group 3 was orally administered 200 mg / kg and Group 4 was intravenously administered 40 mg / kg). 150 to 200 μL of blood was collected in a 1.5 mL centrifuge tube and K2-EDTA was pre-added before administration, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 24 hours before oral and administration, and 5 minutes, 15 minutes, thirty minutes, 1 hour, 2 hours, 4 hours and 8 hours before intravenous administration. K2EDTA blood samples were immediately (<5 minutes) centrifuged at 14000 rpm for 10 minutes at 4°C to separate plasma and store the residue at -80°C for Compound 100 analysis and niacin estimation. The study design is summarized in Table 15 above.

[0449] An aliquot (50 μL) of whole blood was collected at the same time and immediately after collection was pulverized with 1 ml of pulverization solution, vortexed for 2 minutes, and stored at -80°C until analysis of NAD and NADH estimates. Twenty-four hours after dosing, animals were sacrificed without perfusion and kidneys and livers were collected. Immediately after collection, tissue samples were snap-frozen in liquid nitrogen and stored at -80°C until homogenization and analysis (tissues were homogenized in methanol: water (1:1), maintaining a ratio of 1 g to 19 mL of solvent before analysis).

[0450] Other details of the surgery are shown in Table 16 below.

[0451] Table 16

[0452]

[0453] Bioanalysis of the analytes in each sample (NAD, NADH, Compound 100 and NA) was performed by using an API 4500Q trap system. All analyte quantifications were analyzed using Analyst software.

[0454] The results of Group 2 and Group 1 were as follows Fig. 10A and 10B The results of Group 4 and Group 3 are shown in Fig.11A and 11B shown.

[0455] Table 17 lists the pharmacokinetic parameters of Group 2.

[0456] Table 17

[0457] 83 mg / kg IV Compound 100 niacin <![CDATA[T 1 / 2 (h)]]> 1.01±0.22 0.644±0.038 <![CDATA[T max (h)]]> 0.139±0.096 0.389±0.529 <![CDATA[C max (μM)]]> 188.0±97.2 66.38±28.70 <![CDATA[AUC 0-1 (μM)]]> 148.01±34.0 70.57±7.53 CL(L / h / kg) 2.26±0.57 NA <![CDATA[V ss (l / kg)]]> 3.40±1.62 NA

[0458] Table 18 lists the pharmacokinetic parameters of Group 4.

[0459] Table 18

[0460] 40 mg / kg IV niacin <![CDATA[T 1 / 2 (h)]]> 0.448±0.277 <![CDATA[T max (h)]]> 0.25±0.00 <![CDATA[C max (μM)]]> 1240±833 <![CDATA[AUC 0-1 (μM)]]> 1077±426 CL(L / h / kg) 0.304±0.093 <![CDATA[V ss (l / kg)]]> 0.211±0.156

[0461] Table 19 lists the pharmacokinetic parameters of Group 3.

[0462] Table 19

[0463]

[0464]

[0465] Compound 100 IV pharmacokinetics describes a biphasic rapid distribution followed by clearance. Compound 100 delivered by IV may be 1 / 2 After oral administration, the T of compound 100 1 / 2 Consistent with in vitro hepatocyte stability (5-6h).

[0466] No distribution phase is observed following intravenous administration of niacin. Fig. 12A As shown in Figure 1-C, compound 100 and niacin were detected in liver and kidney tissues 24 hours after oral and intravenous injection of compound 100. The niacin level detected in the niacin treatment group was not significant. Fig. 12A As shown in Figure 1-C, compound 100 is more effective than niacin in delivering niacin to tissues. In summary, compound 100 shows superior in vivo pharmacology to niacin, with a longer half-life, lower maximum concentration (C), better bioavailability, and accumulation effect in the kidney and liver.

[0467] Example 21: Efficacy of Compound 100 in a cisplatin-induced mouse renal injury model

[0468] This study was performed using a protocol approved by the Institutional Animal Ethics Committee (IAEC) in accordance with the CPCSEA Guide for the Care and Use of Animals. BALB / c female mice aged 6-8 weeks were divided into 5 groups of 6 mice each. The temperature and relative humidity of the animal room environment were monitored twice a day. The temperature range was 22°C ± 3°C and the humidity range was 30-70%, although the upper limit of the humidity could be exceeded during room cleaning. Animals were housed in an IVC system and received a 12-h light and 12-h dark cycle throughout the study. SDS chow (M / s. SDS Diet Services) and autoclaved drinking water were provided ad libitum.

[0469] The group parameters are shown in Table 20 below.

[0470] Table 20

[0471]

[0472]

[0473] The vehicle for cisplatin was 0.9% saline, while the vehicle for Compound 100 was PBS at pH 6. Compound 100 formulations were prepared prior to each preparation. The study was divided into 5 groups.

[0474] Prior to the study, animals were acclimatized. Before cisplatin administration, they were pretreated with compound 100 for 3 days. On day 3 of the study, animals in group 1 were weighed and given vehicle, and groups 2, 3, 4, and 5 were injected intraperitoneally with a single dose of 25 mg / kg cisplatin. The oral dose groups (groups 3-5) were dosed with compound 100 twice a day for 6 days (3 days before and 3 days after cisplatin administration).

[0475] Blood samples were collected in 2 ml Eppendorf tubes at the end of the study (12 hours after the last dose, by cardiac puncture), and serum was separated and stored at -20°C for clinical chemistry analysis.

[0476] All animals survived and were sacrificed by carbon dioxide overdose at the end of the study (12 hours after the last test compound dose). Liver, kidney, and muscle (gastrocnemius and soleus / vastus lateralis) were collected, weighed, and snap-frozen in liquid nitrogen and stored at -80°C for analysis. On the last day of blood collection, serum creatinine and blood urea nitrogen (BUN) were determined using a clinical chemistry analyzer, and the results were as follows: Fig.13 and Fig.14 As shown in Groups 1-5.

[0477] Mice in group 2 were sluggish from day 5 until sacrifice. Weight loss was observed in groups 2 and 5, with the greatest weight loss in group 2. Mild to moderate kidney discoloration was observed in group 2. No obvious abnormalities of the kidney were found in the other groups.

[0478] Compared with group 1, serum creatinine and BUN were significantly increased in group 2 mice [p<0.05]. Compared with group 2, when taken orally twice a day for 6 days, treatment with compound 100 showed significant reductions in serum creatinine and BUN at all three doses (i.e., groups 3-5) [p<0.05]. There were no significant differences in serum creatinine and BUN between groups 3, 4, and 5. In summary, in the cisplatin-induced acute kidney injury (AKI) mouse model, all three oral doses of compound 100 showed renal protective effects.

[0479] Example 22: Long-term solid stability of compound 100

[0480] Compound 100 was stored in a well-sealed glass bottle at -15°C to evaluate its solid state stability in a deep freezer. The purity of the compound in the vial was evaluated by UPLC at two different time points (day 0 and day 93 (3 months)). Table 21 describes the solid state stability results obtained based on the purity measurements performed on day 0.

[0481] Table 21

[0482]

[0483] Compound 100 was stable in the solid state when stored at -15°C for up to three months.

Claims

1. A compound of structural formula (I): or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein: R1 is -H, R8C(O)-, R2 is -H or R9C(O)-; R3 is -H or R 10 C(O)-; R4 is -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl, R 11 C(O)- or R6 is -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl; R5, R7, R8, R9, R 10 and R 11 are independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl; Provided that at least one of R1 or R4 is 2. The compound according to claim 1, wherein R4 is -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, aralkyl, heteroaryl, heteroaralkyl, R 11 C(O)- or 3. The compound according to claim 1, wherein R4 is -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, R 11 C(O)- or 4. The compound according to claim 1, wherein R4 is alkyl, alkenyl, R 11 C(O)- or 5. The compound according to claim 1, wherein R8, R9, R 10 and R 11 and R is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, aralkyl, heteroaryl or heteroaralkyl.

6. The compound according to claim 1, wherein R8 and R 11 is alkyl, substituted alkyl, alkenyl, substituted alkenyl or heteroaryl, R9 and R 10 are independently alkyl, substituted alkyl, alkenyl or substituted alkenyl.

7. The compound according to claim 1, wherein R8 and R 11 is alkyl, substituted alkyl, alkenyl, substituted alkenyl or heteroaryl, R9 and R 10 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3, or -CH(NH2)CH(CH3)2.

8. The compound according to claim 1, wherein R8 and R 11are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2 or heteroaryl, R9 and R 10 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3, or -CH(NH2)CH(CH3)2.

9. The compound according to claim 1, wherein R9 and R 10 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

10. The compound according to claim 1, wherein R1 is 11. The compound of claim 1, wherein R5 is alkyl, alkenyl, aryl, substituted aryl, aralkyl, heteroaryl or heteroaralkyl.

12. The compound of claim 1, wherein R5 is alkyl, alkenyl, aryl or substituted aryl.

13. The compound of claim 1, wherein R5 is aryl.

14. The compound of claim 1, wherein R6 is -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, aralkyl, heteroaryl or heteroaralkyl.

15. The compound of claim 1, wherein R6 is -H, alkyl, substituted alkyl, aralkyl, or heteroaralkyl.

16. The compound of claim 1, wherein R7 is alkyl, alkenyl, aryl, substituted aryl, aralkyl, heteroaryl or heteroaralkyl.

17. The compound of claim 1, wherein R7 is alkyl, alkenyl or aralkyl.

18. The compound of claim 1, wherein R5 is alkyl, alkenyl, aryl or substituted aryl, R6 is alkyl, substituted alkyl, aralkyl or heteroaralkyl, and R7 is alkyl, alkenyl or aralkyl.

19. The compound of claim 1, wherein R5 is aryl or aralkyl, R6 is alkyl, substituted alkyl, aralkyl or heteroaralkyl, and R7 is alkyl, alkenyl or aralkyl.

20. The compound according to claim 1, which is of formula (II):

21. The compound according to claim 20, wherein R9, R10 and R 11 are independently alkyl or substituted alkyl.

22. The compound according to claim 20, wherein R9, R 10 and R 11 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

23. The compound according to claim 20, wherein R2 is R9C(O)-, R3 is R 10 C(O)-, R4 is -H.

24. The compound according to claim 23, wherein R9 and R 10 are independently alkyl or substituted alkyl.

25. The compound according to claim 23, wherein R9 and R 10 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

26. The compound according to claim 20, wherein R2 is R9C(O)-, R3 is R 10 C(O)-, R4 is an alkyl group.

27. The compound according to claim 26, wherein R9 and R 10 are independently alkyl or substituted alkyl.

28. The compound according to claim 26, wherein R9 and R 10 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

29. The compound according to claim 20, wherein R2 is R9C(O)-, R3 is R 10 C(O)-, R4 is R 11 C(O)-.

30. The compound according to claim 29, wherein R9, R 10 and R 11 are independently alkyl or substituted alkyl.

31. The compound according to claim 29, wherein R9, R 10 and R 11are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

32. The compound of claim 20, wherein R2 is -H, R3 is R 10 C(O)-, R4 is R 11 C(O)-.

33. The compound according to claim 32, wherein R 10 and R 11 are independently alkyl or substituted alkyl.

34. The compound according to claim 32, wherein R 10 and R 11 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

35. The compound of claim 20, wherein R2 is R9C(O)-, R3 is -H, R4 is R 11 C(O)-.

36. The compound according to claim 35, wherein R9 and R 11 are independently alkyl or substituted alkyl.

37. The compound according to claim 35, wherein R9 and R 11 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

38. The compound according to claim 1, which is of formula (III):

39. The compound according to claim 38, wherein R8, R9 and R 10 are independently alkyl or substituted alkyl.

40. The compound according to claim 38, wherein R8, R9 and R 10 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

41. The compound according to claim 38, wherein R1 is R8C(O)-, R2 is R9C(O)-, R3 is R 10 C(O)-.

42. The compound according to claim 41, wherein R8, R9 and R 10 are independently alkyl or substituted alkyl.

43. The compound according to claim 41, wherein R8, R9 and R 10 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

44. The compound according to claim 38, wherein R1 is -H, R2 is R9C(O)-, R3 is R 10 C(O)-.

45. The compound according to claim 44, wherein R9 and R 10 are independently alkyl or substituted alkyl.

46. ​​The compound according to claim 44, wherein R9 and R 10 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

47. The compound of claim 38, wherein R1 is R8C(O)-, R2 is -H, R3 is R 10 C(O)-.

48. The compound according to claim 47, wherein R8 and R 10 are independently alkyl or substituted alkyl.

49. The compound according to claim 47, wherein R8 and R 10 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

50. The compound of claim 38, wherein R1 is R8C(O)-, R2 is R9C(O)-, and R3 is -H.

51. The compound of claim 50, wherein R8 and R9 are independently alkyl or substituted alkyl.

52. A compound according to claim 50, wherein R8 and R9 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

53. The compound according to claim 1, which is of formula (IV):

54. The compound according to claim 53, wherein R9 and R 10 are independently alkyl or substituted alkyl.

55. The compound according to claim 53, wherein R9 and R 10 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

56. The compound according to claim 53, wherein R2 is R9C(O)-, R3 is R 10 C(O)-, R9 and R 10 are independently alkyl or substituted alkyl.

57. The compound of claim 56, wherein R5 is aryl or aryl, R6 is alkyl, substituted alkyl, aryl or aralkyl, and R7 is alkyl, alkenyl or aralkyl.

58. The compound according to claim 57, wherein R9 and R 10 are independently -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

59. A compound according to claim 58, wherein R5 is phenyl, naphthyl or benzyl, R6 is CH3, -C2H5, and R7 is -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or cyclopropyl.

60. The compound according to claim 53, wherein R2 is -H, R3 is R 10 C(O)-,R 10 It is an alkyl group or a substituted alkyl group.

61. The compound of claim 60, wherein R5 is aryl or aryl, R6 is alkyl, substituted alkyl, aryl or aralkyl, and R7 is alkyl, alkenyl or aralkyl.

62. The compound according to claim 61, wherein R 10 It is -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

63. The compound of claim 62, wherein R5 is aryl or aralkyl, R6 is alkyl, substituted alkyl, aryl or aralkyl, and R7 is alkyl, alkenyl or aralkyl.

64. A compound according to claim 63, wherein R5 is phenyl, naphthyl or benzyl, R6 is CH3, -C2H5, and R7 is -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or cyclopropyl.

65. The compound of claim 53, wherein R2 is R9C(O)-, R3 is -H, and R9 is alkyl or substituted alkyl.

66. The compound of claim 65, wherein R5 is aryl or aralkyl, R6 is alkyl, substituted alkyl, aryl or aralkyl, and R7 is alkyl, alkenyl or aralkyl.

67. A compound according to claim 66, wherein R9 is -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or -CH(NH2)CH(CH3)2.

68. A compound according to claim 67, wherein R5 is phenyl, naphthyl or benzyl, R6 is CH3, -C2H5, and R7 is -CH3, -C2H5, -C3H7, -CH(CH3)2, -CH2CH(CH3)2, -CH(C2H5)(CH2)2CH3 or cyclopropyl.

69. The compound of claim 1 having the structure:

70. The compound of claim 1 having the structure:

71. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

72. A method for preventing or treating a metabolic disorder, cardiovascular disease, cerebrovascular disease, liver disease, kidney disease or muscle disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1.

73. The method of claim 72, wherein the metabolic disorder is type 1 or type 2 diabetes, impaired glucose tolerance, insulin resistance, obesity, hyperlipidemia, dyslipidemia, hypercholesterolemia, or hypertriglyceridemia; the cardiovascular disease is cardiomyopathy, heart failure, or myocardial ischemia, infarction, or ischemia-reperfusion injury (IRI); the cerebrovascular disease is stroke or cerebral ischemia, neuroinflammation, multiple sclerosis, hepatic encephalopathy, neurodegeneration, Parkinson's disease, disease, or Alzheimer's disease; the liver disease is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic liver disease, alcoholic hepatitis, alcoholic steatohepatitis, liver fibrosis, cirrhosis, cirrhosis, liver failure, acute liver failure or chronic liver failure; the kidney disease is acute kidney injury or renal ischemia or IRI and chronic kidney disease, including diabetic nephropathy; the muscle disease includes muscle atrophy, cachexia, sarcopenia, muscular dystrophy, Duchenne muscular dystrophy (DMD), myositis, neuromuscular degeneration, ataxia, spinocerebellar ataxia, adult-onset mitochondrial myopathy, Friedreich ataxia or ataxia telangiectasia.

74. A method of increasing nicotinamide adenine dinucleotide (NAD+) levels and / or providing cytoprotection in a cell type or tissue in a subject, comprising administering to the subject a therapeutically effective amount of a compound of claim 1.

75. A method of increasing nicotinamide adenine dinucleotide (NAD+) levels and / or providing cytoprotection in a cell type or tissue of a subject where needed, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 and a therapeutically effective amount of a poly (ADP ribose) polymerase (PARP) inhibitor, the therapeutically effective amount of the PARP inhibitor being less than the amount in which the PARP inhibitor is used as an anticancer agent.

Citation Information

Cited By

  • Application of tetra-substituted pyrrole derivative in preparation of product for treating neurodegenerative diseases

    CN120919117A